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ABSTRACT
Research on human genetic variation has shown that the human genome is
not a fixed, invariant framework, but that there can be extensive structural
variation. This variation includes copy number variation (CNV), which can
lead to changes in DNA dosage contributing significantly to variation between
individual human genomes and heritable traits.
Human f3-d.efensinsare small, secreted antimicrobial peptides encoded by
DEFB genes located in a cluster of at least seven genes on 8p23.1. These genes
are highly variable in copy number but accurate measurement of multiallelic
copy number variants is challenging, particularly for high copy numbers, and
has not been intensively studied until recently. A new PRT-based (Paralogue
Ratio Test) triplex assay was developed to accurately measure the multiallelic
f3-d.efensincopy number variation. The Triplex assay was demonstrated to be
an accurate and powerful method to measure copy number variation in large
case-control association studies. This method was used to study the jklefensin
CNV in psoriasis disease, showing that high f3-d.efensin copy number is
associated with susceptibility to psoriasis in Caucasians.
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Studying population variation of CNV showed that variation in copy
number of ~-defensin is not significantly different across human populations.
To understand the evolutionary history of beta-defensin CNV in the primate
lineage, the study of CNV at this locus was carried out in great apes. fklefensin
genes are copy variable in human and chimpanzee, but not in gorilla,
suggesting that variation in copy number of beta-defensin genes may have
arisen in the human-chimpanzee lineage after the divergence with gorilla.
iii
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Figure1: Schematic representation of examples of structural genomic
variation involving rearrangements of one or more regions of DNA
sequence. Top panel illustrates deletion, insertion and inversion of
a DNA segment relative to the reference genome (each colour
represents a different DNA sequence). On the bottom panel is
illustrated the variation in copy number of a DNA segment of at
least lkb relative to the common (reference) situation of 2 copies
per diploid genome 10
Figure2: Chromosome 8p23.1 locus spanning approximately 6.5 Mb,
showing two pairs of segmental duplications, REPD(left) and REPP
(right) represented by grey and orange shading. Genesannotated in
the UCSCHuman Genome Browser are shown relative to their
posltion in the chromosome (~-defensin genes are highlighted). At
the REPD site two ~-defensin clusters are shown in inverted
orientation relative to one another (Figure from UCSCGenome
Browser on Human March 2006 (NCBI36/hg18)assembly) 19
Figure3: Comparison of three major mechanismsunderlying human genomic
rearrangements and CNVformation. A) Intrachromatid NAHR(non-
allelic homologous recombination) event between two directly
orientated low copy repeats (lCRs) sharing high homology (""97%)
(1), represented by grey and blue rectangles. Alignment and
recombination at non-allelic positions (2) leads to deletion or
duplication of part of the lCRs and deletion of the segment
between them (3). B) NHEJ(non-homologous end joining) event
can occur between two sequences with no homology (1)
(represented by grey and blue rectangles) when double stranded
DNAbreaks are created (2).The DSBsare repaired via NHEJthrough
a mechanism that includes modification of the ends to make them
compatible for final ligation, resulting in the deletion or insertion of
few bases at the DNA segment that separates the two sequences
(3). C) FoSTeS(Fork staling and template switching) event only
requires microhomology (2 to 5 base pairs) between the genomic
fragments (1) (represented by grey, blue and green rectangles, with
open triangles representing the microhomology sites between the
grey and blue sequences and the filled triangles bearing sites for
blue and green sequences).The replication forks of each sequence
are shown in the same colour. The leading strand (2) (in the top
grey replication fork) invades the right site replication fork (top blue
replication fork), followed by DNAsynthesis (dotted lines) using the
new replication fork as a template. This event can happen several
times, as illustrated, causingdeletion of the two fragments flanked
by each pair of microhomology sites (3). Juxtaposition of genomic
sequences from multiple distinct regions leads to complex
rearrangements. Figureadapted from Gu et al. (2008) 23
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Figure 4: General principle of Multiplex Amplifiable Probe Hybridization
(MAPH). Test DNA is denatured and hybridised with a set of
amplifiable probes, each recognising a unique region in the
genome. After intensive washing, the bound probes are retained in
the membrane and amplified using a common primer pair, being
quantified after capillary electrophoresis. Figure taken from Armour
et al. (2000) 28
Figure 5: Genomic organization of the ~-defensin locus at 8p23.1. On the top
panel is represented the whole 8p23.1 locus with the REPD and
REPPloci. Segmental duplications and gaps are represented in each
locus. The grey arrows represent inverted and non-inverted
orientation of the region that spans between REPDand REPP.On
the bottom panel is highlighted the genome organization of each
repeat with the seven genes that compose the ~-defensin copy
number variation repeat. (Figure adapted from UCSC Genome
Browser on Human March 2006 (NCBI36/hg18) assembly) 43
Figure 6: Schematic representation of paralogue ratio test (PRT). The PRT
primers (grey segments) simultaneously amplify each copy of test and
reference locus. This is only possible due to the presence of a
paralogue sequence (pseudogene and dispersed repeat region) within
the repeat unit, which is also present elsewhere in the genome but
not in a copy number variable region (reference locus). Therefore,
after capillary electrophoresis the ratio between the 2 copy reference
locus (green) and the test locus (blue) is used to measure the relative
number of copies of a test locus (bottom panel) 68
Figure 7: The scatter-plots above show an example of the calibration
performed in each experiment with selected reference DNA
samples with known copy number for HSPD5.8 (a), PRTI07A (b) and
HSPD21 (c). The unrounded mean ratio of each reference sample
was plotted against the corresponding copy number. The linear
regression obtained in each experiment was used to infer the copy
numbers of unknown samples 73
Figure 8: Examples of the GeneMapper electropherogram for EPEVl (a),
EPEV3 (b) and EPEV5 (c) after capillary electrophoresis. In each
electropherogram the real alleles and the "stutter" peaks are
shown for a sample with 5 copies. The copy number was previously
measured by the Triplex assay and confirmed by microsatellite
assays. The EPEVl shows three "stutter peaks" derived from the
four primary microsatellite alleles (180 bp, 182 bp, 186 bp and 188
bp). On the EPEV3 and EPEV5 electropherogram three main
microsatellite alleles are visible, 136 bp, 140 bp and 142 bp and 152
bp, 157 bp and 159 bp, respectively with two secondary "stutter"
peaks for each microsatellite assay 78
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Figure 9: a) Schematic representation of a microsatellite marker trace showing
"stutter" peaks. Peaks A and B represent the real alleles and C the
"stutter' peak for alleles A and B. b) Hypothetical reconstruction of
areas of the original two peaks X and Y after slippage correction,
assuming that the two alleles slipped equally 78
Figure 10: Principle of the HSPOS.8PRTassay at the 8p23.110cus. The top line
shows the structure of the repeat unit with the black arrows
representing two inverted repeats (March 2006 assembly). The
middle panel shows the location of the seven different ~-defensin
genes (SPAGll, DEFB4 and DEFB103-107) in each of the inverted
repeat units. The bottom line shows the location of the primers
used for this assay, just 2-3 kb upstream of DEFB4 gene, and the
amplified PCR products on chromosome 8 (test locus) and
chromosome 5 (reference locus), as well as the multiple
mismatches with other copies of the HSPOP3pseudogene in other
locations in the genome 89
Figure 11: Principle of the Triplex assay at the 8p23.1 locus. Schematic
representation of the Triplex assay (a), showing on the top line the
structure of the repeat unit (March 2006 UCSCassembly) with the
seven ~-defensin genes (SPAGll, DEFB4 and DEFB103-107), the
dispersed repeat region just upstream of DEFB107 and the heat-
shock protein pseudogene (HSPOP3) ....2 kb upstream of DEFB4. The
bottom panel represents a typical capillary electrophoresis trace for
Triplex assay. Each trace shows the SOEL, PRT107A and HSP021
PCR products in two labelled dyes. PRT107A (b) and HSP021 (c)
amplification details showing the amplified PCR products on test
(chromosome 8) and reference locus (chromosome 11 and 21), as
well as the multiple mismatches with other copies of the dispersed
repeat region and the HSPOP3pseudogene, respectively, elsewhere
in the genome 92
Figure 12: Unrounded copy number values of PRTI07A and HSP021 for ECACC
panel 1 samples typed by the triplex assay. The scatter-plot shows
clear clusters centred in integer values, highlighted by the red
circles (drawn by hand), that correspond to different copy numbers
classes. In this plot, the PRT107A values are more spread than the
HSPD21 copy number values. (The 96 ECACCpanel 1 samples were
typed several times with the Triplex assay making a total of 237
different repeats) 94
Figure 13:Histogram of unrounded copy number distribution ofPRT107A (a),
HSPD21 (b) and the mean of PRT107A and HSP021 (c), showing a
clustered distribution centred in integer values (the 96 ECACCpanel
1 samples were typed several times with the Triplex assay making a
total of 237 different repeats). The standard deviation shown for
each assay was calculated using normalized copy number values
from PRT107A, HSPD21and the mean PRT, respectively 96
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Figure 14: Comparison of copy number residuals of PRT107Aand HSPD21
from ECACCHRCpanel 1 data. The residuals were calculated from
the difference between the measured unrounded copy number
value of each PRTand the integer copy number (ML CN) given by
the maximum likelihood program for 94 samples 97
Figure15: Histogram showing the frequency distribution of copy number
residuals from PRT107Aand HSPD21performed in Triplex assayfor
the ECACCpanel 1 HRC panel 1 samples. The residuals were
calculated from the difference between the measured unrounded
copy number value of each PRTand the integer copy number (ML
CN)given by the maximum likelihood program 97
Figure16: p-defensin copy number frequency distribution in CEU (CEPH
individuals with northern and western European ancestry from
Utah, USA)(a), YRB(Yoruba from Ibadan, Nigeria) (b) and CHB/JPT
(Chinese from Beijing, China and Japanese from Tokyo, Japan) (c)
HapMap collection samples. All histograms show frequency copy
number distribution given by McCarroll et al. (2008), Conrad + 1
(Conrad et al. 2010) and the Triplex assay.Additionally, in the CEU
histogram copy numbers frequencies from Aldhous et al. (2010),
Fellermann et al. (2006) and Bentley et al. (2010) are also
represented 100
Figure 17: Quantile-quantile plots of PRT107A(a), HSPD21(b) and arithmetic
mean of PRTs(c) comparing normalized CN distribution on the Y-
axis to a standard normal distribution on the X-axis (theoretical
normal distribution). The linearity of the points suggests that the
data are normally distributed 101
Figure 18: p-defensin frequency copy number distribution in a UK population
cohort (ECACCHRCpanel 1). The histogram shows integer copy
numbers obtained from the Triplex assay.The copy number for each
samplewas defined by the result with a higher minimum ratio .... 103
Figure 19: Location of dye peaks generated from FAM, HEXand NEDprimers
on a triplex PRT-basedassay.The blank control shows the position
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in the blank control. On both samples 1 and 2, the variable mobility
of the dye peaks is shown 112
Figure20: Results produced by HSPD21PRTsystem in Triplex assaygiven by
the data analysisof peak areas and peak heights for FAM and NED
dyes. a) Scatter-plot of unrounded ratios from peak height for FAM
and NEDdyes showing a high concordance between the two data
sets and clustering of values, presumably corresponding to integer
values. b) Scatter-plot of unrounded ratios from peak area for FAM
and NEDdyes showing a poor concordance between the two data
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around integer values 122
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CHAPTER 1: INTRODUCTION
1.1 HUMAN GENETIC VARIATION
Ten years on after the first release of the human genome sequence
(Human Genome Project) it is remarkable how our knowledge of the human
genome has dramatically changed, bringing a new perspective into the real
genetic variation that distinguishes and characterizes each individual identity,
and defines us as humans.
Genomes can differ at many different scales, ranging from a single base to
thousands of DNA nucleotide bases. Human genetic variation can be defined
as the differences in DNA sequence observed between individuals. These
genetic differences can be observed at large-scale (cytogenetic) level,
comprising more than 3 Mb of DNA sequence and thus detectable by the light
microscope, and at small-scale involving less than 3 Mb of DNA sequence and
only detectable at the molecular (submicroscopic) level.
Until recently the most studied and best known types of genetic variation
were at the sequence level, involving single nucIeotides (indels, single
nucleotide polymorphisms and point mutation), microsatellites and
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minisatellites or at the chromosomal level, involving large chromosomal
rearrangements. For a long time the knowledge of human genetic variation was
limited by the detection methods available, and focused primarily on the
heterochromatin polymorphisms large enough to be visible at the light
microscope and to the sequence variation identified by traditional PCR-based
DNA sequencing. Since then, new technologies filled the resolution gap
between these earlier approaches to detect different classes of genetic variation,
especially submicroscopic structural variation, contributing to a wider vision of
the complex variation of the human genome. These technologies allowed the
discovery of several genetic variants that play an important role in disease
susceptibility. Since then, the study of human genetic diversity has become a
major priority in human genetics as it is essential to understand the phenotypic
differences observed between individuals, which either lead to "normal"
human variation or confer susceptibility to disease.
1.1.1 Large-scale chromosomal variation
The evidence for human genetic variation at the DNA level started with
the visualization of chromosomes under the light microscope (Tjio and Levan
1956; Speicher and Carter 2(05). Since then, abnormal number or structure of
chromosomes has been associated with disease phenotypes. The earlier
cytogenetic techniques, without the use of staining methods, only allowed the
visualization of differences in length, number and centromere position of the
chromosomes, and therefore were only able to detect for example polyploidies,
aneuploidies, marker chromosomes and isochromosomes Gacobs and Strong
1959; Lejeune 1959). With the development of chromosome-banding
techniques, such as G-banding (Rowley 1973; Caspersson et al. 1999) and
fluorescence in situ hybridisation (FISH) (Bauman et al. 1980), more discrete
chromosomal abnormalities could be detected, such as translocations,
deletions, duplications and inversions (Speicher and Carter 2005). Since the
first application of in situ hybridization using fluorescent microscopy by
Bauman et al. (1980), in situ hybridization techniques have played a main role
in mapping the position of genes on human chromosomes. Today, now that
the Human Genome Project is complete, FISH and related in situ hybridization
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methods are mainly used for clinical diagnoses. However, in other species, for
which the entire genome has not been sequenced, this technique continues to
be an essential tool to map the position of genes on chromosomes. The
resolution of this technique has always been limited by the ability of light
microscopy to distinguish between two points along the length of a
chromosome. Typically the resolution for chromosomes at metaphase is
expected to be resolution in the range of a few megabases (5-10 Mb), while for
interphase chromosomes the resolution improves to the range of a few tens or
hundreds of kilobases (50 kb to 2 Mb) (Levsky and Singer 2003; Speicher and
Carter 2(05). This method had a crucial impact in the understanding of
chromosomal rearrangements, although the low resolution was a motivation to
develop more powerful cytogenetic techniques such as fiber-FISH, which
chromosome rearrangements can be identified on elongated chromatin strands
(5 to 500 kb) [Floriin et al. 1995; Speicher and Carter 2005).
The numerical chromosomal variation which refers to the variation in the
number of chromosomes relative to a diploid genome, can either involve the
presence of more than two paired homologous sets of chromosomes, also
known as polyploidy, or the presence of a numerical change in part of the
chromosome set, aneuploidy, within the cells. Polyploidy can arise in
metaphase I during meiosis in the germ line or during mitosis by abnormal cell
division, leading to the formation of triploid (3n) or tetraploid (4n) genomes,
respectively. The majority of embryos cannot survive with triploid or tetraploid
genomes and are spontaneously aborted. Polyploidy of the entire genome is
rare and normally lethal, but all humans have some polyploid cells, such as
hepatocytes (2n to Bn) or cardiomyocytes (4n to Bn) (Korver et aJ. 199B).
Within the aneuploidies the most common numerical chromosomal
abnormality is trisomy, which refers to the presence of three copies of a
particular chromosome instead the normal two copies. However, aneuploidy
can also involve the loss of one chromosome (monosomy) or a pair of
chromosomes (nullisomy) or on the other hand, the gain of two or three
chromosomes (tetrasomy, pentasomy), occurring either in autosomes or sex
chromosomes. Aneuploidies normally arise when two homologous
chromosomes fail to separate (disjoin) in anaphase, and migrate together into
3
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the same gamete during mitosis or meiotic events, also called non-disjunction.
Alternatively, aneuploidies can also result from the delayed movement
(lagging) of a chromosome or chromatid, failing to be incorporated into one of
the daughter cells during anaphase, referred as anaphase lag. Trisomies, in
particular, have been described to be the cause of different autosomal
syndromes, such as Down's syndrome, a trisomy of chromosome 21 (Lejeune
1959), Edward's syndrome, a chromosome 18 trisomy (Edwards et a1. 1960)
and Patau's syndrome, with an extra chromosome 13 (Patau et a1. 1960).
Down's syndrome was first described by Langdon Down in 1866 (Down 1866)
as a clinical entity and one of the most common trisomies, possibly due to its
high survival rate through adulthood. However, the majority of trisomic
variations are not compatible with life; the larger and more gene-dense the
chromosome involved the more likely the serious dysfunction. The occurrence
of Down's syndrome has been associated with advanced maternal age and it
occurs in about one in every 700 live births. Individuals with Down's syndrome
share some mental and physical features, which can range from mild to severe
symptoms. Often the individuals have learning disabilities and may have
dementia. Another common feature is the high frequency of characteristic
associated conditions like congenital heart disease and leukaemia.
Among the sex chromosomes, different syndromes have been described to
be associated with chromosomal aneuploidies. An example is Turner's
syndrome that is caused by the absence of all or part of the second sex
chromosome. Frequently only one X chromosome is inherited with the other
one lost during early development (2n=45, XO) Uacobs et a1. 1997). This
syndrome occurs with a frequency of 1 in 2000 to 2500 live female births and is
characterized by abnormal anatomical features, such as short stature and
webbed neck, together with infertility and ovarian dysgenesis. Conversely, an
additional X chromosome can be found in one of every 500 male newborns,
causing Klinefelter's syndrome (47, xxy) Uacobs and Strong 1959).
Individuals with this condition mainly have problems in the reproductive
system, namely infertility or reduced fertility, although some degree of
developmental delay can also be observed.
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Autosomal monosomies have far more lethal consequences than trisomies,
which may be a direct consequence of the absence of expression of gene
products encoded on the lost chromosome. On the other hand, the variation in
the number of sex chromosomes has fewer negative effects in individuals than
autosomal trisomies. This could be because the Y chromosome carries very
few genes (as the major role is to determine the male sex) and because the X
chromosome has an X chromosome inactivation mechanism, which results in
dosage equalization (Ohno et aJ. 1959; Beutler et aJ. 1962).
1.1.2 Large-scale structural variation
Structural variation encompasses a group of genomic rearrangements
which affect segments of DNA larger than 50 bp that can be microscopic
~arge-scale) or submicroscopic (small-scale). Depending on the size, structural
variation normally involving DNA segments larger than 3 Mb (large-scale) can
be detected by cytogenetic methods. Structural variation can be quantitative
(comprising deletions, duplications, insertions, copy number variation,
isochromosomes and marker chromosomes), positional (which refers to
translocations) and orientational, as is the case of inversions. This section will
discuss different types of large-scale structural variation.
Autosomal abnormalities involving the deletion of part of a chromosome
are associated with recognized clinical syndromes, mainly associated with
intellectual disability and several congenital malformations. Deletion of the
short arm of chromosomes 5 and 4 was found to be the cause of Cri-du-chat
and Wolf-Hirschhorn syndromes, respectively. Other deletions involving
smaller segments of DNA (microdeletions) have also been associated with
different syndromes, for example Prader-Willi (Ledbetter et aJ. 1981) and
Angelman syndromes (Knoll et aJ. 1989). Patients with such syndromes have an
interstitial deletion on the proximal portion of the long arm of chromosome 15
(15ql1.2-I3) either from paternal (Prader-Willi) or maternal derived
chromosome (Angelman). The deletion commonly cover about 4 Mb of DNA
sequence (Ledbetter et aJ. 1981; Knoll et aJ. 1989) but later studies in families
defined an imprinting centre on human chromosome 15 estimated to span a
minimum interval of 42 to 60 kb (Buiting et aJ. 1995). This structural
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rearrangement involves the deletion of seven genes, which differ in expression
according to paternal or maternal origin of the derived chromosome;
Angleman syndrome is likely to be due to loss of maternal UBE3A function,
whereas a more complex pattern of loss is necessary explain the features of
Prader-Willi syndrome. Normally people inherit one copy of each gene from
each parent but certain genes, for example the ones on chromosome 15, are
expressed in a parent-of-Origin-specific manner. This phenomenon of genomic
imprinting explains the phenotypic differences associated with each syndrome
(Ledbetter et a1. 1981;Knoll et a1. 1989).
Although many of the copy number variable regions are too small to be
detected by cytogenetic methods, some CNV s showing large expansions of the
repeat unit can be cytogenetically identified. Known examples are the copy
number regions at 8p23.1, 15q11.2 and 16p11.2 (Barber et a1. 1998; Ritchie et
a1. 1998; Barber et a1. 1999; Hollox et a1. 2003). The p-defensin gene cluster at
8p23.1 is highly polymorphic in copy number, with individuals showing
between 2 and 12 copies per diploid genome. Using FISH, chromosomes with
7 or more copies of this repeat have been cytogenetically reported as
euchromatic variants (Barber et a1. 1998; Hollox et a1. 2(03). Similar to 8p23.1,
at the 15q11.2 and 16p11.2 loci, chromosomes can contain up to -20 and -12
tandemly repeated copies, respectively, which appear as visible euchromatic
variants (Ritchie et a1. 1998; Barber et a1. 1999).
Isochromosomes are a rare type of structural variation, consisting of a
chromosome with two genetically and morphologically identical arms, either
two long arms or two short arms. They may arise from recombination between
sister chromatids due to the formation of an abnormal U-type structure.
Isochromosomes have been observed in some females with Turner's
syndrome, i(Xq), and in individuals with Down syndrome, i(21q) (Feuk et a1.
2006). Marker chromosomes, also known as "supernumerary" chromosomes,
are rare structurally abnormal chromosomes, and very little is known about
their origin or importance, though their phenotypic effects are variable and
depend on the genes contained within the marker (Feuk et a1. 2006).
Structural chromosomal abnormalities can also result from misrepair of
chromosome breaks or recombination between non-homologous regions of
6
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chromosomes. Chromosome breaks occur as a result of damage or as part of
the mechanism of recombination, but cells have natural mechanisms to prevent
recombination between unrepaired chromosomes through chromosome break
repair or apoptosis. Nevertheless, when these mechanisms fail, acentric
(absence of centromere) or dicentric (two centromeres) chromosomes can be
formed, which will normally be lost because they are not stable through mitosis
(McClintock 1939; Stimpson et a1. 2010). Conversely, chromosomes with only
one centromere even with structural abnormalities, such as acrocentric
(centromere located near one end of the chromosome) chromosomes, can
stably recombine during meiosis frequently resulting in chromosomal
translocations. Recombination of acrocentric chromosomes can occur between
the proximal short arms of chromosomes resulting in the formation of a
Robertsonian translocation and loss of the distal acentric parts of the two shorts
arms (Robertson 1916; Hamerton et a1. 1975). With the loss of one
chromosome the karyotype will be reduced to 45 chromosomes. In
Robertsonian translocations both centromeres are present but because they are
very close together, they function as one, segregating normally. This
translocation has been seen in all acrocentric chromosomes, namely 13, 14, 15,
21 and 22 (Stimpson et a1. 2010). Another type of translocation is called
reciprocal and results from the exchange of chromosome material of one of the
arms of chromosomes between two non-homologous chromosomes (Evans et
a1. 1978). No phenotypic consequences are observed in the carriers of
reciprocal or Robertsonian translocations, even though some genetic material
has been lost at least in the Robertsonian translocations. For this reason such a
translocation is regarded as a balanced structural variation. Nevertheless,
carriers of translocations can produce unbalanced gametes and generate
zygotes with chromosomal imbalances such as trisomy and monosomy.
Moreover, some individuals show additional problems with infertility and
recurrent spontaneous abortion (Berend et a1. 1998).
Unlike other types of structural variation, inversions have been regarded as
balanced rearrangements as they involve the change in orientation of a DNA
segment without the loss of genetic material. However, Tuzun et a1. (2005)
demonstrated that inversions can often be not balanced, as they are frequently
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accompanied by gain or loss of genetic material. Inversions can be pericentric
if the inverted segment includes the centromere or paracentric if it does not
contain the centromere. Although most inversions may not have a direct effect
on the phenotype, there is increasing evidence that polymorphic inversions can
predispose to further chromosomal rearrangements in subsequent generations
(Sharp et al. 2006). A known example is the inversion flanked by the segmental
duplicated olfactory receptor genes at 4p16 and 8p23. The occurrence of
individuals with the recurrent translocation t(4;8)(p16;p23) is more frequent
among those with parents who are carriers of the inverted heterozygous state of
these inversions (Giglio et al. 2(01). Therefore, inversion of regions flanked by
segmental duplications can lead to an abnormal meiotic recombination and
increased susceptibility to unequal non-allelic homologous recombination
(NAHR) (Iafrate et al. 2004; Sebat et al. 2004; Sharp et al. 2005; Tuzun et al.
2005; McCarroll et al. 2006). Apart from translocations the inverted state may
also be associated with inverted duplications and marker chromosomes
(Sharp et al. 2006).
1.1.3 Small-scale structural variation
As described in the previous section, structural variation can also involve
genomic rearrangements of smaller segments of DNA «3 Mb). At this scale,
genomic variation can involve one to several bases of DNA, including from
Single nucleotide polymorphisms (SNPs), short repetitive DNA sequences
(micro satellites, minisatellites and mobile elements), and small
insertions/deletions (less than 1 kb) to large copy number variants and
inversions (Feuk et al. 2(06). However, the detection of smaller and more
abundant variation was only possible with the advent of new methods in
molecular biology, in particular genome-scanning array technologies (Solinas-
Toldo et al. 1997; Iafrate et al. 2004; Sebat et al. 2(04) and comparative DNA-
sequence analysis (Feuk et al. 2005; Tuzun et al. 2005). These techniques were
especially important to detect intermediate-scale variation, since variation at the
karyotype and nucleotide levels can be detected by cytogenetic and
conventional sequence analysis, respectively. These intermediate variants
ranging from -1 kb to 3 Mb in size are defined as submicroscopic structural
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variation (small-scale structural variation), which include copy number variants,
segmental duplications or low copy repeats, deletions, insertions, inversions
and translocations (Figure 1) (Feuk et a1. 2006; Alkan et a1. 2011). At first it was
believed that small genetic variants «1 kb), such as single base pair changes,
would constitute most human genetic variation. However, in recent years
hundreds of CNVs (Dhami et a1. 2005; Sharp et a1. 2005; Tuzun et al. 2005;
Freeman et a1. 2006; Redon et a1. 2006; Conrad et a1. 2010) and inversions
(Stefansson et a1. 2005; Tuzun et a1. 2005; Visser et al. 2(05) have been
described. When referring to submicroscopic structural variation it is not
directly implied that it has obvious phenotypic consequences, but because this
type of variation encompasses millions of bases of DNA which can comprise
entire genes, it is likely to influence gene dosage and therefore cause or give
susceptibility to genetic diseases (Inoue and Lupski 2002; The Wellcome Trust
Case Control Consortium 2010). In such cases, the term structural abnonnality is
used. Some of these structural rearrangements can occur in more than 1% of the
population and can be called polymorphisms (Feuk et a1. 2006; Alkan et a1. 2011).
Insertion and deletion (indels) of DNA segments involve gain and loss of
few hundred to several million nucleotides of the genome and are collectively
known as copy number variants. Small indel events represent the most common
type of structural variation in the human genome and are a major source of
human biological diversity. In a recent study almost 2 million small indels were
reported in the human genomes of 79 individuals, comprising between 1 bp to
10000 bp (Mills et a1. 2011). This type of rearrangement was associated with earlier
identified human genetic traits, such as colour blindness (Nathans et a1. 1986;
Vollrath et a1. 1988) and a-thalassaemia (Vollrath et al. 1988;Higgs et al. 1989).
The red and green opsin pigment genes, OPN1L W ("opsin 1 long-wave-
sensitive" for the red photopigment) and OPN1MW ("opsin 1 medium-wave-
sensitive" for the green photopigment) are located head-to-tail in a tandem
array on the human X chromosome and share a high sequence similarity,
which in combination predispose to unequal recombination or gene
conversion. This mechanism is responsible for the fusion of red and green gene
pigments and the observed variation in green-pigment gene number among
individuals with colour blindness (Nathans et a1. 1986; Vollrath et a1. 1988).
9
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Reference Deletion Insertion Inversion
Copy number variation
1 Copy 2Coples 3 Copies 4Coples
Figure 1: Schematic representation of examples of structural genomic variation involving
rearrangements of one or more regions of DNA sequence. Top panel illustrates
deletion, insertion and inversion of a DNA segment relative to the reference genome
(each colour represents a different DNA sequence). On the bottom panel is
illustrated the variation in copy number of a DNA segment of at least lkb relative to
the common (reference) situation of2 copies per diploid genome.
Non-allelic homologous recombination between paralogous sequences is also
responsible for the deletion of a-globin genes that result in a-thalassaemia.
Normal individuals have four alpha-globin genes, with one copy of each highly
homologous gene, alpha-1 (HEAl) and alpha-2 (HBA2), present on each
chromosome 16. High sequence similarity between these genes was thought to
drive unequal recombination and lead to recurrent deletion of one or two
copies of the a-globin genes causing a-thalassaemia (Higgs et al. 1989). On the
other hand, duplication of these genes was also observed in individuals from
different ethnic backgrounds, showing up to five copies of alpha-globin genes with
apparently no clinical or haematological abnormalities (Goossens et a1. 1980).
Another example is the case of the Rhesus blood group antigens. The RllD gene
at chromosome 1p34.1-1p36 is flanked by two DNA segments called Rhesus
boxes, with 98%homology. This molecular structure supports the occurrence of
unequal crossing over between the Rhesus boxes accompanied by the frequent
deletion of the entire RHD gene (depending on the population between 3%
and 25%in Caucasians) (Ottolenghi et a1. 1974; Wagner and Flegel 2000).
10
INTRODUCTION
More recently two studies using dense SNP genotype data from family
trios from the International HapMap Project identified several (around 500
each study) deletion polymorphisms demonstrating the importance and extent
of copy number polymorphisms (CNPs) in the human genome (Conrad et al.
2006; McCarroll et al. 2006). The deletion polymorphisms identified range
from 1 kb to 750 kb spanning several genes with roles in sex steroid
metabolism, olfaction and drug response (McCarroll et al. 2006). In particular,
deletions of 5 kb or larger were found to be widespread in the human genome
proving that the abundance of this type of polymorphism had been
underestimated (Conrad et al. 2006). This evidence is supported by Hinds et
al. (2006) who used array-based comparative genomics to detect 215 deletions
in 24 unrelated individuals. Overall, around 1.5 million indels were identified
within known genes in the human genome, with about 5,500 of them located in
the promoters and exons of genes where it is expected they could influence
gene expression and function (Mills et al. 2006). Indel polymorphisms in
several genes have also been reported to influence a variety of common
phenotypes. Homozygous deletions of the glutathione S-transferase genes
(GS1Ml and GS1Tl) for example are associated with increased risk of a
variety of cancers (Garcia-Closas et al. 2005), whereas duplication of the
CYP2D6 gene, a cytochrome P450 CYP2D6 drug-metabolizing enzyme
involved in the metabolism of several drugs and xenobiotics, causes alteration
of the metabolism of CYP2D6 substrates and is also a risk factor for lung or
larynx cancer [Agundez et al. 2001).
Another class of genetic variation involves changes in the number of
repeated DNA sequences arranged in tandem arrays, generally known as
variable number of tandem repeats (VNTRs). This class covers different scales
of variation in which micro satellites and minisatellites, tandem arrays with
variable repeat units typically between 2 and 100 bp in length and also satellite
DNA, which comprises large tandem arrays spanning from hundreds of
kilobases to several megabases in size, are included. Microsatellites, also known
as short tandem repeats (STRs), are tandem DNA arrays composed of repeat
units 1 to 6 bp in length. Typically these arrays contain between 10 and 30
repeats spanning not more than approximately 200 bp. On the other hand, the
11
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repeat array length of minisatellites normally spans from 100 bp to 20 kb with
each repeat unit between 8 and 100 bp in length.
The substantial length polymorphism of VNTRs, in particular of
microsatellites and minisatellites, makes these useful and very informative
genetic markers to study genetic diversity. The highly polymorphic length of
minisatellites, due to allelic variation in repeat copy number, was discovered in
1985 by Jeffreys et al. (1985a; 1985b) and was subsequently used in DNA
fingerprinting. The highly variable microsatellite profiles found in the human
genome can be used in individual identification, paternity testing and forensic
studies. While some satellite DNA normally lies at the centromeres and
telomeres, composing functional components of chromosomes, some
microsatellites and minisatellites lie within the coding regions of genes or in
regulatory regions. Although some tandem repeat loci are seen as neutral
markers, others can play a functional role and variation can affect gene
expression and function and therefore have phenotypic effects (Armour 2006).
Well known examples are the "triplet repeat diseases" in which expansions of
micro satellite arrays are associated with Single-gene inherited disorders. One
example is fragile-X syndrome, which is associated with expansion in the
number of tandem CGG trinucleotide repeats upstream of the human FMRI
gene, normally from 5-50 repeats to 50-4000 repeats, leading to reduced or
silenced transcription (Pieretti et al. 1991; Homstra et al. 1993). Other well
known examples of triplet repeats are those caused by CAG (glutamine)
tandem repeats within the coding region of a gene. The polyglutamine
expansions were described in Huntington disease and in a number of
spinocerebellar ataxias (SeAs) and cause a dominant gain-of-function
neurotoxicity (MacDonald et al. 1993; Michalik and Van Broeckhoven 2003).
The cause of the autosomal dominant neuromuscular disorder,
facioscapulohumeral muscular dystrophy (FSHD) has also been linked to
satellite repeat markers. Increased evidence suggests that an epigenetic
mechanism causes FSHD involving the contraction of a tandem DNA repeat
(D4Z4) on chromosome 4q35. However, is still unclear how this deletion
causes the disease (van der Maarel and Frants 2005). In addition, minisatellite
polymorphisms were also reported to have influence on phenotype. Upstream
12
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of the insulin gene INS (=IDDM2, insulin-dependent diabetes mellitus 2) on
human chromosome llpI5.5, there is a polymorphic minisatellite which was
described as a susceptibility factor for type I diabetes (Bennett et al. 1995).
Transcription of the insulin gene was correlated with allelic variation of this
minisatellites (Bennett et al. 1995).
Analysis of DNA sequence data reveals that the human genome comprises
an estimated 5.2% of duplicated sequences (segmental duplications, SDs), also
termed low-copy repeats (LCRs) (Bailey et al. 2001; Bailey et al. 2002; Cheung
et al. 2003; She et al. 2004). Segmental duplications are blocks of DNA that
range from 1 to 400 kb in length of highly homologous DNA sequences
sharing a high degree of sequence identity, approximately 9SOk(Eichler 2001).
SDs are interspersed throughout the human genome, but they tend to occur at
pericentromeric and subtelomeric regions. They can be duplicated within a
Single chromosome (intrachromosomal duplication) or in non-homologous
chromosomes (inter or transchromosomal duplication) (She et al. 2004;
Linardopoulou et al. 2005). The presence of large segmental duplications
predisposes these regions to recurrent structural rearrangements via non-allelic
homologous recombination (NAHR), resulting in the formation of different
structural polymorphisms, including deletion, duplication or inversion of
intervening DNA segments (Iafrate et al. 2004; Sebat et al. 2004; Sharp et al.
2005; Tuzun et al. 2005; McCarroll et al. 2006). The location of SDs has been
associated with regions of chromosomal instability or at the breakpoints of
syntenic blocks in the human genome suggesting their involvement in
evolutionary rearrangements (Samonte and Eichler 2002; Armengol et al. 2003;
Bailey et al. 2004). These segments can contain dosage-sensitive genes or
regulatory regions, and as such they have been named as potential mediators
in a number of disease phenotypes, designated genomic disorders (>25
recurrent genomic disorders) (Lupski 1998; Ji et al. 2000; Inoue and Lupski
2002; Stankiewicz and Lupski 2002). One example involves the recombination
(NAHR) between the CMTJA [Charcot-Mane-Tooth disease type lA) repeats
on chromosome 17p containing the PMP22 gene, which encodes a myelin
protein. Duplication of this region (three copies of PMP22 gene) leads to
Charcot-Marie-Tooth disease, while the reciprocal deletion is correlated with
13
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liability to pressure palsy (HNPPj (Lupski 2009). Further examples include the
Smith-Magenis syndrome and Potocki-Lupski syndrome which result from
similar rearrangement mechanisms (Lupski 2(09). NAHR has also been
involved in the formation of large inversion polymorphisms. Two studies, using
different comparative genomic approaches identified several inversion
polymorphisms with the majority (>75%) mapping to sites of segmental
duplications (Feuk et al. 2005; Tuzun et al. 2(05). One of the best known
examples of inversion polymorphisms reported to date is the 900 kb inversion
at chromosome 17q21.31 identified by Stefansson et al. (2005). The inverted
haplotypes appear at increased frequency in the European population (21%)
but at very low frequency in Africans (6%)and Asians (1%)with female carriers
of the inversion showing a small increase in fertility (Stefansson et al. 2(05).
Although inversion polymorphisms have not been associated with alterations in
copy number and subsequently have not been suggested to be a direct cause
of phenotypic variation, many of them confer susceptibility or are the substrate
to further chromosomal rearrangements in the following generations (Sharp et
al. 2(06). Inversion polymorphisms were frequently observed in parents of
deletion carriers that confer different disease phenotypes, such as Angelman
syndrome (Gimelli et a1. 2(03), Sotos syndrome (Osborne et al. 2(01) or
Williams-Beuren syndrome (Visser et al. 2005). Therefore, inversion of the
segment flanked by SDs may predispose to abnormal meiotic pairing leading
to unequal NAHR and subsequently the formation of several chromosomal
rearrangements that confer disease phenotypes.
1.1.3.1 Copy number variation and its consequences
In the past few years copy number variation (CNV) has been
demonstrated to be a prevalent form of structural variation in the human
genome and an important source of genetic variation (Iafrate et al. 2004; Sebat
et a1. 2004; Redon et a1. 2006; The Wellcome Trust Case Control Consortium
2010). CNV can be defmed as a DNA segment 1 kb or greater in size, which is
present at variable number of copies (Feuk et a1. 2006). Numerous copy
number polymorphisms (CNPs) have been associated with the presence of
segmental duplications (Sharp et a1. 2005). Genomic regions enriched for
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segmental duplications are prone to chromosomal rearrangements through
NAHR and are considered hotspots of genomic instability and therefore prone
to copy-number variation (Sharp et al. 2(05). Copy number variation can
involve just simple tandem duplications (also referred as low copy repeats or
segmental duplications) or more complex arrangements, such as gains or losses
of homologous sequences at different sites in the genome (Redon et al. 2006).
Three studies published between 2004 and 2006 strongly contributed to
the perception that copy number variation has a widespread distribution
throughout the human genome accounting for a large portion of the genetic
variation found among human genomes, which may reflect their importance in
genetic diversity and evolution (Iafrate et al. 2004; Sebat et al. 2004; Redon et
al. 2(06). Iafrate et al. (2004) identified 200 large-scale copy-number variants
(LCVs) in the human genome, of which 24 are present in >10%of the studied
individuals. However, by studying 270 individuals from four populations with
different ancestry (Europe, Africa and Asia from the HapMap collection)
Redon et al. (2006) identified 1447 copy number variable regions (CNVRs)
encompassing as much as 360 megabases of the genome (-12%), containing
hundreds of genes with important biological functions.
CNV has been described to influence gene expression, phenotypic
variation and adaptation by disrupting genes and altering gene dosage (Iafrate
et al. 2004; McCarroll et al. 2006), which can lead to disease phenotypes or
confer susceptibility to complex traits such as psoriasis (Hollox et al. 20OBb) or
glomerulonephritis (Aitman et al. 2006). Many copy number variants directly
affect the protein levels, as in the case of the a-synuclein (SNCA) gene (Miller
et al. 2(04); however for n-defensin genes the expression of DEFAI/DEFA3
mRNA is not Simply correlated with the gene copy number (Aldred et al.
2(05). Studying the relative impact of CNV on gene expression phenotypes in
210 unrelated individuals of the International HapMap project, Stranger et al.,
found that 17.7%of the detected genetic variation in gene expression is due to
copy number variation (Stranger et al. 2(07), suggesting that copy number
variation is not limited to intergenic or intronic regions. Also reporting similar
conclusions, a more recent study using the mouse as a model system showed
that CNV s shape tissue transcriptomes and therefore phenotypic variation. The
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Genome-wide expression data generated from six major organs confirmed the
influence that CNV s have on the expression of genes within the CNV and in
their vicinity, an effect that could be extended up to half a megabase
(Henrichsen et al. 2(09). Despite the direct effect that large-scale copy number
variants have in disease phenotypes, these variants are common among the
genomes of phenotypically normal individuals, suggesting an indirect role in
the phenotype through position effects or predisposing to further chromosomal
rearrangements in the following generations with potentially deleterious effects.
Therefore, they have been proposed as a driving force for genome evolution
and phenotypic variation (Sebat et al. 2004; Feuk et al. 2(06).
Perhaps the best and simplest example of copy number variation is the
well known deletion of the RHD gene responsible for the rhesus negative
blood group. The Rh (Rhesus) blood group antigens are products of two
genes, RHD and RHCE, located on chromosome 1p34-36.2. RHD carries the
D antigen, one of the most potent immunogenic blood groups. The deletion of
the whole RHD gene occurs with an approximate frequency of 40% in
Europeans and corresponds to the rhesus-negative phenotype and complete
absence of the D antigen expression (Wagner and Flegel 2(00).
One of the commonest copy number variants described contains the
human salivary amylase gene (AMYl) at chromosome region IpI3.3, that
spans between 150 kb and 425 kb (Groot et al. 1989; Iafrate et al. 2(04).
Relative copy number gains and losses of this locus were detected at about the
same frequency within a population, but the CNV was found to vary between
different populations sampled from Africa, Asia and Europe, according to the
type of diet (Iafrate et al. 2004; Perry et al. 2007). Populations with a diet rich in
starch were found to have more copies of the AMY1A gene than populations
with "low starch" diets (Perry et al. 2007).
Copy number variation in the human genome has been described as an
important determinant for susceptibility to various autoimmune diseases.
Aitman et al. (Aitman et al. 2006), described that variation in copy number of
the FCGR3B [Fcy-receptor-Illb) gene at chromosome Iq23, which encodes an
Fc receptor for IgG, confers susceptibility to immunologically mediated
glomerulonephritis, a major cause of kidney failure and morbidity in systemic
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lupus erythematosus (SLE). Diploid copy number varies between zero and four
copies, but low copy number of FCGR3B, in particular complete FCGR3B
deficiency, was associated with glomerulonephritis in patients with systemic
lupus erythematosus (SLE) (Aitman et al. 2006; Fanciul1i et al. 2007). SLE was
recently also associated with the complement component C4 gene copy
number variation, which ranges from zero to six copies per diploid genome.
After comparison with healthy individuals, a clear high frequency of low copy
number was detected among the patients with SLE (Yang et al. 2(07). The risk
([OR]=6.514; p=O.OOOO2) of SLE disease susceptibility Significantly increased
among individuals with only two or fewer copies of C4 gene, while in
comparison higher copy numbers (3 or more copies) confer protection against
SLE (OR=O.574; p=O.012) (Yang et al. 2(07).
The CCL3L1 locus is a multiallelic copy variable region on the q-arm of
chromosome 17. In Europeans CCL3LJ gene copy number is commonly
polymorphic, varying between zero to four copies, but in African and Asian
populations it is even more polymorphic with copy numbers as high as
fourteen recorded in African individuals (yValker et al. 2(09). Variation in copy
number at CCL3LJ has been reported to be associated with disease
phenotypes such as SLE (Mamtani et al. 2(08), Rheumatoid Arthritis
(McKinney et al. 2(08) and HIV-l/AIDS (human immunodeficiency
virus/acquired immunodeficiency syndrome) (Townson et al. 2002; Gonzalez et
al. 2(05). CCL3LJ gene encodes the CC chemokine ligand 3 like-I (CCL3LI),
which binds to several pro-inflammatory cytokine receptors, including the CC
chemokine receptor 5 (CCRS) a major co-receptor for HIV (Human
immunodeficiency virus). Low copy number of CCL3LJ gene, relative to
population average of the ethnic group, was associated with HIV-l/AIDS
susceptibility and progression (Townson et al. 2002; Gonzalez et al. 2(05). This
fmding is strongly controversial and in recent studies this association failed to
replicate (Shao et al. 2007; Urban et al. 2009). Nevertheless, different studies
have shown evidence of the relationship between gene CNV and susceptibility
to human complex disease related with immunity.
Copy number variants have also been associated with other mendelian
and complex diseases, such as Parkinson's and Alzheimer's diseases. A study
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in patients with Parkinson disease, reported the frequent occurrence of
genomic duplications or triplications of the alpha-synuclein gene (SNCA),
which cause early-onset Parkinsonism with dementia (Chartier-Harlin et aJ.
2(04), whereas other studies reported the importance of the duplication of
amyloid precursor protein (APP) in susceptibility to Alzheimer's disease
(Sleegers et aJ. 2006; McNaughton et aJ. 2012).
There have been several reported examples of genomic copy number
variation, either involving Simple deletion and duplication (diallelic) of a gene
or more complex copy number involving multiple copies of genomic segments
(multiallelic) encompassing several genes, parts of genes or intronic regions
(Wain et aJ. 2(09). One of such multiallelic copy number variant is the human
j3-defensin locus at chromosome 8p23.1. This locus is highly polymorphic in
copy number and is a fascinating example of structural variation in the human
genome. However, not many studies have reported the variation at this locus,
although considering the antimicrobial activity (Ganz 2(03) and the anti-HIV
properties (Klotman and Chang 2006) of ~-defensins, a growing interest can be
expected in the way the ~-defensin CNV is associated with some immune
diseases, such as psoriasis (Hollox et aJ. 2008b). The study of j3-defensin copy
number variation and the phenotypic relevance of this variation has been the
focus of my project and will be explored in more detail in further sections.
1.1.3.2 Human 8p23.1locus
The human 8p23.1 locus, located towards the telomeric end of
chromosome 8p has a complex genomic structural organization showing
several types of structural variation. The region spans approximately 6.5 Mb
and contains two large segmental duplications (SOs), the distal repeat (REPO)
and the proximal repeat (REPP), about 5 Mb apart, sharing a 95-97%sequence
identity (Giglio et al. 2(01). More than 50 different genes have been found at
8p23.1, including defensin genes, olfactory receptor genes and FAM90A cluster
genes (Figure 2). These gene clusters are copy number variable and are located
in the REPO but no defensin genes were reported at REPP until 2009 (Hollox
et aJ. 2003; Aldred et aJ. 2005; Bosch et aJ. 2008). The genome assembly shows
defensin genes, which include alpha (n), beta (~) and theta (9) defensins at
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REPD. However, in 2009, Abu Bakar et al. mapped a ~--defensingenomic locus
to REPP, which is not annotated on the genome assembly, through the analysis
of crossover breakpoints in CEPH segregation data (Abu Bakar et al. 2009). The
~efensin cluster at both locations is highly polymorphic in copy number and
varies independently from the other gene clusters (Groth et al. 2008).
SUlI. 2 Mbf---------------l
Chr8: I 7$1 .... ' e ...... 1 es ..... , 988 .... 1 gs ..... , 18eau • • 1 1858e ... , 11 ...... ' 11'15..... 112 ...... 1 12SU'''1
Chro.)so.. Blinds LOC.l1ZflJ bV "ISH """.,;ng el~s
REPD 80>23, , REPP
QEf"1"I61
D£,.",. I
L~~~~ I ....o='....'~..,.,~.:,__~
LOC72e3S8 I
N""1I:5S7H
"""1\3
""'"""t3t294
,. '''331
Ot781{j191
CU,
[)up !,Cflt" tMS 0' ) lee. 811• • • of Hon-It~.t"HAskl'd Sequenc.
I I (
~~.....,=~JlC11C a.n.S~=1on fIt.~ Ikt i~i', c,::s",'jI('!I?r N'K1XK~V. ~di:. Z '8SC I
"'HIIISt H $91 H fl:fIII C6orfl1!: kK ~ DUet • • LOf«", I
IEItI 1 I Tf'tI(S ....... ,,, &C 137SC st....... Zl'P7MO .. LONftf" 1
"'''''11t38 t TN~' ~ n ,. HTt«9, Gf'ITI'\.' CIUSS I
"'''''1ft'3e f 8CM2.9 1..It"4Q93'i1I foIT~9' CflllTlH H Dffl'SS3',1"'"I flt38 I RLe32~.,s WQ'i~1 • C~74'i666 ~IL21 ~3'II''''' M
ec8, '$78 I CS"26E·S78 ft.I"'lLI ~ C!"749668 f ~IL2. M.39.,8_
C8oM'74 ft I"Ifott'M:U..21 Hl!IL21 rfllM660t
CEtOrfH.. TOti "'Df"'T1 • P'fI'Ift8t.81 I
SOX,. I ec.~ 46 fl'OfFf 1 t I"'flw.a«u J
ec,,435~3!of TO.,. fl'DfI"Tl. f"N1&681 ~
"1 lH TOHI ~DfI"Tl. "~11
,..ut'':!.-f cearfl ....... f"OP"TlI 'NtU81'
ilWr:::t9~ is Ce.ot-f12" ClS8, f....-.s6fU,
''''''6'". CT.e. ,_, t
DC~S1i2. "'fIW'1167". eTse. "~81 I
N<~'7256. eLk 1'Il..39.183 ..
GftIT"' .. "., I"'f'WIf86&1 J
C8Or'f" 49 rl'tMUe I I
"'OfT) t BC.37934 ...
else • ~ 1029982 ~
eTse. f'I<~vel""'"
CT ~. Loce.493es .....
eTse. ~<;7 .. 1'S86
eTse. CfI!59S61t
crse ] 1\)(,'''' ."
crse LOC6"9311J
DUDI~'I
OE:'Bl36\
OE:l"'el~
Jill. '''~f'.~1
lOC3 ''''
,-P\Ma6el I
"-"1'1e6Dl J
""10"" Ifl"t\M&6el t
'_'1
''''''''611'1
"''''H86bl I
I"'~ll
1"'N186eJ I
FNt8681 I
, t-a85,2S
Figure 2: Chromosome Sp23.l locus spanning approximately 6.5 Mb, showing two pairs of
segmental duplications, REPD Ueft) and REPP (right) represented by grey and
orange shading. Genes annotated in the UCSC Hwnan Genome Browser are shown
relative to their position in the chromosome ([3-defensin genes are highlighted). At
the REPD site two [3-defensin clusters are shown in inverted orientation relative to
one another (Figure from UCSC Genome Browser on Human March 2006
(NCBI36jhglS) assembly).
SDs can mediate frequent chromosomal rearrangements leading to the
formation of several types of structural variants, such as copy number variation
and inversion polymorphisms by homologous unequal recombination between
the two duplicated regions at 8p (Giglio et al. 2002; Sugawara et al. 2003).
Although this suggests the importance of SDs in the formation of the
rearrangements observed at 8p23.1, the genome assembly sequence is still
incomplete for these loci.
Allelic recombination between the two distinct genomic locations of
~-defensins was demonstrated to be the main mechanism for ~-defensin copy
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number formation, showing a germ-line rate of copy number change of
approximately 0.7%per gamete (Abu Bakar et al. 2009). At the end points of
the p-defensin CNV repeat, spanning the region between REPD and REPP,
a large inversion polymorphism (-4.7 Mb) was first reported by Giglio et al.
(2001). This polymorphism is present in 25% of Europeans and
approximately 33% of Japanese are heterozygous for the inversion
polymorphism (Giglio et al. 2001; Giglio et al. 2002). Moreover, higher
inversion frequencies were estimated in CEPH families (60%) (Chen et al.
2006a) and in three HapMap populations (42.6%), which showed higher
frequencies, between 50%and 60010in Europeans and Africans but considerably
lower frequency in ASians, only 12.5% (Antonacci et al. 2009). Taking into
consideration the relative high frequency of the inverted orientation it was
suggested that the human reference genome actually represents the minor allelic
configuration, corresponding to the non-inverted orientation (Chen et al. 2006a).
Analysis of multiallelic length polymorphisms at the 8p23.1 locus provided
evidence that the inverted state of this polymorphism has arisen more than
once (Abu Bakar et al. 2009).The inversion polymorphism will influence the
type of rearrangements generated when the two loci recombine, which will be
dependent on the orientation status of the sequence spanning the interval
between REPD and REPP. Therefore, the inversion will have an impact on the
allelic recombination between the two loci and on the de novo generation of copy
number haplotypes. The two types of structural variation seem to be closely
associated and both might be involved in the formation of copy number variation
during recombination.
The presence of SDs seems to be the substrate for the formation of
intrachromosomal rearrangements involving chromosome 8p by unequal
recombination between REPD and REPP, leading to the formation of different
chromosomal rearrangements, including the common inversion polymorphism
(Giglio et al. 2002; Sugawara et al. 2003).
1.1.3.3 Mechanisms of copy number formation
Increasing evidence shows that CNV s often occur in regions of segmental
duplications or flanked by segmental duplications (Iafrate et al. 2004; Sharp et
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al. 2005; Tuzun et al. 2005). Several studies suggest that segmental duplications
are hot-spots for chromosomal rearrangements, since segmental duplications
increase the chance of non-allelic homologous recombination (NAHR)(Figure
3A) (Lupski 1998; Sharp et al. 2006). Segmental duplications by definition
share more than 90% sequence similarity and cover at least 1 kb. They can
arise either by tandem repeats of a particular DNA fragment or through a
duplicative transposition-like process that results in the copying of a DNA
segment and its transposition from one location to another (Eichler 2001).
During NAHR, highly similar duplicated sequences on the same
chromosome can easily recombine and generate rearrangements, such as copy
number changes of the segmental duplicated regions (Inoue and Lupski 2002).
The recombination of segmental duplicates can occur between paralogous
sequence on the same chromatid (which do not lead to deletions or
duplications), between sister chromatids or between homologous
chromosomes. Repeats that are further apart are also less likely to experience
NAHR than closer repeats. When duplicated sequences are in direct
orientation, they can result in deletions or duplications, but when occurring in
inverted orientation, recombination will lead to inversions (Tuzun et al. 2005;
Turner et al. 2008). A comparison of the de novo mutation rate of deletions
against duplications in the male germline reported a higher rate of deletion
generation (Turner et al. 2008). However, these observations are not
concordant with the fact that deletions and duplications are present at similar
frequency in the genome. Such facts might support the hypothesis that
deletions and duplications are subjected to different selective pressures,
resulting in directional selection favouring duplications (Freeman et al. 2006).
Although extensively described as a possible origin of CNV, segmental
duplications overlap just 24% of the total copy number variants and therefore
cannot account for the formation of several human CNV regions (Redon et al.
2006). Another possible mechanism of CNV formation appears to be related to
non-homology based mutational mechanisms, which involve non-f DNA
structures. Such DNA structures can promote chromosomal rearrangements
and seem to be the dominant mechanism among smaller copy repeats (Bacolla
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and Wells 2(04). Nevertheless, little evidence of the real consequences of these
events in the construction of new copy number variants has been reported.
More recently other mechanisms have been proposed to explain part of
the non-recurrent genomic rearrangements including copy number variation:
non-homologous end joining (NHEJ) (Figure 3B) and the Fork stalling and
template switchinglmicrohomology-mediated break induced replication
(FoSTeSjMMBIR) (Figure 3C). NHEJ is a frequent mechanism used by human
cells to repair DNA double-stranded breaks (DSB), involving the modification
and rejoining of the two DNA break ends. In order to repair ends,
modification of the ends needs to occur to make them compatible and
ligatable, which can involve addition or deletion of bases of the segment
between the two DSBs. Conversely to NAHR, this mechanism does not require
the presence of LCRs or segments sharing high sequence similarity (Lieber et
al. 2003; Gu et al. 2(08).
A replication error-based mechanism was proposed to explain the origin of
some complex non-recurrent rearrangements (e.g. deletions and/or duplications
interrupted by either normal or triplicated genomic segments), such as the ones
reported in the dosage-sensitive proteolipid protein 1 (PLPl) gene that cause
Pelizaeus-Merzbacher disease (PMD), which have been difficult to explain by
either NAHR or NHEJ recombination mechanisms (Lee et al. 2007; Zhang et al.
200gb). The FoSTeSjMMBIR event occurs during DNA replication. When
replication fork stall, the 3' primer end of a DNA strand can change templates to
a ssDNA template in a nearby replication fork, depending of microhomology (4-
15 bp) at the 3' end, "priming" and DNA synthesis reinitiation (Lee et al. 2(07).
Depending on the location of the new replication fork, upstream or downstream
of the original replication fork, a deletion or duplication will occur. Similarly, the
orientation of the incorporated fragment, direct or inverted, is dependent on
whether it is the lagging or leading strand, respectively, that is used as a template
in the new replication fork (Hastings et a1. 200ga). DNA replication-based
mechanism of FoSTeSjMMBIR may be a important mechanism for generating
structural variation, namely non-recurrent CNV s and complex genomic
rearrangements in the human genome (Hastings et a1. 200gb; Zhang et al. 2009a).
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Figure 3: Comparison of three major mechanisms underlying human genomic rearrangements
and CNV formation. A) Intrachromatid NAHR (non-allelic homologous
recombination) event between two directly orientated low copy repeats (LCRs)
sharing high homology (-97%) (1), represented by grey and blue rectangles.
Alignment and recombination at non-allelic positions (2) leads to deletion or
duplication of part of the LCRs and deletion of the segment between them (3).
B) NHEJ (non-homologous end joining) event can occur between two sequences
with no homology (1) (represented by grey and blue rectangles) when double
stranded DNA breaks are created (2). The DSBs are repaired via NHEJ through a
mechanism that includes modification of the ends to make them compatible for final
ligation, resulting in the deletion or insertion of few bases at the DNA segment that
separates the two sequences (3). C) FoSTeS (Fork staling and template switching)
event only requires microhomology (2 to 5 base pairs) between the genomic
fragments (1) (represented by grey, blue and green rectangles, with open triangles
representing the microhomology sites between the grey and blue sequences and the
filled triangles bearing sites for blue and green sequences). The replication forks of
each sequence are shown in the same colour. The leading strand (2) (in the top grey
replication fork) invades the right site replication fork (top blue replication fork),
followed by DNA synthesis (dotted lines) using the new replication fork as a
template. This event can happen several times, as illustrated, causing deletion of the
two fragments flanked by each pair of microhomology sites (3). Juxtaposition of
genomic sequences from multiple distinct regions leads to complex rearrangements.
Figure adapted from Gu et al. (2008).
Scientific knowledge up to now indicates NAHR as the major mechanism
responsible for the origin of large structural variation in the human genome
(-48%) (Kidd et al. 2008), but conversely events mediated by NAHR are
relatively rare (-14%) (Korbel et aJ. 2007). This discrepancy may be due to
technical limitations of next-generation sequencing, which is a relatively poor
technique for detecting structural variants within duplication regions of the
genome (Kidd et al. 2008). Although NAHR has been described as the
prevalent mechanism responsible for the formation of recurrent and some non-
recurrent rearrangements, other non-recurrent rearrangements have been
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proposed to occur due to NHEJ or by FoSTeS. So, the mechanisms responsible
for copy number formation are still relatively unclear and further investigation is
essential to understand the formation of de novo copy number mutations.
1.1.3.4 Methods to measure copy number variation
Copy number variation is an important and frequent type of structural
variation in the human genome, which can contribute to phenotypic variation
and even lead to disease (Aitman et a1. 2006; McCarroll and Altshuler 2007; de
Smith et a1. 2008; Hollox et a1. 2oo8b). Such characteristics increased the
interest in human copy number variation, leading to the establishment of
diverse and distinct quantitative methodologies to measure copy number. Such
techniques allow the detection and cataloguing of human copy number
variants but are also used to assess the association of copy number variants
with biological function, recent human evolution and common and complex
diseases (de Smith et a1. 2008).
Until recently, SNPs were thought to account for the majority of genomic
Variability observed in the human genome but recent research showed that
CNV are as common, although their discovery has been limited by the
technology available, which was especially designed for SNP genotypmg
(McCarroll and Altshuler 2007). Accurate typing of copy number is difficult
and more challenging than SNP genotyping, since it requires the ability to
quantitatively distinguish different copies of the same repeat relative to the rest
of the genome. As a consequence, copy number techniques should be precise
and accurate to achieve confident and reliable measurements (McCarroll and
Altshuler 2007). Without a high level of accuracy and precision, differences
between cases and controls can be biased and result in false positive
associations (Clayton et a1. 2005).
Among the techniques that have been applied to measure gene copy
number the more frequent typing methods are: Quantitative real-time PCR,
Multiplex Ligation-dependent Probe Amplification (MLPA), array
Comparative Genome Hybridization (array-CGH), SNP genotyping arrays and
PRT (Paralogue ratio test). Apart from those, Multiplex Ligation dependent
Genome Amplification (MLGA), Multiplex Amplifiable Probe Hybridization
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(MAPH) and more recently, molecular combing have also been used to
measure copy number but not extensively in association studies.
Quantitative real-time PCR describes the amplification and simultaneous
quantification of a targeted DNA molecule during the early phases of the PCR
reaction. It is the most popular method to measure copy number variation and
has been used in several copy number variable regions including the
rHJefensin region (Unzmeier and Ganz 2005; Chen et al. 2006b; Fellermann et
al. 2006; Bentley et al. 2010). For copy number determination, usually two pairs
of primers are used to amplify the target locus and a Single copy of a reference
locus (for example the human serum albumin, ALB gene). Additionally in
some studies, a calibrator plasmid, containing a copy of each of the reference
and target gene, and a control plasmid, incorporating 2 copies of the target
gene and one copy of the reference gene, are amplified simultaneously in
order to calibrate the experiment. The detection and quantification of PCR
products occurs during the exponential phase by fluorescence emission
collected in a laser detector during the course of the reaction (Heid et al. 1996;
Barrois et al. 2004; Chen et al. 2006b). Quantification can be achieved through
two common methods that either use fluorescent dyes (e.g. SYBR Green Dye)
that intercalates with the double-strand DNA (Dall'Ozzo et al. 2003; Linzmeier
and Ganz 2005; Altman et al. 2006; Fellermann et al. 2006) or modified DNA
oligonucleotide probes (e.g. TaqMan Probe) that fluoresce after hybridization
with complementary DNA (Heid et al. 1996; Bentley et al. 2010). The analysis
of the results can be carried out using the standard curve method, comparative
threshold cycle or by melt analysis.
Real-Time PCR has been used in different copy number variable regions,
such as BRCAl (Barrois et al. 2004), FCGR3 (Dall'Ozzo et al. 2003; Altman et
al. 2006) and CCL3Ll (Gonzalez et al. 2(05). At chromosome 8p23, Linzmeier
and Ganz (2005) used quantitative real-time PCR to analyse the independent
copy number variation of a- and Iklefensin genes. They successfully addressed
the question of independent variation between a- and Iklefensin but just 24
samples were typed, giving only weak information about the reliability of this
method to accurately measure copy number variation (Linzmeier and Ganz
2(05). In a study developed by Chen et a1. (Chen et a1. 2006b), the copy
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number polymorphisms in human ~-defensin genes were screened using a
modified quantitative real-time PCR. Again, the study did not include a large
set of samples (44 samples) and did not compare the accuracy of the method
for high copy numbers, such as 8, 9 and 10 but also, no analysis of raw data
was shown (Chen et al. 2006b). Quantitative real-time PCR (TaqMan assay)
was also used in association studies, to evaluate the correlation between
~efensin copy number and Crohn's disease (CD) (Fellermann et al. 2006;
Bentley et al. 2010). Although these studies assessed the ~efensin copy
number in a considerably larger cohort than previous studies, they do not
report the unrounded copy number values and copy numbers were generally
allocated into three main copy number bins, corresponding to lower than,
equal to or higher than 4 copies. The accuracy of quantitative real-time PCR
was not extensively tested in any of the studies above for high copy numbers, a
crucial point in measuring the variable ~efensin cluster that can vary up to 12
copies. Nevertheless, there are some advantages in performing real-time PCR:
the ability to quantify the PCR products during the exponential phase and the
reduced probability of contamination when compared with other
methodologies (Heid et al. 1996). The method itself relies on the use of
plasmids containing one copy each of the target gene and the reference gene,
as a control; however this does not exactly represent the real human genome.
Instead, real reference samples should be applied to calibrate the experiment.
Furthermore, using a multiplex PCR that uses a different pair of primers to
amplify the test and reference locus will reduce the overall specificity and
accuracy of the method.
In a separate group, there are the methods based on multiplex targeted
copy-number analysis, such as Multiplex ligation-dependent probe
amplification (MLPA) and Multiplex ligation dependent genome amplification
(MLGA). MLPA involves the hybridization and ligation of two half-probes,
followed by quantitative amplification of the ligated products, requiring just
20ng of genomic DNA (Schouten et al. 2(02). MLPA has been largely applied
to detect common deletions and duplications in genes with clinical importance,
such as the genes for Duchenne muscular dystrophy (DMD), Becker muscular
dystrophy (BMD) and the low-density lipoprotein (LDL) receptor (Holla et aJ.
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2005; Janssen et al. 2005). Is also a rapid and effective assay for routine
diagnostics of aneuploidies and trisomies (Slater et al. 2003; Herodez et al.
2005). Many studies corroborate their precision to detect common deletions
and duplications, but these methods were never used to measure high copy
number variants, as 6, 7, 8 and 9 copies of a gene or variable region.
MAPH (Multiplex amplifiable probe hybridization) is another method
used in CNV measurement. This approach relies on sequence-specific probe
hybridization to genomic DNA, followed by amplification of the hybridized
probes and semi-quantitative analysis of the resulting PCR products (Armour et
al. 2000). MAPH probes hybridize with genomic DNA fixed to a membrane,
instead of genomic DNA free in solution, as occurs in MLPA and MLGA
(Figure 4). The probes are created from any sequence, except highly copy
number variants as Alus, CC-rich or GGpoor regions, by cloning target
sequences into a plasmid vector, which are then amplified with specific vector
primers. The membranes are intenstvely washed to remove the unbound
probes, while the bound probes are separated from the membrane and
amplified with universal primers. After separation by capillary electrophoresis,
the PCR products are quantified in terms of peak area or height. In this
method the amount of amplified product is directly proportional to the copy
number in the genomic DNA (Armour et al. 2000; Armour et al. 2002; Hollox
et al. 2002a; Hollox et al. 2oo2b). MAPH has been successfully applied to
measure (1- and l3-defensin copy variable genes, which show a large range of
variation up to 12 copies. In different studies, MAPH was combined with other
methods to either clarify the genomic organization of defensin clusters or to
characterize the copy number variation at such loci (Hollox et al. 2003; Aldred
et al. 2(05). When applied in association studies, the copy number reported
from each probe was equivalent and the method showed comparable
accuracy to other methodologies (Hollox et al. 2005; Hollox et al. 2oo8b).
Additionally, MAPH has been used to detect BRCAl duplications in breast and
ovarian cancer (Rad et al. 2001), subtelomeric abnormalities related with
idiopathic mental retardation in children (Sismani et a1. 2001) and a large
deletion in IBX5 gene that causes the Holt-Oram syndrome (Akrami et al. 2001).
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Figure 4: General principle of Multiplex Amplifiable Probe Hybridization (MAPH). Test
DNA is denatured and hybridised with a set of amplifiable probes, each recognising
a unique region in the genome. After intensive washing, the bound probes are
retained in the membrane and amplified using a common primer pair, being
quantified after capillary electrophoresis. Figure taken from Armour et al. (2000).
Furthermore, it was also used to screen for deletions in the Duchenne muscular
dystrophy (DMD) gene (White et al. 2002) and to screen both deletions and
duplications in PMP22 gene, which can be involved in hereditary neuropathy
with liability to pressure palsies (HNPP) and Charcot-Marie-Tooth disease type
lA (CMT1A), respectively (Akrami et al. 2003). MAPH is a reliable and
reproducible method to measure and detect copy number variants, even high
copy number states, at multiple loci (-110) Simultaneously and has been used
for screening cancer genes (Tyson et al. 2009; Tyson et al. 2010). Conversely,
this assay is very time consuming, due to the careful construction of a set of
probes and the labour involved in the washing step and separation of the
bound probes from the membrane. To perform this assay about Iug of
genomic DNA is necessary, an amount that even if it is not prohibitive, is much
higher than employed by other techniques nowadays, compromising its
applicability in large scale (Armour et al. 2002; Hollox et al. 2002a).
Copy number variation can also be identified using DNA micro arrays by
Comparative Genome Hybridization, a method based on DNA arrays.
Essentially, test and reference DNA are differentially labelled and hybridized
together to the array previously spotted with specific DNA fragments (bacterial
artificial chromosome - BAC, eDNA, PCR fragments or oligonucleotides).
After hybridization, the resultant fluorescent ratio between the two DNA
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samples is determined revealing genomic differences, such as copy number
variants (Solinas-Toldo et aJ. 1997; Pinkel et al. 1998). Initially developed from
fluorescent in situ hybridization (FISH) to compare the gene expression of
multiple targets in a single experiment (Kallioniemi et al. 1996), array-CGH has
become a common method to study genome-wide copy-number changes in the
human genome (Sharp et aJ. 2005; Redon et al. 2006; Wong et al. 2(07). With
the growing interest in CNV, a number of studies have identified new
variations using this technology. Studying normal human populations, Iafrate et
al. (2004) identified 255 loci, among 55 individuals, containing genomic
imbalances, while Sebat et al. (2004) found 76 copy number polymorphisms
between 20 individuals. In a recent study by Barber et al. (2007), a duplication
of 550 kb at 8p23.l was revealed by array CGH, which has been associated
with a characteristic facial phenotype including a prominent forehead and
arched eyebrows. Array-CGH is a powerful method to screen the entire
genome in a single experiment with complete coverage; however, in most
implementations it has low resolution (down to -50 kb for BAC array-CGH)
and cannot define efficiently the rearrangement breakpoints (Sharp et aJ. 2(06).
SNP genotyping arrays, Originally developed for determining single base
polymorphisms, can be used to measure genomic copy number by
comparative hybridization intensities of genomic DNA to the oligonucleotide
probes. For CNV detection, intensity ratios with respect to a reference genome
are examined, allowing the determination of the relative number of copies per
locus (Redon et al. 2006; Carter 2007; McCarroll et al. 2(08). SNP platforms
use probes that are specific to detect Single base differences either by single-
base extension methods (lliumina) or differential hybridization (Affymetrix)
(Alkan et aJ. 2011). Both platforms show a good resolution, between 2 kb and
2.5 kb, but probes are not uniformly distributed across the genome with very
poor representation in regions of segmental duplications and copy number
variation (Carter 2(07). Moreover, these platforms are mainly able to identify
simple deletion and duplication polymorphisms, but are very poor in detecting
high copy number variants. Most multiallelic copy number variants are not
tagged by SNPs because these regions are only sparsely covered by unique
SNPs, and the use of probes with SNPs compromise the use of CGH for
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detecting and quantifying copy number. The ability of array-CGH to detect
copy number changes depends greatly on signal-to-noise ratio of hybridization of
probes. It is important, particularly for CNV detection, that measurement
variance in hybridization methods, which lead to false positive and false negative
results are accurately assed. However, cross-hybridization of probes to different
loci frequently leads to incorrectly called regions as eNVs (Carter 2(07).
Molecular combing (MC) is a method for single DNA molecule analysis
which allows the direct visualization and size measurement of the relevant loci
on numerous individual molecules at 1 kb resolution (Lebofsky and Bensimon
2003). Essentially, an array of combed single DNA molecules is prepared by
stretching molecules attached by their extremities to a silanised glass surface
with a receding air-water meniscus. Followed by fluorescent hybridisation on
combed DNA, genomic probe position can be directly visualised, making
possible the construction of physical maps and detection of micro-
rearrangements (Lebofsky and Bensimon 2(03). This method has not been
extensively used in copy number measurement but has proved very useful to
investigate the allelic combinations associated with Facioscapulohumeral
dystrophy disease (FSHD) (Nguyen et al. 2011). FSHD is associated with a
reduction in the copy number of the D4Z4 repeat array at subtelomeric region
of 4q35 and a particular genomic organization different from its chromosomal
counterpart at 10q26. Accurate discrimination and description of the 4qter and
lOqter D4Z4 repeat arrays were detectable by Me, which is extremely important
in FSHD diagnosis (Nguyen et al. 2011). MC can also be applied to other copy-
number-variants or repeat expansion arrays associated with human diseases.
Paralogue ratio test is a newly developed method for copy number
measurement. PRT is a comparative PeR-based method, where the same
primer pair amplifies test and reference loci (Deutsch et al. 2004; Armour et al.
2(07). This important technical detail, which clearly distinguishes PRT from
multiplex PeR-based assays (e.g. real-time PCR) is the amplification of test and
reference loci at very similar kinetic properties using a single pair of primers.
This reduces the reproducible differences commonly observed in multiplex
PCR, when test and reference loci are amplified by 2 pairs of primers.
Although PRT is limited by the precise design of primer sequences that
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exclusively match test and reference loci, many copy number variable regions
have been shown to have these characteristics (Armour et a1. 2007). Moreover,
the precision and accuracy of PRT are equivalent to MLPA and MAPH, with
the advantage of requiring smaller amounts of genomic DNA (10-20ng)
(Armour et al. 2(07). For these reasons, PRT allows high-throughput analysis of
copy number variation and has been successfully applied to measure different
CNVs, such as the J3-defensingenes (Armour et a1. 2007; Hollox et a1. 2008b;
Aldhous et a1. 2010), n-defensins genes (DEFA1/DEFA3J(Fayeza Khan,
personal communication) both at 8p23.1, CCL3Ll/CClALl copy number at
17q12 (Walker et a1. 2(09) and the immunoglobulin-receptor genes FCGR3A
and FCGR3B on chromosome lq23.3 (Hollox et a1. 2(09).
The knowledge of copy number variants and their importance in the risk
of common human diseases led to the development of several technologies to
measure copy number of variable regions. Analytical methods that use either
global or targeted approaches have been used to address the copy number, but
many of them show characteristics that either compromise the accuracy or the
applicability on large scale, due to the amount of genomic DNA required or
the cost involved. The I3-defensin cluster is an interesting copy number variable
repeat region, showing high copy number states, with a complex genomic
architecture (Hollo x et a1. 2(03). Many of the methods described do not
appear to be accurate for measuring such high copy numbers. On the other
hand, the methods with improved accuracy at this level are very difficult to
perform on a large-scale or the cost can compromise their applicability. For
these reasons, the development of an improved technology to measure the
copy number, at this or other loci highly polymorphic in gene number, will be
essential in this field.
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The innate immune response in plants and animals is mediated by
"natural antibiotic peptides", These peptides are present among eukaryotes,
including mammals, birds, amphibians, insects, plants and protozoa (Gabay
1994; Ganz 2(03). In mammals, these peptide antibiotics form a large family of
small cationic antimicrobial peptides, with no more than 50 amino acids,
generally known as defensins. The defensins have an important role in innate
immunity, acting against microbial invasion of several pathogens. On the other
hand by Signalling to chemokine receptors on dendritic cells and T-cells, they
can also contribute to the regulation of host adaptive immunity (Ganz 1999a;
Yang et al. 1999; Yang et al. 2002). Defensins are produced by cells and tissues
that are involved in host defence against microbial infection, mainly leukocytes
and mucosal epithelial cells, which are active against a range of bacteria,
including Gram-positive and Gram-negative species, virus and fungal
pathogens (Ganz 2003; KIotman and Chang 2(06).
The defensins are small pep tides of around 3.5.{j kDa with characteristic
l3-sheet structures. Six cysteine residues stabilized by three intramolecular
disulphide bonds characterize their structure. According to the spatial
arrangement of the disulfide bridges between the cysteine residues, the
mammalian defensin family is divided into three subfamilies, the alpha, beta
and theta-defensins. In n-defensins the six cysteine residues are linked in the 1-
6, 2-4 and 3-5 pattern (Cysl-Cys6, Cys2-Cys4 and Cys3-Cys5) while in
l3-defensins, the linkages are between the 1-5, 2-4 and 3.{j (Cysl-Cys6, Cys2-
Cys4 and Cys3-Cys5) residues. In the 8-defensins, due to its circular structure,
the disulphide pairing has a distinct configuration from the u- and ~-defensins,
with a I-S, 2-5 and 3-4 (Cysl-Cys6, Cys2-Cys5 and Cys3-Cys4) pattern (Tang et
al. 1999; Ganz 2003; KIotman and Chang 2006).
In humans, DEF A and DEFB genes, mainly located in a cluster on
chromosome 8p23.l locus, encode the n- and ~-defensins respectively.
Additionally, they can also be found in a cluster on chromosome 6 (6pI2) and
in two clusters on chromosome 20; 2Op13 and 20qll.l (Unzmeier et al. 1999;
Ganz 2003; Taudien et al. 2004). The 9-defensin genes (DEFf) are only present
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in humans as non-functional copies (pseudogenes), which have been identified on
chromosome 8p23 and chromosome 1 (Nguyen et al. 2003; Carsten Munk 2(04).
1.2.1 Human defensins: alpha, beta and theta
Five different genes encode the u-defensins, DEFAl to DEFA6. Alpha-
defensins encoded by DEFAl to DEFA4 genes are constitutively contained in
neutrophil granules (Ganz et al. 1985; Linzmeier et al. 1993), while DEFA5 and
DEFA6 are expressed in Paneth cells of the small intestine (Ghosh et a1. 2002),
(fable I). The majority of these genes are located in a cluster at the telomeric
end of chromosome 8p23.l (Aldred et a1. 2(05). DEFAl and DEFA3 encode
different peptides, human neutrophil-derived alpha-defensin 1 (HNP-I) and 3
(HNP-3), respectively, which differ just by the first (N-terminal) amino acid of
the mature peptide due to a single-nucleotide polymorphism, C3400A (Ganz
and Lehrer 1995). This polymorphism is human specific suggesting a recent
origin to the human lineage (Aldred et al. 2005). The HNP-2 peptide is highly
homologous to HNP-I and -3, missing only the first residue, but no gene has
been identified for this peptide. It has been suggested that HNP-2 is a proteolytic
product of one or both of DEFAI and DEFA3 peptides (Ganz 2003; Linzmeier
and Ganz 2(05).
Alpha-defensins are synthesized as prepropeptides of 90-100 amino-acid
precursor sequences composed of an amino (N)-terminal signal sequence (-19
amino acids), an anionic propiece (-45 amino acids) and a carboxy (C)-terminal
mature cationic defensin (-30 amino acids), after which translational proteolytic
cleavage produces the mature peptide, including the HNP-2 [Harwig et al. 1992).
Human n-defensin-I, -2, -3 and -4 are synthesized by neutrophil precursor cells,
promyelocytes, in the bone marrow and stored in neutrophil granules before
mature neutrophils are released into the blood, where they may migrate to sites
of inflammation (Ganz 2(03). In contrast, for human a-defensin-5 (HD5) the
maturation process takes place outside the cell (Ghosh et al. 2002).
DEFAl (HNP-I) and DEFA2 (HNP-2) show a strong antimicrobial activity
against Candida albicans (Chertov et al., 1996), as well as Gram-negative
bacteria, Enterobacter aerogenes and Escherichia coli, and Gram-positive
bacteria, Staphylococcus aureus and Bacillus cereus (Ericksen et al., 2(05).
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Additionally, DEFA1 (HNP-l) was also described to have a strong anti-HIV-l
activity with a direct effect on the virus (Chang et al., 2004). Apart from
humans, u-defensins have been found in different mammals, including
non-human primates, Rhesus macaque and some rodent species, in which they
participate in similar functions to those described for humans (Ganz 2003).
Table 1: Summary of defensins present in the Human genome.
Human Chromosomal
Gene symbol Expression Functiondefensins location location
DEFAI and 3 Neutrophils Antimicrobial
granules activity against
a-defensin 8p23.l Gram-positive
and Gram-
DEFA4, 5 and 6 Paneth cells negative
bacteria
DEFB1,4, 103-107, Antimicrobial
8p22-p23 109, 130, 135-137 and
Mainly in activity againstSPAGll
epithelial tissues Gram-positive
and Gram-
6p12.3 DEFB110, 112-114 for eg.: negative
and 134 keratinocytes;
respiratory and bacteria,
~-defensin 20ql1.21 DEFB115,116,118-124 gastrointestinal cytokine-like
tract; urogenital properties and
and respiratory pro-
2Op13 DEFBI25-129,132 system; amniotic
inflammatory
fluid activity(particularly
DEFB103)
8p23.1 Pseudogenes: Bone marrow, Unknown:DEFTIP,IPl and IP2 inactivated
8-defensin spleen, thymus, pep tides due totestis and skeletal
lq23.1 Pseudogene: DEDD muscle a premature
stop codon
Human I3-defensins are encoded by DEFB genes, mainly located on
chromosome 8p23-p22, that include thirteen different ~-defensin genes, DEFB1,
DEFB103-107, DEFB109, DEFB4, DEFB13o, 135-137 and SPAGll (HE2jEP2).
Seven of these genes (DEFB103-107, DEFB4 and SPAG11) are clustered in a
repeat unit at chromosome 8p23.1, which is highly polymorphic in copy
number (Hollox et al. 2003; Groth et al. 2008; Abu Bakar et al. 2009). Three
other ~-defensin gene clusters have been identified by in silica analysis, one at
chromosome 6p12.3 (DEFE11O, 112-114 and DEFB134) and two at chromosome
20, 20ql1.21 (DEFBl15, 116, 118-124) and 20p13 (DEFB125129, 132) but they
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do not appear to exhibit copy number variation (Schutte et al. 2002; Rodriguez-
Jimenez et al. 2003; Hollox and Armour 2(08), (Table 1). To date, more than 30
j3-defensin genes have been identified that are mainly expressed in epithelial
tissues, including the skin and respiratory tract (Schutte and McCray 2002;
Schutte et al. 2(02).
The genomic structure of the majority of (3-defensin genes is composed of
two exons separated by one intron of variable length, except for the DEFBI05
gene, which has an extra exon and intron. The first exon of j3-defensin genes
includes the 5' untranslated region and encodes the Signal and pro-sequence,
whereas the second exon encodes the mature six-cysteine defensin peptide,
which normally has between 38 and 42 amino acids (White et al. 1995; Ganz
2003; Lehrer 2(04). For DEFB1, the first exon encodes both the pre-peptide
and the mature peptide (Liu et al. 1997).
Tracheal antimicrobial peptide (TAP) was the first member of the
~-defensin family to be described in mammals by Diamond et al. (1991). This
peptide was isolated from the bovine tracheal mucosa and shows a broad-
spectrum of antimicrobial activity similar to other ~-defensins, namely the
human ~-defensin 2 (human homologue) (Diamond et al. 1991). In humans,
hBD-l (DEFBl gene) was the first (3-defensin to be identified and isolated from
human plasma (Bensch et al. 1995). DEFBI shows high homology with TAP
and is predominantly expressed in leukocytes and epithelial cells from the
respiratory tract (Bensch et al. 1995; Fulton et al. 1997; Ali et al. 2001). Apart
from its antimicrobial activity, DEFBI is a potential tumor suppressor gene for
urological cancers, inducing apoptosis of renal cancer cells (Sun et al. 2006). A
second human j3-defensin, hBD-2, encoded by DEFB4, was initially isolated
from psoriatic lesions. hBD-2 is expressed in skin, mainly in keratinocytes, and
epithelia of the airway system, such as respiratory tract, gastrointestinal tract
and urogenital system, where it contributes to its antimicrobial defence (Harder
et al. 1997b). Nevertheless, hBD-2has been identified in other sites, such as in
the amniotic fluid, which accounts for the host defence against microorganisms
within the amniotic cavity (Soto et al. 2007). Another antimicrobial peptide,
human ~efensin-3, hBD-3 (DEFB103). was also isolated from human psoriatic
scales and cloned from keratinocytes. hBD-3 is expressed in different tissues
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including skin, tonsils and lung (Harder et al. 2001). hBD-2 antimicrobial
activity is especially directed against Gram-negative bacteria such as
Escherichia coli and Pseudomonas seruginosa (Harder et al. 1997a) but other
j3-defensins, as hBD-3, can also show strong antimicrobial activity for Gram-
positive bacteria, such as Staphylococcus aureus (Harder et al. 2001).
hBD-2 and hBD-3 also have cytokine-like properties. Both defensins were
described to be specific human chemoattractants for cytokines mediating the
recruitment of neutrophils to sites of inflammation and infection. This finding
reveals their capacity to mediate the innate and adaptive immune responses
(Harder et al. 2001; Niyonsaba et al. 2(04). Recent evidence from Niyonsaba et
al. (2007) enhances the functional role of j3-defensins, hBD-2, -3 and -4, but not
hBD-l, in skin immunity. These pep tides promote keratinocyte migration and
proliferation and stimulate cytokine/chemokine production (Niyonsaba et al.
2(07). In addition to their pro-inflammatory action, human j3-defensin 3 (hBD3)
was recently described to have anti-inflammatory properties (Semple et al. 2010).
hBD-3 can effectively inhibit the accumulation of pro-inflammatory cytokines
TNF~ and IL6 after stimulation by lipopolysaccharide (LPS). The novel
functions of hBD-3 suggests a role in the resolution of inflammation and in tissue
repair damage caused by effectors of antimicrobial action (Semple et al. 2010).
In most mammals coat colour patterns are controlled by the melanocortin
system, a seven transmenbrane-domain receptor and its extracellular ligand,
encoded respectively by the melanocortin J receptor (Mel/} and Agouti genes.
This process, commonly known as pigment "type-switching", controls the
production of two types of pigments: yellow (eumelanin) and black
(phaeomelanin) (Ollmann et al. 1998). However, in dogs the production of
these pigments is also controlled by CBDJ03, an orthologue of human
DEFBJ03. A study undertaken in domestic dogs reported that a mutation in
CBD J03, controls pigmentation through the melanocortin I receptor and
correlates with black coat colour in 38 different breeds. In the presence of the
wild-type alleles for all three genes the Agouti binds to Me 1r resulting in yellow
coating. However, dogs carrying the dominant black allele of CBDJ03, the
respective peptide binds with high affinity to the melanocortin 1 receptor
(Mc1r) competing with Agouti and affecting the pigment type-switching
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mechanism in domestic dogs and transgenic mice (Candille et al. 2007). This
discovery associated a new function to the (3-defensins in mammals and
suggests a similar new role for (3-defensins, not yet investigated, in humans.
Three epididymis-specific ~-defensins, hBD-4, hBD-5 and hBD-6 (encoded
by DEFB104, 105 and 106 genes) were identified by Basic Local Alignment
Search and annotated at the 8p23.1 locus (Yamaguchi et al. 2002). These
peptides are specifically expressed in human epididymis, which is highly
vulnerable to microbial invasion, thus suggesting the role of (3-defensins in host
defence against bacterial pathogens, protecting the spermatozoa (Yamaguchi et
al. 2002). In addition to these ~-defensins, SPAGlllocated within the 8p23.l
copy variable repeat unit, also encodes a epididymis-specific secretory peptide
that was described as a conserved component of the innate epididymal
epithelial defence system in primates (Horsten et al. 2004).
Although the (3-defensinswere firstly known for their antimicrobial activity
against a range of microorganisms, several studies have demonstrated their
additional functional activity, including a role in the adaptive immune system as
Signallingmolecules. As such, they are referred as a multifunctional gene family.
The 9-defensin subfamily is the most understudied and so far, only six
9-defensin (DEFl) genes have been identified in the human genome; five on
chromosome 8p23 and one on chromosome 1 (Table 1). They appear to be
expressed pseudogenes that encode antimicrobial peptides, also called
retrocyclin (Nguyen et al. 2003; Carsten MOnk 2004). Although O-defensin
mRNA transcripts have been found in human bone marrow, spleen, thymus,
testis and skeletal muscle they are inactivated due to a premature stop codon
that disables their translation (Cole et al. 2002).
Homologues of the human theta-defensin genes have been found in
chimpanzees and gorillas, containing the same premature stop codon, whereas
active genes were found in several Old World monkeys and orangutans
(Nguyen et al. 2003). Human theta-defensin peptides are homologous to rhesus
macaque (Macaca mulatta) circular minidefensins. These are termed rhesus
theta-defensin-l (RID-I), RID-2 and RID-3 and were isolated from granules
of neutrophils and monocytes (Tang et al. 1999; Cole et al. 2002). The
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biosynthesis of the mature pepndes involves the fusion of two alpha-defensin-
related nonapeptides (van der Maarel and Frants 2005) followed by cyclization
through the formation of two new peptide bonds (Tang et a1. 1999). This result
in a cyclic octadecapeptide molecule stabilized by three disulphides bonds, the
only cyclic peptide known in animals (Selsted and Ouellette 2005). It has been
suggested that DEFT genes and theta-defensins arose by mutation of a pre-
existing n-defensin gene in Old World monkeys. The inactivation of
theta-defensins in humans occurred after the orangutan and hominid lineage
divergence (Nguyen et aI. 2(03). All defensin pepndes share similar antimicrobial
properties but for the theta-defensins, retrocyclin, Cole et al. (2002) suggested an
additional strong anti-lllV-l infection activity. In vitro, retrocyclin protects human
CD4+ cells from infection by T-tropic and Mtroplc strains of mv-l.
1.2.2 Defensins and immunity: mode of action
In higher vertebrates, such as mammals, the immune system is composed
by two types of immunity; innate and adaptive immunity. Whilst innate
immunity is activated immediately after microbial invasion providing a rapid
and direct protection against foreign agents, the adaptive immune response
mediated by T and B cells can take several days to unfold. Important
components of the innate immune system are the antimicrobial substances,
which include the defensins.
The defensins have a broad spectrum of antimicrobial activity in vitro
against Gram-positive and Gram-negative bacteria, yeast, fungi and enveloped
virus and are important players in innate immunity (Ganz and Lehrer 1995;
Ganz 2003). The activity of a-, J3- and Bdefensins becomes effective at
concentrations of 0.5-5f.JM and for most a- and p-defensins their activity is
regulated by physiological concentrations of NaCI, divalent cations and serum
components (Selsted and Ouellette 2005). At high ionic concentrations of salt
(NaCI) these defensins have reduced antimicrobial activity. Therefore, the
direct antimicrobial activity of a- and p-defensins in vivo is likely to occur in the
phagocytes and epithelial tissues, where the salt concentrations are low (Ganz
and Lehrer 1998; Lehrer and Ganz 1999; Schroder 1999). Conversely, these
factors seem not to influence the activity of 8-defensins, which have been
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suggested to correlate with its cyclic conformation (Tang et al. 1999; Tran et a1.
2002). The antiviral activity of defensins is not influenced by salt concentration
or the absence of serum components (Klotman and Chang 2006). In the
particular case of viruses the mechanism of antiviral activity by defensins can
occur in the absence of serum with the inactivation of enveloped virus particles
by disruption of viral envelope or by interaction with viral glycoproteins
(Klotman and Chang 2006). For some p-defensins, such as human j3-defensin 1,
the antimicrobial activity is regulated by redox conditions. hBD-l showed
potent antimicrobial activity under reducing conditions that characterize
anaerobic environments. After reduction of disulphide-bridges, hBD-l becomes
an effective antimicrobial peptide against Gram-positive Biiidobecterium and
Lactobacillus species and fungus Candida albicans (Schroeder et a1. 2011).
Anaerobic environments can be found in mucosal membranes of the intestine,
vagina and oral cavity as well as in cutaneous sweat, sebaceous glands and
infectious sites where hBD-I is constitutively produced and can provide an
effective barrier against colonisation by anaerobic pathogens and commensals
(Schroeder et a1. 2011).
Although defensin antimicrobial mechanisms are not completely
understood, it is agreed that it may involve the disruption of structural elements
of the microbial cell membrane. The main mechanism of action is membrane
depolarization and penneabilization, which is dependent on differences in
membrane composition of both host and microorganism, followed by
disruption of some physiological processes (Yang et al. 2002; Selsted and
Ouellette 2005). In contrast to host cells, most of the microorganism's
membranes lack cholesterol and are composed of negatively charged
phospholipids. Defensin peptides are cationic and amphiphilic, allowing them
to insert within the phospholipids and interact with the negatively charged
(anionic) microbial membrane (Lehrer and Ganz 1999; Kamysz et a1. 2003;
Selsted and Ouellette 2005). Subsequently, some defensins can aggregate and
form ion channel pores or cover the microbial membrane, forming a
carpet-like arrangement which leads to the penneabilization and disruption of
membrane integrity and function resulting in the lysis of the microorganism
(Schroder 1999; Hoover et a1. 2000). At high concentrations (I5-30I-lM),
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defensins can have cytotoxic activity against tumor cell growth in vitro
(Lichtenstein et a1. 1986). Moreover, it was suggested that the differences
observed in membrane composition of tumor cells that are rich in
phosphatidylserine, makes them more susceptible to membrane
permeabilization by defensin pepttdes. Defensin peptides are expressed in
several tumor cell lines and depending on concentrations they can exert a
necrotic or mitogenic activity (Kamysz et al. 2(03).
The defensins have also been linked to the adaptive immune system. The
first findings focused on the role of defensin in innate immunity were in
alpha-defensins (HNP-l and HNP-2), which were shown to be chemotactic for
human monocytes and naive T-cells (Territo et al. 1989; Chertov et al. 1996;
Yang et al. 2(00). Later, [3-defensin hBD-3 and hBD4 were also described to
have chemoattractant properties for monocytes, while hBD-2 mediates the
recruitment of memory T'cells and immature dendritic cells via human
chemokine receptor 6 (CCR6) (Yang et a1. 1999; Conejo Garcia et al. 2001;
Garcia et a1. 2(01). These studies seem to indicate that CCR6 is a receptor for
both CGchemokine ligand 20 (CCL20 or chemokine macrophage inflammatory
protein 3a) and [3-defensins(Yang et a1. 1999). In addition, HNP-1, hBD-3, and to
a lower extent hBD-l, are chemotactic for immature dendritic cells, with hBD-3
able to recruit macrophages as well (Yang et a1. 1999; Yang et aJ. 2000; Garcia et
al. 2(01). As just described, defensins can share the same receptors with some
chemokines to mediate the recruitment of immune cells for sites of infection,
suggesting that defensin and chemokines can have similar functions. Other
findings showed that some chemokines have defensin-like antimicrobial activities,
despite their distinct amino acid structure (Cole et al. 2(01). Moreover, defensins
stimulate the production of several cytokines, soluble proteins of low molecular
weight produced by all immune cells, which regulate the innate and adaptive
immune responses. Defensins were found to stimulate the production of TNF-a
and ILl in monocytes and IL8 in lung epithelial cells (Van Wetering et a1. 1997;
Chaly et al. 2(00). In immature dendritic cells the production of llr2 can be
induced by HNP-1, hBD-2 and hBD-3 (Yang et a1. 2(02).
The first evidence that defensins could have mitogenic properties was
given by Murphy et al. (1993), who showed that, at concentrations that would
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allow antimicrobial activity, defensins could also stimulate fibroblast and
epithelial cell division in vitro. The same range of defensin concentrations is
expected in vivo during wound healing, suggesting a dual role of defensins in
cell growth and wound healing. Such ideas were later confirmed by Aarbiou et
a1. (2004) who showed the same role of defensins in lung epithelial cells.
Human neutrophil peptides (HNP) (a-defensins) can also regulate angiogenesis
by affecting endothelial cell adhesion, migration, proliferation and
differentiation (Chavakis et a1. 2(04). These studies provide new insight into the
role of defensins in the regulation of inflammation by stimulating the
restoration of epithelial tissue and neovascularisation, a critical part of
inflammation and wound repair after a microbial invasion.
Defensins are chemoattractant for monocytes and macrophages, which are
phagocytes involved in the direct immune response of the organism against
invading foreign particles, such as bacteria. Thus, defensins also indirectly
enhance innate immunity and phagocytosis through the recruitment of cells
from the adaptive immune system (Yang et a1. 2(02). Given the capacity of
defensins to enhance phagocytosis, promote the recruitment of several adaptive
immune cells and stimulate the production of cytokines, they have been
described as regulatorsjrnodulators of the innate host immune defence and as
adjuvant of the adaptive immune response against microorganism invasion.
The rapid expression of antimicrobial defensins and the recruitment of
adaptive immune cells with a prolonged cellular and humoral response to a
potential pathogen show the dual role of defensins in immunity linking the two
types of immune response, innate and adaptive (Yang et a1. 2002; Selsted and
Ouellette 2(05). Defensins have a concentration-dependent activity that at
lower concentrations stimulates cytokine production or become
chemoattractant for immune cells, while at higher concentrations are involved
in microbial and tumor cell lysis (Kamysz et a1. 2(03).
1.2.3 Copy number variation of human defensin
Copy number variation of defensin genes was first reported in somatic cell
hybrids mapping chromosome 8, for genes encoding the human neutrophil
defensins HP-I and HP-3 (DEFAl and DEFA3j, which comprised between two
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and three copy repeats (Mars et al. 1995). Copy number variation of a-
defensins was later confirmed by Aldred et al. (2005) and Linzmeier and Ganz
(2005) but the extension of copy number variation proved to be more complex
than initially reported. DEFAl and DEFA3 are located in a multi-copy array at
8p23.1, showing variation in both number and position between normal
individuals (Aldred et al. 2005; Linzmeier and Ganz 2(05). The a-defensin
repeats appear in arrays of 19 kb, in a "Full repeat", containing one a-defensin
gene and the DEFfl pseudogene, and in a 9.5 kb "partial repeat" with only
one a-defensin gene. The interchangeable position of DEFAl and DEFA3 in
the repeat unit suggest that both genes are located at the same locus,
subsequently renamed DEFA1A3 (Aldred et al. 2(05). The diploid copy
number varies between 3 and 11 copies in Europeans but in Africans and
Asians the copy number can go up to 17 copies (Fayeza Khan, personal
communication). Other a-defensin genes, DEFA4, DEFA5 and DEFA6, are not
commonly copy number variable (Aldred et al. 2(05). The DEFA3 gene is
absent in about 10% of the UK population and in 37% of the sub-Saharan
African population (Yoruba), although the effects that this common deletion
might have in immunity are not yet known (Ballana et al. 2007). Analysis of
expression levels in neutrophils indicated that HNP-l, HNP-2 and HNP-3
peptide levels are proportional to DEFAl and DEFA3 copy number
(Linzmeier and Ganz 2(05). However, although Aldred et al. (2005) also
suggested a correlation between the relative proportions of DEFA1:DEFA3
mRNA and gene copy number, the combined mRNA levels of
DEFA1+DEFA3were not proportional to the total gene copy number.
The presence of multiple copies of human lXlefensins at chromosome
band 8p23.1 was first reported as a cytogenetic duplication of the short arm of
chromosome 8 by FISH (Barber et al. 1998). The p-defensin gene cluster at
8p23.1 includes six defensin genes, DEFB103, DEFB104, DEFB105, DEFB106,
DEFB107 and DEFB4 and a defensin-like gene, SPAGll, in a repeat unit,
which is highly polymorphic in copy number (Figure 5) (Hollox et al. 2003;
Groth et al. 2008; Abu Bakar et al. 2(09). The size of the repeat unit is
unknown, but from pulse-Held gel analysis it was demonstrated to span at least
260 kb (Hollox et al. 2003). Moreover, the p-defensin genes also vary
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concordantly in copy number as a block (tandem repeat) with no internal
duplications or deletions (Groth et al. 2008). Diploid copy numbers commonly
range between 2 and 7 copies, but copy number up to 12 was found in some
individuals (Hollox et al. 2003; Abu Bakar et al. 2009). Higher copy numbers
between 9 and 12 can be visualized as euchromatic variants by cytogenetic
analysis (Barber et al. 2005). Information about the haploid copy number states
was recently investigated in CEPH reference pedigrees through segregation
analysis. The study found between one and five copies of ~-defensin genes per
haploid genome (Abu Bakar et al. 2009). Null alleles are very rare, but they
can be found at a very low frequency, about 0.2%. Functional consequences
associated with the null homozygote might be strongly deleterious and lead to
its elimination from the population by purifying selection (Hollox et al. 2008a).
Analysis of mRNA transcript levels in lymphoblastoid cells by semi-quantitative
RT-PCR showed a positive correlation with the genomic copy number of
DEFB4 (Hollox et al. 2003).
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Figure 5: Genomic organization of the ~-defensin locus at Sp23.1. On the top panel is
represented the whole Sp23.l locus with the REPD and REPP loci. Segmental
duplications and gaps are represented in each locus. The grey arrows represent
inverted and non-inverted orientation of the region that spans between REPD and
REPP. On the bottom panel is highlighted the genome organization of each repeat
with the seven genes that compose the ~-defensin copy number variation repeat.
(Figure adapted from UCSC Genome Browser on Human March 2006
(NCBI36;hgIS) assembly).
1.2.4 Defensins in human disease
Defensins constitute a gene family with multiple functions; however, their
role in immunity has highlighted defensins as candidate genes for inflammatory
and autoimmune human diseases.
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Several studies have been focused on the consequences of genetic variants
and copy number variation of defensin genes in disease susceptibility.
Defensins have attracted attention in cancer research since a link has been
established between inflammation and cancer development (Karin et al. 2006;
Lu et al. 2006). The presence of tissue damage caused by microbial infection,
chemical irritation or wounding, initiates an inflammatory process which
involves the recruitment of a wide variety of immune cells (neutrophils, mast
cells, macrophages, leukocytes and lymphocytes) to the site of infection, as well
as the release of various proinflammatory cytokines, chemokines and growth
factors. These cells will contribute to antibacterial tissue breakdown and are
important to maintain the defence against infection (Coussens and Werb 2002;
Philip et al. 2004). The regulation of inflammation by apoptosis and
phagocytosis of inflammatory cells is mediated by anti-inflammatory molecules.
However, dysregulation of these processes lead to chronic inflammation, which
will maintain the activation of immune cells and the recruitment of
proinflammatory cytokines, chemokines and growth factors. These are
responsible for the persistent tissue damage, cell proliferation and
differentiation and release of reactive oxygen and nitrogen species that may
cause DNA damage, thus predisposing to neoplasia (Lu et al. 2006). The
development of cancer from inflammation may be mediated by inflammatory
cells and regulators, including cytokines and chemokines that facilitate
angiogenesis and promote cell growth, invasion and metastasis of tumor cells
(Lu et al. 2006). In prostate cancer, the presence of persistent bacterial
colonization in epithelial cells of prostate gland has been suggested to induce
carcinogenesis through the associated inflammatory response (De Marzo 2007).
Antimicrobial peptides such as the j3-defensins have been suggested to playa
role in the development and progression of this and other types of cancer
(Schullerus et al. 1999; Donald et al. 2003; Zheng et al. 2004; Huse et a1. 2008).
However, no evidence found so far, supports this hypothesis. Although the
impact of j3-defensins in carcinogenesis is not yet clear, they may playa role in
the pathogenesis of several cancers either by acting directly as a barrier against
pathogens or/and by activating inflammatory response.
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Chronic inflammation is also typically observed in chronic obstructive
pulmonary disease (COPD). COPD is a progressive inflammatory disease of
the airways characterized by narrowed airways leading to limitation of the
airflow to and from the lungs. COPD is caused by toxic particles or gas, most
frequently from tobacco smoking, which triggers an abnormal inflammatory
response in the lung (Rabe et al. 2(07). A recent finding shows the association
between higher genomic copy number variation of J3-defensin, especially
DEFB4 and COPD, revealing the potential functional role of J3-defensins in
airway epithelial cells and triggering inflammation. As chemoattractant peptides,
the increased copy number of J3-defensinmay enhance the chronic inflammatory
cascade contributing to the pathogenesis of COPD [janssens et al. 2010).
Bacterial infection can also trigger the pathogenesis of other inflammatory
diseases, such as cystic fibrosis. Chronic bacterial colonization of the lungs,
especially by Pseudomonas seruginose; is a major cause of morbidity in
patients with cystic fibrosis. Given the expression of the human J3-defensin 2
peptide (encoded by DEFB4J in the lung epithelia and its strong antimicrobial
activity against Pseudomonas serugiaose; it has been suggested that DEFB4 can
be a potential candidate modifier gene for cystic fibrosis (Schutte and McCray
2(02). However no association was found that would support the hypothesis of
J3-defensincopy number as a modifier for CF (Hollox et al. 2(05).
More recently, using quantitative real-time PCR approaches, two studies
found association between J3-defensin copy number variation and Crohn's
disease (Fellermann et al. 2006; Bentley et al. 2010). Crohn's disease is a
chronic inflammatory bowel disease mediated by T lymphocytes and
characterized by intestinal ulceration affecting mainly the ileum and colon. The
aetiology remains unclear but genetic factors, host immune response,
environmental factors, nutrition and enteric microflora all contribute to Crohn's
disease susceptibility. However, it is suggested that Crohn's disease "arises in
genetically susceptible individuals as a result of a breakdown in the regulatory
constraints on mucosal immune responses to enteric bacteria" (Shanahan
2(02). Given the functional role of J3-defensins in immune system, as
antimicrobials and cytokines (Ganz 2003; Niyonsaba et al. 2(04), it is possible
that they could play a role in Crohn's disease susceptibility. In 2006,
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Fellermann et al. (2006) reported an association between low j3-defensin copy
number and Crohn's disease of the colon, suggesting that a reduced
antimicrobial barrier in the gut could trigger the development of Crohn's
disease. Conversely, high j3-defensin copy number was also associated with
Crohn's disease by Bentley et al. (2010), supporting the idea that increased
dosage of DEFB4 gene leads to chronic inflammatory response that has also
been described as a possible factor causing Crohn's disease. However, neither
of the associations previously reported have been replicated in subsequent
studies carried out using a PRT-based assay to assess the p-defensin copy
number in more than 1500 samples (Aldhous et al. 2010), or oligonucleotide
array-CGH in more than 2000 cases and 3000 controls (WfCCC 2009).
Defensins were first reported in 1993 to have antiviral activity against
HIV-l, inhibiting its replication in vitro (Nakashima et al. 1993). Theta-
defensins are not actively present in humans, but synthetic putative ancestral
human peptide, retrocyclin, has the ability to inhibit proviral DNA formation
and protects CD4+ lymphocytes cells from in vitro infection by HIV-l (Cole et
al. 2(02). On the other hand, alpha-defensins can exhibit anti-HfV activity by
directly inactivating virus particles and by targeting CD4 + T cells and thus
affecting the virus replication (Mackewicz et al. 2003; Chang et al. 2005).
j3-defensins, in particular hBD2, are expressed at higher levels than a-defensins
1 and 3 in oral epithelium making them strong candidates for innate resistance
to oral IDV infection. hBDI (DEFBf), hBD2 (DEFB4J and hBD3 (DEFBI03J
were all reported to inhibit, to some extent, HIV-infection by direct inactivation
of virions and suppressing viral replication in human oral cavity
(Qumones-Mateu et al. 2003; Sun et al. 2(05). The defensins appear to have an
important role in innate and adaptive resistance to viral infection through both
their antiretroviral effect and chemokine-like effect against HIV.
An important inflammatory disease associated with j3-defensins is psoriasis.
The j3-defensins, especially hBD-2 (DEFB4 gene), which was first isolated from
psoriatic lesions, has recently been highlighted as a possible candidate gene for
psoriasis. The role of j3-defensins in the immune system and the aetiology of
psoriasis strongly support such a hypothesis, but until 2008 no study had
investigated this relationship. Understanding the role of p-defensin, especially
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the consequences of J3-defensin copy number variation in psoriasis was a
central aim of my PhD project, which I will explore in more detail.
1.2.4.1 Immuno-genetics of psoriasis
Psoriasis is a chronic inflammatory skin disorder with 2 to 3%prevalence in
the European population and a complex aetiology strongly influenced by
genetics (Lebwohl 2(03). In other human populations psoriasis is less common
with an incidence of only about 0.1% in Asians and even lower values in
Africans (Bowcock 2(05). Psoriasis is a T-cell-mediated inflammatory disease
characterized by uncontrolled proliferation of keratinocytes and recruitment of
T-cells into the skin (Valdimarsson et a1. 1995). Long described as an
autoimmune disease, its pathogenesis fits the classical definition of an
autoimmune disease: "clinical syndrome caused by the activation of T -cells
and/or B-cells, in the absence of an ongoing infection or other discernable
cause" (Davidson and Diamond 2(01).
Psoriasis can be present in different forms - Psoriasis Vulgaris, Guttate,
Flexural and Pustular, varying according the age of onset, severity and the part
of the body affected. Both sexes are affected equally. Psoriasis Vulgaris can be
further sub-divided into type I, if onset occurs earlier in life «=40 years), often
associated with a positive family history and inheritance of particular HLA
alleles that predispose to a higher incidence of streptococcal infection triggering
psoriasis, and type II, if it is associated with a late onset (>40 years) and
absence of the family history and without predisposing HLA antigens (Bhalerao
and Bowcock 1998; Weisenseel et a1. 2(02).
The most common type of psoriasis, psoriasis vulgaris or plaque psoriasis,
is characterized by epidermal hyper-proliferation, vascular remodelling and
inflammation resulting in the formation of elevated, scaly, erythematous and
thickened plaques normally located on the elbows, knees, scalp, nails and
joints. It can nevertheless also develop in any other part of the body (Lebwohl
et a1. 2(03). About 15%of the individuals with psoriasis also develop psoriatic
arthritis (PA), normally within the first 10 years after the diagnosis of psoriasis
(Ibrahim et a1. 2(09).
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Psoriasis can occur in association with other complex diseases such as
Crohn's disease (CD), type II diabetes (Wolf et a1. 2008) and human
immunodeficiency virus (HIV) infection (Duvic 1990). Psoriasis and Acquired
immune deficiency syndrome (AIDS) are immune-mediated disorders and
have been associated with HLA antigens (Duvic 1990). Psoriasis has also been
reported to share genetic variants with both CD and type II diabetes,
suggesting that some genes play a role in different inflammatory pathways and
may contribute to the pathogenesis of multiple diseases (Capon et a1. 2007;
Cargill et a1. 2007; Wolf et a1. 2008).
The pathogenesis of psoriasis is complex and involves the activation and
continuous stimulation of T -cells with excessive infiltration of many types of
leukocytes, namely dendritic and T-cells, into the dermis and epidermis
(Bowcock and Krueger 2005). The cellular and inflammatory pathway in
psoriasis is initiated with T-cell activation through IL-12 and IL-23 cytokines that
trigger the differentiation of naive CD4 + T-cells (ThO) into different T-cell subsets
followed by their consequent clonal expansion. The T-cell activation through
IL-23 and IL-12 leads to the activation of a cascade pathway characterized by the
synthesis of T-cell-derived pro-inflammatory cytokines that stimulates the
proliferation of keratinocytes and endothelial cells, resulting in marked
thickening of the epidermis and permanent inflammation recognized in psoriasis
(Lowes et a1. 2007; Duffin et a1. 2010). The Th17 cells, a particular activated
T-cell subset implicated in the pathogenesis of psoriasis, synthesize cytokines
such as Ilr 17 and Ilr22 which activate keratinocytes, resulting in their
proliferation and release of pro-inflammatory cytokines, chemokines, TNF-
a (tumour necrosis factor-alpha) and antimicrobial peptides (P-defensins) that
promote inflammatory responses and are responsible for the persistent
inflammation characteristic of psoriatic lesions (Lowes et a1. 2007; Duffin et a1.
2010).
T-cell activation requires the interaction with antigen-presenting cells
(Langerhans cells), through a variety of cell-surface molecules, such as the
MHC. They express many different pattern recognition receptors (PRR) in
their surface that interact with a range of microorganisms, such as bacteria and
viruses, leading to their maturation and migration to lymph nodes. Here,
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antigen-presenting cells present antigens to the antigen-specific receptors of
T-cells, leading to their activation and proliferation (Lebwohl 2003; Duffin et al.
2010). The factors leading to dendritic cell activation are not yet completely
clear. However, some mechanisms have been suggested, which include
activation through cytokines, pattern-recognition receptors, heat-shock proteins
or direct interaction with counter-receptors in T-cells (Lebwohl 2003; Lowes et
al. 2007). Many environmental factors have been linked with T-cell activation.
These have been described to initiate and enhance the progression of psoriasis
(Leung et al. 1995; Valdimarsson et a1. 1995). The exact contribution and
importance of both genetic and environmental factors to psoriasis susceptibility
is not yet completely clear; however, it is commonly accepted that genetics may
have a stronger role in the risk of developing psoriasis. Nevertheless, psoriasis
is regarded as a multifactorial disease in which several genes interact with each
other and where environmental factors can play a role in the development of
the disease. This evidence is provided by studies in monozygotic and dizygotic
twins. Such studies reveal that monozygotic twins have a higher rate of
concordance for psoriasis (between 70-72%) than dizygotic twins (between
15-23%),supporting a genetic origin of psoriasis (Farber et al. 1974; Brandrup et
al. 1978). However, the heritability of psoriasis in the Australian population is
not so high, showing only 35%concordance among monozygotic twins and 12%
concordance in dizygotic twins (Duffy et a1. 1993). Since not all monozygotic
twins share the disease, together with the fact that concordance of psoriasis
never reaches 100% in any population studied, suggests that environmental
factors can also playa role in psoriasis susceptibility.
In order to elucidate the exact contribution of genetics in the development
of psoriasis, several linkage and association studies have been carried out in the
last 30 years with the aim of mapping genes conferring susceptibility to
psoriasis. As a result, psoriasis has been associated with ten different loci
(PSORSl to PSORS1Oj, each of them normally including more than one gene.
In the early 1970s, Russell et al., first described an association between psoriasis
and the human leukocyte antigens (HLA) in the major histocompatibility locus
complex (MHC) on chromosome 6. The MHC locus has been consistently
identified in many studies since then and is one of the major susceptibility loci
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for psoriasis. This locus is also known as "psoriasis susceptibility 1" or PSORSI
comprising a 300 kb region in the MHC on chromosome 6p21.3, which
includes the genes that encode the human leukocyte antigens (HLA) (Russell et
al. 1972). The HLA-Cw6 (HLA) has been identified as the primary risk allele
for psoriasis with 60% of patients with early onset psoriasis carrying this allele
[Tiilikainen et al. 1980; Gudjonsson et al. 2003; Nair et al. 2006). However,
only 10-15%of HLA-Cw6 carriers develop psoriasis, highlighting the fact that
other genetic factors may contribute to the risk of psoriasis (Duffin et al. 2010).
The association of psoriasis with the HLA-Cw6 allele suggests that MHC class I
molecules are involved in the T-cell activation process through antigen-
presenting cells (APC), namely in the APC binding to the respective ligands on
T-cells (Gottlieb and Krueger 1990). The PSORSIIocus contains several other
candidate genes, such as CCHCRI (HRC) and CDSN that encode for the
coiled-coil a-helical rod protein 1 and comeodesmosin, respectively
(Asumalahti et al. 2000; Bowcock and Krueger 2005). CCHCRI is upregulated
in psoriatic epidermis and might negatively regulate keratinocyte differentiation
and proliferation. Comeodesmosin, a protein involved in keratinocyte cohesion
and desquamation, is overexpressed in the epidermis of psoriatic patients and
could be involved in the decreased (impaired) desquamation, contributing to
the abnormal scaling process of psoriatic lesions (Bowcock and Krueger 2005).
The precise location of the PSORSI locus is highly controversial. It has
been suggested that genes encoding the classical HLA class I molecules (HLA-
A, HLA-B and HLA-C) are not included in this region which could mean that
HLA-Cw6 is a marker in linkage disequilibrium with PSORSIIocus rather than
the susceptibility allele itself (Nair et al. 2000; Orru et al. 2005). On the other
hand, several other studies exclude the CCHCRI (HRC) and CDSN genes
and map the PSORSIIocus to the HLA-C region (Helms et al. 2005). Due to
the strong linkage disequilibrium among the associated alleles of the PSORSI
locus the exact extent of this region is difficult to disentangle. Despite the well
documented evidence of the role of MHC class I molecules, in particular the
l/LA-Cw6 allele, in the susceptibility to psortasis, the exact genetic contribution
of the PSORSIIocus in psoriasis is still not completely clear (Enlund et al. 1999).
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The first psoriasis-susceptibility locus other than the MHC locus was
described on chromosome 17q2~25 by Tomfohrde et al. (Tomfohrde et al.
1994). This psoriasis-susceptibility locus, known as PSORS2, includes three
different genes, SLC9A3RJ (solute-carrier family 9, isoform 3, regulator 1),
NA 1'9 (N-acetyltransferase 9) and RAPTOR (regulatory associated protein of
mammalian target of rapamycin (MTOR)) (Tomfohrde et al. 1994; Helms et al.
2003). SLC9A3RJ encodes for a binding phosphoprotein with two PDZ
domains that interact with the cytoskeleton proteins ezrin, radixin and moesin.
This phosphoprotein is involved in several epithelial membrane protein-protein
interactions, especially in the interaction of antigen-presenting cells and T-cells.
It has been proposed that the binding complex formed between the
SLC9A3RJ domains and cytoskeleton proteins leads to the inununological
synapse formation and ultimately to T-cell activation (Helms et al. 2003;
Bowcock and Krueger 2005). A Single nucleotide polymorphism lying between
SLC9A3RJ and NA1'9 leads to the loss of RUNXI binding, suggesting a
defective regulation of SLC9A3RJ and NA1'9 by RUNXI (a transcription
factor protein involved in DNA binding). Therefore, these genes have been
identified as a susceptibility factor for psoriasis (Helms et al. 2003). Psoriasis has
also been associated with variants in the RAPTOR gene (Helms et al. 2003).
Since the variants were found in the non-coding region of the gene, this suggests
its role as a regulatory gene of the MTOR protein. Therefore, alteration in the
regulatory pathway of MTOR can lead to modifications in the normal cell
growth and proliferation rate of T-cells and keratinocytes (Capon et al. 2004).
With the use of linkage analysis in large families, a "psoriasis susceptibility
3" locus was located on chromosome 4q25. This evidence was demonstrated
through a genome-wide scan in which the micro satellite marker, D4S1535,
shows a maximum pair wise LOD score of 3.03 (Matthews et al. 1996). Located
just 50 kb from the PSORS3 locus lies the human IFR2 gene (interferon
regulatory factor 2) showing two markers, located in IFR2 exon 9, associated
with type 1 psoriasis (Foerster et al. 2004). This gene is also involved in
interferon (IFN) regulation and has a role as transcriptional repressor of a- and
~-interferon target genes. Genetic variants, such as SNPs, may have an effect on
the transcriptional regulation of IRF2 resulting in a deficient expression or
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function of the gene, which can lead to hyperresponsiveness to type 1
interferon signalling, a process involved in the pathogenesis of psoriasis
(Foerster et al. 2004).
The epidermal differentiation complex (EDC) spans about 2 Mb on
chromosome lq21 and includes several genes involved in epidermal
differentiation and maturation. A PSORS410cus located within the EDC region
was associated with psoriasis (Capon et al. 1999). Taking into consideration the
role of the EDC genes, it is possible that genetic variants could affect
keratinocyte proliferation and differentiation. Such a relationship can lead to
the development of an abnormal inflammatory response, such as in psoriasis
(Lowes et al. 2007). Within the EDC region are placed two different clusters of
genes, the genes encoding SlOO proteins (small proline-rich proteins) and the
late cornified envelope (LCE) proteins. A deletion comprising the LCE3B and
LeE3c, genes from the LeE gene cluster, is strongly associated with risk of
psoriasis (p-value=1.38xlfrB) in the European and North American population.
The LCE3C_LCE3B_delis in strong LD with a nearby SNP (rs4112788) 4.5 kb
upstream, suggesting a Single origin (de Cid et al. 2009). Moreover, the
biological implication of these genes for psoriasis was also confirmed in a
genome-wide association study in the Chinese population (Chinese Han
ancestry). In this study, Zhang et al. identified another SNP within the LCE
gene cluster that confers susceptibility to psoriasis (rs4085613, p"'Value=6.69xl0-
30) (Zhang et al. 2009c). This SNP is found in the same linkage disequilibrium
block of the rs4112788, reported by de Cid et al., and they are in almost
complete LD (Zhang et al. 2009c). These studies bring to attention the
importance of genetic variants within LeE genes for the development of
psoriasis. Since the LCE proteins play a role in the epidermal terminal
differentiation of keratinocytes, genetic variation within these genes may lead to
the formation of an abnormal cornified envelope with poor adherence causing
the release of cells and the scaling appearance found in psoriatic lesions (de
Cid et aI. 2009; Zhang et aI. 2009c).
The PSORS5locus maps to chromosome 3q21. So far only one candidate
gene, SLCl2A8, has been identified and associated with risk of psoriasis in this
locus (Enlund et al. 1999; Hewett et aI. 2002; Htiffmeier et al. 2005). PSORS5
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encodes for a member of the solute carrier family 12 proteins (member A 8).
These are integral membrane proteins with cation/chloride co-transporter functions
that may play a role in the control of keratinocyte proliferation. In the study of a
Swedish population, a five-SNP haplotype spanning the 3' half of the SLCl2A8
gene has been identified and associated with psoriasis (p-value of 3.8xlO-5) (Hewett
et a1. 2(02). However, in a more recent study in a German population only one
SNP (rs2228674) with very weak association with psoriasis was found within the
PSORS5 locus (Hilffmeier et al. 2005). Therefore, the variants that make
PSORS5 a psoriasis susceptibility locus still remain to be investigated.
A genome-wide linkage scan in a German population was the first study to
identify a psoriasis susceptibility locus at 19q13 (PSORS6) (P=O.OOO2)
comprising about 15 cM (Lee et a1. 2000). The interval spanning the PSORS6
region is occupied by several genes, and one of them is the gene coding for
ICAM-I, an intercellular adhesion molecule-I (Nickoloff et al. 1993). ICAM-l is
expressed in leukocytes, fibroblasts and endothelium, and mediates leukocyte
migration into sites of infection and T-cell activation, suggesting that
keratinocytes may have a role in the regulation of T-cell activation, a crucial
process involved in the pathogenesis of psoriasis (Nickoloff et al. 1995).
Moreover, the I9p13 psoriasis susceptibility locus is in interaction with the
HLA region on chromosome 6p (Lee et al. 20(0). The interaction between
PSORS6 and PSORSI loci is also evident in a study where the observed
association of PSORS6 with psoriasis is only true in type I psoriasis patients
carrying the PSORSI risk allele, suggesting epistasis between these two loci
(Hnffmeter et al. 2009).
A further susceptibility locus, known as PSORS7, was initially described
by Veal et al., at chromosome lp (Veal et al. 2001). This psoriasis susceptibility
locus has been reported in several genome-wide association scans carried out
in large cohorts of Caucasian individuals. These studies reveal the association
between psoriasis and SNPs within the IL12B (encoding the IL-12p40 subunits
of two cytokines, IL12 and IL23), IL23R (encoding a subunit of the IL23
receptor) and IL23A (encoding the p19 subunit of IL23J genes (Cargill et al.
2007; Nair et al. 2009). While IL23R and IL23A are located within the PSORS7
locus at Ip31.3, IL12B maps outside this locus on chromosome 5q31.1-q33.l
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(Cargill et al. 2007). All these genes are involved in Il.r23 signalling, regulating
the immune responses and promoting the survival and proliferation of Th 17 as
well as the release of IL17, a key cytokine involved in the pathogenesis of
psoriasis. Il.r23R and Il.r23A have also been associated with other autoimmune
diseases, such as Crohn's disease, Ulcerative colitis and Psoriatic arthritis
(Duerr et al. 2006; Cummings et al. 2007; Liu et al. 2008; Nair et al. 2009).
From these studies is evident that several autoimmune diseases can share the
same disease-risk alleles.
Although other PSORS loci (8, 9 and 10) have been mapped to
chromosome 16q, 4q31 and 18pll, there is very little evidence to show
association with psoriasis disease (Nair et al. 1997; Zhang et al. 2002;
Asumalahti et al. 2003; Karason et al. 2003; Zhang et al. 2(07).
In addition to the psoriasis susceptibility genes just described, other genes
not mapped to any of the psoriasis susceptibility loci have been associated with
psoriasis. At chromosome 20q13 is the SNP rs495337, a disease-associated
variant (p-value=1.4xlo-B) mapping to the SPATA2 gene (encodes the
spermatogenesis-associated protein 2) (Capon et al. 2008). The function of this
gene might not be particularly interesting for psoriasis, but the SNP rs495337 is
in strong ID with 5 other SNPs in the ZNF313 gene, which is expressed in
skin, T-Iymphocytes and dendritic cells. The function of ZNF313 is unknown,
but from homology studies it was suggested that ZNF313 has similar functions
to those included in a RING domain E3 ubiquitin ligase family, regulating
T-cell activation (Capon et al. 2(08). Such evidence puts the ZNF313 gene on
the long list of genes conferring susceptibility to psoriasis disease.
More recently, several genome-wide association studies, including large
cohorts of individuals not just from European ancestry but also from a Chinese
Han population, have identified new susceptibility loci associated with
psoriasis. The TRAF3IP2 gene and the NOS2 gene were identified from
GWAS. TRAF3IP2 gene is involved in the IL 17 signalling, while NOS2 gene
encodes an inducible nitric oxide synthase, which is involved in the regulation
of dendritic cells and many other immune system activated cells (Ellinghaus et
al. 2010; HufImeier et al. 2010; Stuart et al. 2010). Some psoriasis susceptibility
loci appear to be population-specific, conferring susceptibility to the disease just
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in a particular population but not for all human populations (Sun et al. 2010).
While some susceptibility loci identified in candidate gene studies have been
replicate in recent GWAS showing a genome-wide level of statistical
Significance, such as HLA-G, three genes involved in IL-23 signalling (IL12B,
IL23A, IL23Rj, SPATA2, 1RAF3IP2 and NOS2, the association of other loci
with psoriasis have not been supported by these studies (Nair et al. 2009;
Ellinghaus et al. 2010; Huffmeier et al. 2010; Stuart et al. 2010). This might be
explained by the small sample sizes used in association studies, which could
lead to false positive associations, compared with the large sample sizes used
nowadays in GWAS. The use of large cohorts in GWAS increase the power of
the association, which leads to the more reliable discovery of loci genuinely
involved in disease phenotypes.
The susceptibility loci described so far give support to the classification of
psoriasis as a complex immune disease with a strong genetic background. Even
so, many of these genetic factors only explain a small fraction of the risk of the
disease. So, it still remains to be discovered which other genetic variants
account for the risk of psoriasis. In addition to SNPs, copy number variation
(CNV) has been identified as an important risk factor in the susceptibility for
complex diseases, such as psoriasis (Hollox et al. 2oo8b). While the
psoriasis-susceptibility loci based on SNP variants lead to alterations in gene
function and regulation, copy number variation may lead to a change in gene
dosage. This highlights the importance that genetic variants other than SNPs
should be taken into consideration as risk factors in several complex diseases,
such as psoriasis, Crohn's disease and diabetes.
1.2.5 Defensins and CNV in non-human primates
Defensins are present across all vertebrate species. In birds and some
mammalian species (cows and pigs) only l3-defensins (Gallinacin in birds) have
been identified (Harwig et al. 1994; Zhao et al. 2001; Ganz 2003; Thouzeau et
al. 2003). Peptides structurally homologous to p-defensin were found in the
venom of reptile species (Nicastro et al. 2003) and l3-defensin orthologues are
present in different mammalian species, such as dog, rat, mouse and non-
human primate species, for example chimpanzee (Patil et al. 2005). This
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suggests that j3-defensin is the primordial defensin and the common ancestor
for all vertebrate defensins. Comparative analysis of the chicken and
mammalian j3-defensin gene clusters revealed shared synteny, which may
indicate that they arose before the divergence of mammals from birds (Xiao et
al. 2004). At some stage in mammalian evolution, successive rounds of
duplication followed by substantial divergence involving positive selection gave
rise to a diverse cluster of genes, the u-defensins, in glires and primates about
91 million years ago (Patil et al. 2004; Crovella et al. 2005). An alpha-defensin
cluster is located adjacent to the j>-defensin cluster in humans, mouse and rat,
but is absent in the canine genome (Patil et al. 2005), suggesting that the
a-defensin cluster evolved in a species-specific manner during mammalian
evolution (Crovella et al. 2005).
In primates a third class of defensins, theta-defensins has been suggested to
derive from a process involving the fusion and cyclization of two a-defensin
related monopeptides, which occurred only after divergence of primates from
other mammals around 23 million years ago (Tang et al. 1999). The close
relationship between theta-defensins and u-defensms has also been shown by
Leonova et al. (2001), who with the aim to identify the theta-defensin
precursors, undertook a cloning strategy and found several n-defensin
transcripts whose sequence contained a premature stop codon after the third
cysteine residue. This indicates that these circular defensins are products of a
process that generates molecular diversity without corresponding genome
expansion (Tang et al. 1999; Leonova et al. 2001).
The theta-defensin genes have been found to be active in orangutans and
Old World monkeys but not in humans or New World primates (Nguyen et al.
2003). The presence of multiple, divergent subsets of defensin genes in each
species may suggest that the evolution of these antimicrobial peptides occurred
in response to different environmental pressures reflecting an evolutionary
adaptation of the innate immune system to diverse "microbial ecology"
(Crovella et a1. 2005; Selsted and Ouellette 2005).
The chromosomal location of the genes encoding the ~-defensins appear
to be conserved in mammals, supporting the idea of a pre-mammalian origin of
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lHlefensins (Crovella et a1. 2(05). Although the majority of lHlefensins are
conserved across different mammalian species, there are some species-specific
gene lineages indicating that some lHlefensins evolved after the last common
ancestor of mammal (Patil et a1. 2(05). In the rat, mouse and dog, four different
j3-defensin clusters are present, whereas human and chimpanzee show five
different clusters. The five lHlefensin clusters in the chimpanzee genome are in
conserved synteny with the human p-defensin genes (Patil et a1. 2005). This
suggests that after duplication, j3-defensin genes were subjected to positive
selection earlier in mammalian evolution (Semple et a1. 2(05). In primates
different selective pressures acted on j3-defensin genes in different evolutionary
lineages, leading either to positive or negative selection, during the divergence
of primates (Semple et a1. 2005; Semple et a1. 2006).
Widespread copy number variation has been described in the genomes of
chimpanzees (Perry et a1. 2006; Perry et a1. 2(08), rhesus macaques (Lee et a1.
2008), mice (Li et a1. 2004; Cutler et a1. 2007; Egan et a1. 2007; Graubert et a1.
2007), rats (Guryev et a1. 2008) and even in the genomes of Drosophila
melanogaster (Dopman and Hartl 2007) and Plasmodium Ielcipsrum, the
malaria parasite (Emerson et al. 2(08). Differences in copy number in the
Drosophila melanogaster genome have been most notably found to encompass
toxin-response genes (Emerson et al. 2008). The CNV s described in mammals
and non-human primates are particularly interesting and important to
understand the functional and evolutionary Significance of human CNVs. The
studies of CNV in other mammalian species are limited; however, a number of
CNV regions have been revealed, many of them overlapping human CNV s. In
rats, 113 CNV s were identified in regions orthologous to human CNV s, of
which 80 are implicated in human disease (Guryev et a1. 2008). Analysis of
copy number variation in rhesus macaque, using array-based comparative
genomic hybridization (array-CGH), revealed that about 20% (25) of the 123
identified macaque CNV s are mapped to regions of the human genome
previously found to contain CNV s in 270 Hap Map individuals (Lee et a1.
2008). However, more recently, using an array-CGH platform specifically
designed to study copy number variation in the rhesus macaque, Gokcumen et
a1. (2011), identified 1160 CNVs, of which 385 overlapped with 467 human
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CNV s. The considerable difference in the number of CNV s identified between
studies may reflect the use of a species-specific array platform, instead of
human-based arrays, which are inadequate taking in consideration the
sequence divergence between species. This suggests the importance of the
design of spectes-specfflc arrays to realistically assess the CNV in non-human
primates. In the chimpanzee genome, CNVs, identified in 30 wild born
chimpanzees, were observed for 438 autosomal regions of which 144 overlapped
to human CNVRs (perry et a1. 2(08). This value was soon proved by Gokcumen
et a1. (2011) to under represent the real frequency of CNV in chimpanzee
genome, which identified 556 chimpanzee CNV s overlapping with more than
one thousand (1387) distinct human CNVs; 170 human CNVs were found to
overlap with both chimpanzee and rhesus macaque (Gokcumen et a1. 2011).
A common feature between the human and other primate genomes is the
frequent location of CNV s in regions of segmental duplications with high levels
of sequence identity, compared with the genomes of other mammals (Bailey
and Eichler 2006). In the human genome, several studies have shown that
CNVs regions are enriched by segmental duplications (SDs) (Iafrate et a1. 2004;
Sebat et a1. 2004; Tuzun et a1. 2005; Redon et a1. 2006; Korbel et a1. 2007; Kidd
et a1. 2008). It was suggested that about 51.6% of CNVRs overlap segmental
duplications in the human genome and a similar level of enrichment was
observed in the chimpanzee genome (39%) (Perry et al. 2008). SDs have also
been found to be enriched at CNV regions in the genome of rhesus macaque
(Lee et a1. 2008) and orangutan (Marques-Bonet et a1. 2009). However,
orangutan has fewer rearrangements and segmental duplications than humans
and chimpanzees (Locke et a1. 2011).
Humans and chimpanzees have significantly more SDs than the other
primate species, with a large portion being shared between human and
chimpanzee (Marques-Bonet et al. 2009). SDs have been strongly associated
with genomic instability and large-scale chromosomal rearrangements, since
their high sequence homology gives rise to recurrent NAHR (Lupski 1998;
Sharp et a1. 2006). This suggests their involvement in evolutionary
rearrangements and eventually in the origin of novel genes in the primate
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lineage (Samonte and Eichler 2002; Annengol et aJ. 2003; Bailey et aJ. 2004;
Bailey and Eichler 2006).
The presence of copy number variation at orthologous genomic regions in
both human and chimpanzee or rhesus macaque genomes (shared CNVs) are
likely to reflect unstable genomic regions that have been prone to recurrent
rearrangements during primate evolution, rather than maintenance of ancestral
polymorphisms. This suggests that structural features shared between primate
genomes, such as SDs, may predispose certain chromosomal regions to
structural instability in these primate species (Kehrer-Sawatzki and Cooper
2008; Perry et aJ. 2008), as previously reported for the human genome
(Samonte and Eichler 2002; Annengol et aJ. 2003; Bailey et aJ. 2004). On the
other hand, lineage-specific CNV s, which either evolved by positive selection
in one species or by negative selection in other contributing to intra- and
interspecies phenotypic variation, are important to understand the mechanisms
under the origin and evolution of CNV (Kehrer-Sawatzki and Cooper 2008).
The majority of primate CNV s have been shown to overlap functional
genomic regions, especially enriched by genes involved in immunity and
environmental response (Nguyen et aJ. 2006; Redon et aJ. 2006; Korbel et aJ.
2008; Gokcumen et aJ. 2011). Similar patterns of common copy number
diversity between humans and other primates were found for FCGR3AjB,
CCLBLI and the j3-defensin cluster. In human and chimpanzee genomes,
FCGR3AjB genes commonly show 4 copies per diploid genome, but fewer
individuals can have three or five copies, in humans (Perry et aJ. 2008). CCLBL
CNV was observed in chimpanzee and rhesus macaque (Lim et aJ. 2010).
Consistent with later findings in humans (Shao et aJ. 2007; Field et aJ. 2009;
Urban et aJ. 2009), suggesting that CCLBLI CNV is not associated with RN-I,
in rhesus macaque the CNV of CCLBL is not associated with susceptibility to
AIDS in individuals infected with simian immunodeficiency virus (SIV) (Lim et
aJ. 2010). Copy number variation of (1- and ~-defensin genes has been
described in humans and other primates but not in other mammals. In humans
~-defensin genes at 8p23.1 are highly polymorphic in copy number. Variation
in copy number of these genes was reported in chimpanzee (Perry et aJ. 2008)
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and in rhesus macaque the DEFB4 gene was observed to be copy number
variable as well (Lee et al. 2(08).
In a study carried out within the Drosophila melanogaster genome, genes
overlapped by CNV s were reported to have increased evolutionary rates
(Dopman and Hartl 2(07). In humans, elevated evolutionary rates were also
observed for genes located within CNV regions (Nguyen et al. 2008). Moreover,
it has been suggested that CNV regions are enriched by genes implicated in
"environmental" functions, possibly essential for the adaptation to the rapid
changing environments during human evolution (Gibbs et al. 2004; Feuk et al.
2006; Nguyen et al. 2006; Sharp et al. 2(06). The rHiefensin genes are key
components of the innate immune system with important roles in immunity,
reproduction and pigmentation. Their multifunctional role, and increasing
evidence that j3-defensinCNV is implicated with disease phenotypes in humans,
suggests that this CNV could be a hotspot for evolution. Therefore, it is essential
that the study of CNV will be extended to other great ape, such as gorilla and
orangutan, to shed light into the origin and evolution of CNVs in primate lineage
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1.3 AIMS OF THE PhD
The proposed PhD project will examine the variation in human ~-defensin
gene number and its effects in disease, human diversity and human evolution.
The research will include investigation of novel methodology for gene copy
number measurement for analysis of variable defensin genes, analysis of
association between gene copy number and disease, and exploration of
mechanisms of gene copy number variation in human populations.
The project is divided into three major objectives for the proposed
research. Firstly, new methods will be developed to accurately but conveniently
assess copy number variation, making use of the paralogue ratio test (PRT), to
build an accurate and high-throughput multiplex assay for ~-defensin copy
number measurement (chapter 3). Secondly, these newly developed methods
will be used in collaborations to evaluate copy number in collections of clinical
samples, to look for association between the copy number of j3-defensin genes
and disease states in psoriasis (Section 4.1). Finally, examination of copy
number in human populations (Section 4.2) and non-human primates (chapter
6) will be used to investigate human inter-population diversity and investigate
when variation in copy number has arisen in human populations. This work
hopes to contribute to the increased effort to understand the consequences of
DNA variation for health and disease.
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CHAPTER 2: MATERIALS AND METHODS
2.1 MATERIALS
2.1.1 DNA samples
2.1.1.1 ECACCHuman random control (HRC) samples
The study of unrelated UK Caucasians used control samples from the
ECACC Human Random Control (HRC) panels 1 and 2
(http://www.hpacultures.org.ukjproductsjdnafhrcdnafhrcdna.jsp). These samples
were from unrelated UK Caucasian blood donors and were prepared at a
lOnglJ.11DNA concentration. The genomic DNA was extracted from
lymphoblastoid cell lines derived by Epstein Barr Virus (EBV) transformation
of peripheral blood lymphocytes from Single donor blood samples. Then, the
DNA samples were subjected to standard techniques of DNA extraction and
purification and were provided at a standard concentration of lOOnglJ.1lin
lOmM Tris-HCI buffer (pH 8.0) with ImM EDTA. Due to its standard
concentration and consistently high quality provided these DNA panels were
frequently used as internal reference controls in the PRT assays.
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2.1.1.2 HapMap CEU/yRI/CHB/JPT
In this study DNA samples from the International HapMap Project
collections (http:/;hapmap.ncbi.nlm.nih.govtindex.html.en) were used to study
the j3-defensin copy number variation in different human populations. These
samples were collected from blood donors of four different Human
populations: Han Chinese from Beijing, China (CHB); Japanese from Tokyo,
Japan (JPf); Yoruba from Ibadan, Nigeria (YRI) and US residents from Utah
(CEPHjCEU). A set of 30 US trios (90 samples) with northern and western
European ancestry were collected by the Centre d'Etude du Polymorphisme
Humain (CEPH) and included in the CEPHjCEU HapMap collection. Another
set of 30 parent-adult child trios (90 samples) with Nigerian ancestry, with all
parents described to have four Yoruba grandparents, was included in the YRI
collection. In the]PT collection 45 unrelated individual samples from people
whose grandparents were all Japanese were included while in the CHB
collection, equally composed by 45 unrelated individuals, all samples came
from individuals with at least three Han Chinese grandparents. The DNA
concentration provided for all samples was 25OnglJ..llwith 50l-lgof DNA per well.
2.1.1.3 Disease status samples
A Dutch cohort (from Nijmegen) was used with the aim of studying the
~-defensin copy number variation in psoriasis disease and testing the
applicability of the HSPD5.8 PRT and the Triplex system in large association
studies. Both controls and cases from the Dutch cohort were from native
European Dutch origin and were supplied by our collaborator, Joost
Schalkwijk from the Department of Dermatology at the Radboud University
Nijmegen Medical Centre, Netherlands. 202 psoriatic DNA samples were
obtained from patients diagnosed with psoriasis vulgaris from the outpatient
clinic of the Radboud University Medical Centre. This patient group included
individuals diagnosed with moderate to severe psoriasis aged between 39 and
69 years old (male:female ratio of 70:30). Sixty-four healthy control samples
were obtained from the Nijmegen Biomedical study (NBS). The mean age of the
control cohort was 58 (±13) years with a male:female ratio of 56:44. The genomic
DNA from all blood donors was isolated through standard methods (Q!agen
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column or salting-out procedures). All samples from the cases and about half of
the controls were prepared by the same method [Qjagen) (Hollox et al. 2008b).
2.1.1.4 Non-human primates samples
In this study ten non-human primates were used, namely five gorilla
(GoriUa goriDa), three chimpanzees (Pan troglodytes), one bonobo (Pan
paniscue and one orangutan (Pongo sp.) from unknown subspecies. The
chimpanzee EBl76 JC and the gorilla EB JC DNA samples are from ECACC
(http://www.hpacultures.org.ukjproducts/dnafprimatedna.jsp). The exact origin
of DNA samples of Candy and Violet chimpanzees, orangutan, bonobo and
gorillas, Sylvia, Tomoka, Guy andJ79 were not possible to track, though they
were supplied by Professor Alec jeffreys's laboratory from the University of
Leicester. The DNA concentration provided was O.SnWml for bonobo,
200nWI.1lfor orangutan, chimpanzee EBl76 JC and gorilla EB Je and 5OnglJ.!l
for the remaining samples.
2.1.2 Reagents
2.1.2.110X PCR MIX
The "lOX PCR buffer", with high concentrations of MgC12 and dNTPs,
was essential to perform the HSPDS.8 PRT. This buffer consists of final
concentrations of SOmM Tris-Hel (pH8.8), 12mM ammonium sulphate, SmM
magnesium chloride (Mge12), 12Sflglml BSA, 7.4mM 2-mercaptoethanol and
1.lmM of each dNTP.
2.1.2.2 lOX Ld PCR Mix
The "lOX LeI" ("Low dNTP") rcn mix was used for the Triplex system,
microsatellites and RFLP (restriction fragment length polymorphism) assays.
This buffer contained a final concentration of SOmM Tris-Hel (pH 8.8),
12.SmM ammonium sulphate, 1.4mM magnesium chloride, 12SJ.1g1mlBSA,
7.SmM 2-mercaptoethanol and 200flM of each dNTP.
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2.1.2.3 TE buffer
TE buffer was used to dissolve and dilute DNA. The IxTE buffer was
composed of 10 mM Tris-HCI (pH B),which maintains the solution at a specific
pH and ImM EDTA, a chelator of divalent metals ions, particularly Mg2+ and
Ca2+which are co-factors for many enzymes including nucleases. As such, the
EDTA helps to protect DNA and RNA from enzymatic degradation.
2.1.2.4 O.SXTBEBuffer
This buffer was used in agarose gel electrophoresis and was made from
lOX TBE buffer, which contained a final concentration of 1M Tris-HCI, 1M
boric acid and IOmM EDTA pH B.O.
2.1.3 Primer design
PCR primers for the ~-defensin region at Bp23.1 were designed from the
human reference sequences available on the UCSC Genome Brower March
2006 assembly (http://genome.ucsc.eduf). The study of non-human primates
also used the orangutan and chimpanzee reference sequences available on the
UCSC Genome Brower on Orangutan July 2007 (WUGSC 2.0.2fponAbe2)
assembly and Chimpanzee Mar. 2006 (CGSC 2.1fpanTr02) assembly,
respectively. The Ensembl genome browser was used to look for gorilla
reference sequences in order to design PCR primers specific for this species at
the region of interest (http://www.ensembl.orWmdex.html).
The thermodynamic properties of PCR primers were confmned and
established by the Primer3 software (http://irodo.wi.mit.eduf). A Basic Local
Alignment Search Tool (BLAST) (http:j;blastncbLnlm.nih.gov) was used to
compare the PCR primer sequences (query sequence) with a library of sequences
[Trace Archive, NCB!) and identify library sequences that were similar to the
query sequences above a certain threshold. These bioinformatics tools were
essential to check for common sequence variants underneath the primers.
65
MATERIALS AND METHODS
J.2 MI1Hl!P\
2.2 METHODS
2.2.1 Polymerase chain reaction (peR)
2.2.1.1 peR in lOX peR MIX and lOX Ld peR MIX
PCR reactions were set up in a master mix of 1O~ or 20111final volume
using the lOX PCR or lOX Ld PCR buffer as described in sections 2.1.2.1 and
2.1.2.2. The lOX PCR mix was mainly used in the PCR for HSPD5.S PRT
(section 2.2.3.1), while all the other PCR reactions used the lOX Ld PCR
buffer. In addition to the lOX PCR or lOX Ld PCR buffer, PCR master mix
reactions contained final concentrations of 0.5J.LMof each primer, 0.05U Taq
DNA polymerase and lOng input DNA.
Subsequently, PCR products were amplified using 22-37 standard cycles
that included denaturation, annealing and extension/elongation steps (e.g. 95 G C
for 30 seconds, 5SGC for 30 seconds and 70"C for 1 minute). Cycle
temperatures, duration and number varied according to the properties of the
primers used and the products expected. The PCR cycle was frequently
followed by a Single "chase" phase of annealing for 1 minute and extension for
20 or 40 minutes to reduce levels of Single-stranded DNA and complete
terminal3' dA addition. In the presence of GC-rich regions the PCR cycle was
preceded by an initial denaturation of 95 G C for 5 minutes.
2.2.2 DNA electrophoresis
2.2.2.1 Agarose gel electrophoresis
Gel electrophoresis, using an electric field applied to an agarose gel
matrix, was used for the separation of DNA PCR products. The sizes of PCR
products were determined by comparison with a DNA ladder (100 bp DNA
Ladder, New England BioLabs) containing DNA fragments of known size,
which were loaded alongside with the PCR products. The gels were prepared
with an agarose concentration of 2-3% (wjv) and the appropriate volume of
0.5X TBE containing 0.5g1ml ethidium bromide.
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In order to run the DNA samples, these were prepared in a 10%solution of
5X loading buffer (0.02%bromophenol blue dye, 40% sucrose and 2.5x THE
buffer) and loaded after into the wells. The electrophoresis was normally
carried out at 100-130V for 1 to 2 hours and bands were visualized using a Gel
doc apparatus, which uses illumination under DV light. The results were
record by a eeD camera incorporated in the instrument.
2.2.2.2 Capillary electrophoresis
To perform capillary electrophoresis, a multi-colour fluorescence-based
DNA analysis system with 16 capillaries, the 3100 Genetic Analyser, was
utilized (Applied Biosystems, UK). The fluorescently-labelled peR products
were prepared to run on the capillary electrophoresis instrument by mixing 1
to 2,.11of peR products with 1O/l1HiDi formamide and 2/l1of ROX, an internal
size standard (GeneScan-ROX500, Applied Biosystems, UK). After this
procedure, the peR products were subjected to denaturation for 3 min at 96· e
and were separated on POP-4 polymer (Applied Biosystems, UK). Finally,
GeneMapper version 3.0 Software (Applied Biosystems, UK) was used for the
genotyping analysis and to collect peak area/height of the fluorescent-dye-
labelled peR products for analysis.
2.2.3 Paralogue ratio test (PRT)
The Paralogue ratio test (PRT) is a comparative peR based approach that
uses a precisely-designed pair of primers to simultaneously amplify a variable
repeat unit (test locus) and an additional unlinked reference locus that does not
vary in copy number (Figure 6) (Armour et al. 2007). The products are then
discriminated by size according to internal sequence differences. Paralogue
sequences were firstly used in a peR based method, Paralogue sequence
quantification (PSQ), for the detection of chromosomal aneuploidies (Deutsch
et al., 2004). While the PSQ used paralogous genes the PRT uses paralogue
sequences, not necessarily from paralogue genes.
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Figure 6: Schematic representation of paralogue ratio test (PR1'). The PRT primers (grey
segments) simultaneously amplify each copy of test and reference locus. This is only
possible due to the presence of a paralogue sequence (pseudogene and dispersed
repeat region) within the repeat unit, which is also present elsewhere in the genome
but not in a copy number variable region (reference locus). Therefore, after capillary
electrophoresis the ratio between the 2 copy reference locus (green) and the test locus
(blue) is used to measure the relative number of copies of a test locus (bottom panel).
In order to measure the diploid copy number of ~-defensins, three PRT
systems were developed showing slight modifications from the first developed
PRT, HSPD5.8 (Armour et al., 2007). The PRT primers were designed to
amplify from different locations within the p-defensin repeat at 8p23.1. All PRT
primers used are shown in Table 2.
Table 2: PCR primer sequences for the three PRT systems developed. The three PRTs were
used to amplify different locations in the (3-defensin copy number variable repeat.
PRT primer name Primer sequence (5'-3') Size resolved inABI
capillary electrophoresis
HSPDS.8
Forward:
CCAGATGAGACCAGTGTCC
Labelled Reverse:
TTTTAAGTTCAGCAATTACAGC
PRTl07A
Labelled Forward:
AGCCTCATTTAACTTTGGTGC
Reverse:
GGCTATGAAGCAATGGCCTA
HSPD21
Forward (human specific):
GAGGTCACTGTGATCAAAGAT
Forward (gorilla specific):
GAGGTCGCTGTGATCAAAGAT
Labelled Reverse:
AACCTTCAGCACAGCTACTC
After HaellI digestion:
Chr8: 302 bp
ChrS: 315 bp
Chr8: 157 bp
Chrll: 155 bp
Chr8: 172 bp
Chr21: 180 bp
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2.2.3.1 HSPDS.8
At the J3-defensincluster, the HSPD5.8 was the first PRT to be developed.
This method utilises sequence from a processed pseudogene for the heat-shock
protein HSPD, located 2 kb upstream of the DEFB4 gene and in 10 locations
elsewhere in the genome. The designed primers match the copy near DEFB4
and just one other copy on chromosome 5, with multiple mismatches at the
other locations in the genome (Armour et al. 2007). The primers therefore
amplify only the copy near DEFB4 (test locus) and the copy on chromosome 5
(reference locus), resulting in product fragment sizes of 443 bp and 447 bp,
respectively. However, these products are similar in size, differing just by 4 bp,
which makes it difficult to distinguish them by ABI capillary electrophoresis.
Therefore, a Haem digestion was performed, producing smaller and more
distinguishable products from chromosome 8 (302 bp) and chromosome 5 (315
bp) that can easily be resolved by ABI capillary electrophoresis.
The products were amplified by peR, performed in lOx peR mix as
described in section 2.2.1.1, for 30 cycles of 95 • e for 30 seconds, 53' e for 30
seconds and 70' e for 30 seconds. To reduce the occurrence of Single-stranded
DNA and allow the complete terminal addition of 3'dA this peR was followed
by a single "chase" phase of 530 e for 1 minute and 70' e for 20 minutes. In
order to increase the accuracy and precision of the measurement assay each
sample was amplified twice by a duplicate peR, each performed with a different
labelled primer, one with FAM-reverse labelled primer and the other with
HEX-reverse labelled primer. IJlI of each peR product was then digested with
Haem, in a lOJlIdigestion reaction containing lOx ReAct 2 buffer (New England
BioLabs) and 5U of Haem and incubated at 37'e for 4 to 16 hours. The use of
two distinct labels allows the multiplexing of the duplicate peR for each
sample in the same capillary lane. After HaeIII digestion, 2JlI of digest product
was added to 10JlI Hi-Di formamide with R-500 marker (Applied Biosystems)
and analysed by capillary electrophoresis as described in section 2.2.2.2.
2.2.3.2 HSPD21
The HSPD21 PRT is a modified version of HSPD5.8 PRT and was
designed in a way that allows the differentiation between test and reference
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locus without the need of a restriction digestion step. This system uses
sequence from the same processed pseudogene for the heat-shock protein
HSPD used for HSPD5.8 PRT, and a reference locus on chromosome 21. The
precisely designed pair of primers is very specific, resulting in products
exclusively from test (172 bp) and reference locus (180 bp). Although the
HSPD21 primers have counterparts in 8 other locations in the genome, none of
these locations has enough sequence similarity to compromise the specificity of
the primers to uniquely amplify the target sequences.
The PCR was performed in a lOx LeI PCR mix (section 2.2.1.1) in a
duplicate reaction for each sample, with either FAM-reverse labelled primer or
NED-reverse labelled primer. The peR amplification was preceded by a pre-
denaturation at 95· C for 5 minutes followed by 22 cycles of 95· C for 30
seconds, 58· e for 30 seconds and 70· e for 1 minute. The amplification was
finalised with a single "chase" phase of 58·C for 30 seconds and 70· e for 40
minutes; 1 ...1 of each reaction was added to 10...1 Hi-Di formamide with
Rox-500 marker (Applied Biosystems) and analysed by capillary
electrophoresis as described before (section 2.2.2.2).
2.2.3.3 PRTI07A
The variable region includes not only the DEFB4 gene but also other
defensin genes such as DEFBJ07. A PRT system was designed from a
dispersed repeat region near the DEFBJ07 gene that is also present in many
other locations in the genome. The primers have counterparts in seven other
locations in the genome but match perfectly only with two loci, a region just
upstream of the DEFBJ07 gene on chromosome 8 and a reference locus on
chromosome 11. Although the resultant products have just 2 bp difference in
length, 155 bp and 153 bp for test and reference locus respectively, capillary
electrophoresis can resolve and distinguish the two products.
The peR amplification and analysis of peR products by capillary
electrophoresis on the ABI was carried out under the same conditions
described for HSPD21 and in section 2.2.1.1 and 2.2.2.2. However, in this case
the forward primers were labelled with FAM and HEX dyes.
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2.2.3.4 Data analysis
For analysis of PRT data either peak area or peak height of the resultant
test and reference locus for each system was used. For HSPD5.8, peak areas of
test and reference locus were recorded by the GenescanjGenotyper software
(Applied Biosystems) and GeneMapper software (Applied Biosystems),
respectively. In the case of PRT107A and HSPD2l, GeneMapper software
(Applied Biosystems) records peak heights. The peak heights were chosen
instead of peak areas for the PRT107A and HSPD21 systems as the ratios given
by peak areas, for HSPD2l in particular, were repeatedly higher than the ratios
given by peak heights. This was mainly due to the presence of a NED dye
peak co-migrating with the test peak of HSPD21, which increased the peak area
and consequently the ratios. Thus, peak heights gave more accurate
measurements than peak areas.
A criterion for peak selection was applied to all peaks of the 4 different
PRT systems. Peaks that showed saturation, merged test and reference peaks
(only seen in the PRTI07A system), split peaks, tails or shoulder peaks that
change the peak height or a peak height lower than 50-100, were rejected and
not included on the analysis of the copy number.
For the first developed PRT, HSPD5.8, the peak areas corresponding to the
302 bp HaeIII fragment from the test locus on chromosome 8 and the 315 bp
fragment from the reference locus on chromosome 5 were recorded for both
FAM- and HEX-labelled products and the ratio between test and reference locus
calculated. The ratios of the two duplicates (FAM- and HEX-) were compared
and the results were accepted if the difference between the ratios was <;15%of
their mean. The mean ratios of the accepted tests, which corresponded to
about 90%of those attempted, were then used for further analysis.
The peak heights of PRTI07 A and HSPD21 test and reference products
were recorded for both dyes and the ratios between the corresponding
testjreference pairs of each system were calculated. The mean ratio of
HEX-jFAM-labelled products for PRT107A and FAM-jNED-labelled products
for HSPD21 were calculated and used for further analysis.
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In each experiment using HSPD5.8, PRTI07 A and HSPD21 selected
reference samples with known copy number were amplified Simultaneously
with the samples for which the copy number was unknown. The mean ratios of
the reference samples were then used to calibrate each experiment and the
resultant linear regression (least-square) used to infer the copy number of
unknown samples. The reference samples were selected based on their
reproducibility and agreement of results from numerous experiments either
performed with PRT or MAPHjREDVR (Figure 7, a, b and c).
a) Calibration of HSPDS.8 with reference samples
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c) Calibration of HSPD21 with reference samples
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Figure 7: The scatter-plots above show an example of the calibration performed in each
experiment with selected reference DNA samples with known copy number for
HSPDS.8 (a), PRTI07A (b) and HSPD21 (c). The unrounded mean ratio of each
reference sample was plotted against the corresponding copy number. The linear
regression obtained in each experiment was used to infer the copy numbers of
unknown samples.
2.2.4 Indel ratio measurements
Insertion deletion (indel) ratio assays were developed to confirm the
~-defensin copy number measured from the PRT assays. The indel assays
measure the ratio between the different alleles to predict the copy number.
Two indel assays, 5DEL and 9 bp indel, were used to investigate the copy
number of ~-defensin (Table 3).
Table 3: PCR primer sequences of the two indel assays used. The two indel assays were used
to amplify different polymorphisms in the ~-defensin copy number variable repeat.
Primer
Name Primer sequence (5'- 3')
Size resolved ID AB!
capillary electrophoresis
Labelled Forward: AAACCAATACCCTTTCCAAG
SDELIV
Reverse: TTCTCTTTTGTTTCAGA TTCAGATG
123 bp to 128 bp
9 bp indel
Labelled Forward: CCAAATGGAAGAATGGCGTA
Reverse: GTCCA TTGGGITCTCAAACT
298 bp and 308 bp
2.2.4.1 rsS889219 (SDEL)
Within the j3-defensin gene cluster at 8p23.1, about 10 kb upstream of
DEFB10J (chr8: 7,363,859-7,364,008), there are closely adjacent 2 bp and 5 bp
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deletions. Taking advantage of the proximity of the two deletions, a pair of
primers was designed to span the 2 bp / 5 bp deletions. The ratio between the
3 observed alleles was then used to predict the copy number. This assay was
performed together with the two PRT assays to form the Triplex assay.
Genomic DNA (lOng) was amplified by PCR in lOX Ld peR mix (section
2.2.1.1) for 22 cycles of 95' e for 30 seconds, 58' C for 30 seconds and 70' C for 1
minute. These PCR cycles were preceded by a pre-denaturation at 95°e for 5
minutes and followed by single "chase" phase of 5S'e for 30 seconds and 70"e
for 40 minutes to complete 3' dA addition. Each sample was amplified in duplicate
using either FAM or HEX-reverse labelled primers. Finally, the peR products
were analysed by capillary electrophoresis (section 2.2.2.2) by adding 1111 of each
reaction to WillHi-Di formamide with R-500marker (Applied Biosystems).
2.2.4.2 9 bp indel
A 9 bp insertionjdeletion found in the DEFB4 gene by sequencing (Abu
Bakar 2010), was used with the aim to clarify the segregation of copy numbers
from parents to children in an Sp23.1 inversion family case study. Two possible
alleles, corresponding to deletion or insertion of the 9 bp sequence, were
obtained and the ratio measured between them used to predict the p~efensin
copy number.
Using the primers listed in Table 3, genomic DNA was amplified with a
FAM labelled dye only by PCR with lOX Ld PCR mix (section 2.2.1.1) for 27
cycles of 95 • C for 30 seconds, 50' C for 30 seconds and 72' C for 1 minute and
then followed by a Single "chase" phase of 50' C for 1 minute and 72' e for 40
minutes to avoid the formation of Single-stranded DNA. IJ11of peR product
was added to 1OJ11HiDi formamide with R-500 marker (Applied Biosystems)
and examined by capillary electrophoresis as described in section 2.2.2.2.
2.2.4.3 Data analysis
The peak heights corresponding to both FAM- and HEX-labelled peR
products from 5DEL and Hex-labelled peR products from 9 bp indel were
recorded by GeneMapper software (Applied Biosystems).
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For the analysis of three or more alleles, such as the three alleles obtained
from 5DEL, a program was developed by John Armour (Institute of Genetics,
University of Nottingham) to evaluate the copy numbers. To calculate the copy
number, the program uses a "squared difference score" between the measured
ratio and the expected ratio, as described in more detail in section 2.2.7.2.
2.2.5 Microsatellite measurements
Microsatellites are highly polymorphic and abundant throughout the
human genome and due to their co-dominant and easy amplification by
polymerase chain reaction (peR); they have been widely used as genetic
markers to identify particular sequences of DNA in the human genome.
Microsatellites within the j3-defensin region have also been used to validate
copy number measured by PRT assays. Since the number of microsatellite
repeats is variable between alleles, these markers can be very informative and be
used to study duplications and deletions, but also to dissect the haploid copy
numbers and to look at the segregation of those copy number from parents to
children. So, to clarify the ~-defensin copy numbers, pairs of primers have been
designed to genotype three different microsatellites within the ~-defensin
cluster, EPEVl, 3 and 5, producing diverse product lengths corresponding to
different alleles (Table 4). After amplification, the ratio between the peaks
corresponding to different alleles is used to predict the copy number.
Table 4: PCR primer sequences for three microsatellite assays used to amplify different
regions of the JXlefensin copy number variable repeat.
Primer name PrImer sequence (5'-31 Size resolved inAB!
capillary electrophoresis
Labelled Forward:
EPEVI GGCAGTATTCCAGGATACGG 167 bp to 191 bp
Reverse: GAACAA TTAGAT ATCCCT ATGC
Labelled Forward:
EPEV3 GATACTGTGAACTACAGATCAC 127 bp to 151 bp
Reverse: CTGCCCTGA TTCAGT ATTGAAC
Labelled Forward:
EPEV5 ACCATTGTTGGTCATTTGTTCTT 150 bp to 160 bp
Reverse: TCAGGCAACTGGACAA TCAG
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2.2.5.1 EPEV1, 3 and 5
Three microsatellites were identified within the J3-defensin locus, EPEV1, a
variable er repeat located just downstream of DEFB106 (chr8:
7725964+7726151) and the two other microsatellites, EPEV3 and EPEV5, both
located within the DEFB107 gene (chr8: 7707791+7707933 and chr8: 7707822-
7707975, respectively). EPEV3 is characterized by a variable number of eA
repeats while EPEV5 has variable numbers of TA and TG repeats.
The microsatellites were amplified by peR with a HEX-labelled dye in a
lOX Ld peR mix (section 2.2.1.1). Genomic DNA (lOng) was amplified for 25
cycles of 95· e for 1 minute, 56 to 60· e for 1 minute and 72· e for 1 minute,
followed by a single "chase" phase of 72· e for 40 minutes (EPEV3) or 20
minutes (EPEVI and EPEV5). Annealing temperatures were variable according
to the micro satellite to be amplified (56, 58 and 60· e for EPEV3, 1 and 5,
respectively). As described earlier, peR products were analysed on capillary
electrophoresis (section 2.2.2.2) by adding 1.5J.LlpeR product to 1Oj..l1 HiDi
formamide with R-500 marker (Applied Biosystems).
EPEVI and EPEV3 were resolved in the same capillary electrophoresis, as
they have distinct product size ranges of alleles. The EPEV5 analysis was
carried out only in the 8p23.l inversion family case study (section 4.3) and
performed in a single capillary electrophoresis, since the peR product sizes
were very close to those of the EPEV3 assay.
2.2.5.2 Data analysis
Microsatellites are widely used as genetic markers and its analysis is
normally easy and straightforward. However, due to small differences in allele
size, the appearance of non-specific peaks adjacent to the main allele peaks is
quite frequent, posing a problem for correct allele-calling that could lead to
genotyping error. Sources of error include poor or non-specific amplification,
incomplete 3'-dA nucleotide addition and appearance of minor slippage products
("stutter" peaks). Typically 1 to 10 repeat units smaller than the main allele product
can appear due to slippage synthesis errors of Taq DNA polymerase during peR
elongation. This phenomenon is quite frequent during amplification of di-, tri-
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and tetranucleotide microsatellites, generating a characteristic and complex
migration profile, which nevertheless can be visually detected if using fluorescent
capillary electrophoresis. As such, all micro satellite traces were visually checked
to manually correct the allele calls given by the software.
peR amplifications of EPEVI, EPEV3 and EPEV5 microsatellites were
efficient and showed the expected product sizes. In the absence of peR
artefacts the intensities of peR products from microsatellites could be used
directly to infer their likely numbers. However, the formation of minor
products was observed in these microsatellites through the presence of "stutter"
peaks, usually with about 10-20%of the adjacent main allele peak area/height
(Figure 8). For EPEV3 and EPEV5, three main allele peaks were obtained, the
other ones being recognized as "stutter" peaks. The EPEVI can show up to five
primary micro satellite alleles and usually two minor products ("stutter" peaks)
resultant from peR slippage.
To analyse the effect of slippage, is important to first recognize if there are
any overlap between "stutter" peaks of different alleles. For the microsatellites
in question, the alleles overlapped, meaning that peR slippage created
products which were the same size for more than one allele, making it difficult
to recognize the original allele and the corresponding slippage product. The
commonest case observed is when two adjacent peaks (A and B, in Figure 9a)
show only one slippage product [C in Figure 9a). The peak e represents a
slippage product from B, but the slippage product from A is not visible
because it is "under" B. Therefore, to analyse the effect of slippage (degree of
influence) in the two main adjacent alleles a quadratic equation for three peaks
was applied: X=A+I;2(B-"(B2-4AC)), y=e+I(2(B+"(B2-4AC)) where A, B and e
are the observed peak areas, and X and y the corresponding original peak
areas, without slippage (Figure 9). The analysis described here only took into
account "first-level" slippage products and assumes that all alleles are affected
by slippage to the same (proportionate) extent. Since this quadratic equation
only analysed the effect of "stutter" peaks in the two adjacent peaks, for
microsatellites with more than three peaks, such as the EPEVI, an approximate
solution was applied to simulate the original peak areas when 3, 4 or 5 adjacent
peaks were present.
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Figure 8: Examples of the GeneMapper electropherogram for EPEVI (a), EPEV3 (b) and
EPEV5 (c) after capillary electrophoresis. In each electropherogram the real alleles
and the "stutter" peaks are shown for a sample with 5 copies. The copy number was
previously measured by the Triplex assay and confirmed by microsatellite assays.
The EPEVI shows three "stutter peaks" derived from the four primary microsatellite
alleles (180 bp, 182 bp, 186 bp and 188 bp). On the EPEV3 and EPEV5
electropherogram three main microsatellite alleles are visible, 136 bp, 140 bp and
142 bp and 152 bp, 157 bp and 159 bp, respectively with two secondary "stutter"
peaks for each microsatellite assay.
a) b) y x
c B A
Figure 9: a) Schematic representation of a microsatellite marker trace showing "stutter" peaks.
Peaks A and B represent the real alleles and C the "stutter" peak for alleles A and B.
b) Hypothetical reconstruction of areas of the original two peaks X and y after
slippage correction, assuming that the two alleles slipped equally.
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2.2.6 Restriction fragment length polymorphism (RFLP)
Restriction fragment length polymorphisms (RFLPs) have been used as
genetic markers to detect base-substitution variation by differences in the length
of restriction fragments. Since restriction enzymes cleave specific sequences,
mutations in a sequence can change the specific restriction site of an enzyme
creating a new sequence not recognized by the enzyme or, on the other hand,
creating a new restriction site. These polymorphisms are identified by changes
in the lengths of restriction fragments detected by DNA probes, RFLPs.
One SNP was found in initial analysis to be in linkage disequilibrium with
the proximal site (REPP) of J3-defensincopy number repeat at the 8p23.1 locus,
and therefore it could potentially be used to "tag" the copy number. To
investigate this correlation, rs12548700 was genotyped in different samples from
ECACC and HapMap cohorts (fable 5).
Table 5: PCR primer sequences designed to genotype one SNP found to be in LD with the
jHlefensin copy number variable repeat by the Haploview software.
Primer
name
Primer sequence (5'-3')
Size resolved in
agBI'08e gel
electrophoresis
Produdl ajzes
after digesU.OD
rs12548700
Forward:
GCTTGCCAATTCCAAAGAAG
228 bp
RsaI: 171, 38
and 19 bp or
146, 25, 38 and
19 bp
Reverse:
CCATGCTTGAAAATGTCTGAATGG~
2.2.6.1 rs12548700
To genotype the rs12548700 SNP a mismatch in reverse primer was
deliberately produced to create a context for RsaI (GTJ'lAC) RFLP, allowing
the discrimination between the two alleles (GjC). PCR using these two primers
produced a sequence different from the one present on UCSC due to the
mismatched reverse primer, creating a third restriction enzyme site if the
polymorphic base G was present.
Genomic DNA (lOng) was amplified by PCR in lOX Ld PCR mix (section
2.2.1.1) for 37 cycles of 95' C for 1 minute, 60' C for I minute and 70' C for I
minute. PCR was finalized with a single "chase" phase of 72 •C for 20 minutes.
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To allow the reverse primer to anneal efficiently, the peR was performed at
60· e annealing temperature even though the reverse primer had a higher
predicted melting temperature. The extra 5 to 6· e of "leniency" allowed the
reverse primer to perform efficiently, despite the mismatch. peR products of
228 bp were digested with Rsa! restriction enzyme. On digestion with Rsa!, the
228 bp product was cut into 171 bp, 38 bp and 19 bp in every sample.
However, if the polymorphic base was a G instead of e, there would be an
extra cut to split the 171 bp into smaller fragments of 146 bp and 25 bp. PCR
products were separated and visualized in 2% agarose gel electrophoresis
(section 2.2.2.1). The smaller fragments, such as the 19 bp, 25 bp and 38 bp
were not visible in the agarose gel, so in practice the 171 bp fragment indicated
the presence of the C allele (uncut), while the 146 bp fragment corresponded
to the G allele (cut).
2.2.7 Triplex system
The Triplex system resulted from the combination of two PRT systems
(PRTI07 A and HSPD21) and the 5DEL system, developed to measure the
~-defensin copy number. For each sample, two parallel amplifications were
performed using two different dyes, one with a FAM or NED label and the
other with HEX or NED label. Since the peR products, resulting from the
DNA amplification using each of these systems, were sufficiently different to be
distinguished by capillary electrophoresis, this makes possible to run the three
systems together in one capillary. The PRT systems were amplified together in
one peR reaction, while the 5DEL system was amplified in a separate peR
reaction. All peR reactions were carried out in lOX Ld peR mix (section
2.2.1.1) using lOng of genomic DNA following the peR cycles previously
described for PRT systems in section 2.2.3 and for 5DEL system in section
2.2.4.1. Finally, 0.5J..11to IJ..11of peR products, resulting from each reaction,
were added to Will HiDi fonnamide with Rox-500 marker (Applied
Biosystems) and separated by capillary electrophoresis (section 2.2.2.2).
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2.2.7.1 Data analysis
For data analysis the peak heights of each labelled product for
PRTI07A, HSPD21 and 5DEL (155 bp and 157 bp, 172 bp and 180 bp, and
123 bp to 128 bp, respectively) were recorded using GeneMapper software
(Applied Biosystems).
Mean copy number of both PRT systems was predicted from the mean
ratio of the two labelled products obtained for each PRT, using the calibration
equation taken from reference samples. To calibrate each experiment reference
samples were used as described in section 2.2.3.4. The unrounded copy
number of each PRT and the peak heights of the 5DEL alleles were introduced
in a likelihood program (section 2.2.7.2), which inferred the most likely copy
number for each sample.
2.2.7.2 Maximum likelihood analysis
A maximum likelihood program, written in C++ was developed by John
Armour to evaluate the copy number given by the Triplex system using a
likelihood analysis. An input file, including the unrounded mean copy
numbers of PRT107A and HSPD21 and the peak heights/areas of the 5DEL
system was used to run the program. The program evaluates the probability of
the data for each possible copy number from 2 to 9 for each individual PRT
and 5DEL systems, scoring the relative probability of the data for each copy
number class relative to the highest probability across all copy numbers (to 1)
(Table 6). In addition, the program also gives a combined probability, resulting
from the combination of the three systems together, with an overall probability
that indicates the maximum likelihood copy number (MLCN) for each given
sample. Simultaneously, a "minimum ratio score" which indicates the
probability of the data for the MLCN relative to the next most likely copy
number accompanied each MLCN. This "minimum ratio" value is therefore a
good indicator of confidence in the copy number, with best results represented
by a higher minimum ratio.
The probabilities, obtained from PRT data for each copy number group,
were calculated taking in consideration a normal distribution with a mean on
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integer values and a standard deviation of each copy number class for each
PRT system based on empirical observations. The 5DEL probabilities, on the
other hand, were calculated using a "difference score" (R_X)2, between the
measured ratio (R) and the expected ratio being tested (X). If more than two
peaks applied, the program uses the sum of two "difference scores" obtained
from the two ratios and takes the reciprocal of this value, so that the "difference
scores" are taken as proportional to the probability (the lower the difference
score, the higher the probability). Maximum likelihood analysis as described
here, relies not just on the accuracy of the standard deviation provided for each
copy number class of each PRT system but also assumes that each copy
number is equally likely before any test is performed. Despite knowing that the
prior probabilities of different copy numbers are not equal in reality, here a
conservative assumption of "flat priors" was followed.
Table 6: Output data from the likelihood analysis showing the relative probability of the data
at each copy number from 2 to 9 for PRTl07A, HSPD21 and 5DEL data. The best
copy number for this sample is also shown, as well as the minimum ratio associated
with the result observed. The minimum ratio indicates that the copy number of 5
(with the highest probability) is 399.16 times more likely than a copy number of 6
(second highest probability).
Sample C65
Area of peak Best copy
2 3 no.
SDEL 2474 2341 1330 5
PRTI07A 5.27
HSPD21 5.02
minimum 399.16
ratio
Relative likelihood values for Nz: Ratio Ratio
Test peaks 1:2 peaks 1:3
analysis
2 3 4 5 6 7 8 9
Combined 0 8.15Fr50 3.74EDB 1 0.002505 3.79E-1O 1.01E-ll 1.06E-16
PRTI07A 1.71E-135 4.84E-17 0.002397 1 0.372553 0.000406 0.000166 2.B9E-06
HSPD21 9.46E-99 2.24E-32 2.59E-32 1 0.09001 5.7BE-06 1.70E-07 4.B9E.10
SDEL 0 0.0747095 0.060208 1 0.07471 0.161496 0.358414 0.07471 1.05681 1.B6015
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2.2.8 DNA sequencing
To follow the investigation of the j3-defensin copy number variation in
non-human primates, sequencing analysis was performed for the loci of
interest, since very little sequencing information was available for some of the
species included in this study, particularly for gorilla. Sequencing analysis was
performed for different loci (chromosome 21 and DEFBJ03 gene), in order to
clarify the primates' DNA sequence or confirm the results given by PRT. PCR
and sequencing primers were designed in regions conserved in human,
chimpanzee and orangutan in order to increase the chance of amplification of
the gorilla and bonobo genomes (unknown sequence).
2.2.8.1 Chromosome 2110cus
In order to investigate the presence of the hspd3 pseudogene (reference
locus on human chromosome 21 for HSPD21 PRT) in the gorilla and bonobo
genomes and confirm the sequence information in chimpanzee and orangutan
for this locus, sequence analysis was carried out in all non-human primates; five
gorillas, three chimpanzees, one bonobo and one orangutan.
PCR amplification was performed using forward Chr21F and reverse
Chr21R (Table 7) in a lOX Ld PCR mix reaction (section 2.2.1.1).
Amplification was carried out for 37 cycles of 95· C for 1 minute, 63· C for 1
minute and 72· C for 1 minute. The amplification was finalised with a single
"chase" phase of 72· C for 20 minutes.
Table 7: PCR and sequencing primer sequences used for sequencing of the chromosome 211ocus.
Primer name Primer sequence (5'-a') Size resolved in agaroae gel
electrophoresis
Chr21
Forward:
CCAATGCTCACCGT AAGCITITGG
Reverse:
AATCTGACCGTGGCATCACAACC
734 bp (human and
chimpanzee)
726 bp (orangutan)
83
MATERIALS AND METHODS
2.2 1\111 Tf1nr'·
2.2.8.2 DEFB10310cus
In order to sequence the whole region of the DEFBJ03 locus, a pair of
primers was used to amplify a 1.8 kb product. Additional internal primers were
also designed to complete the sequence analysis of this locus.
Gorilla DNA was initially amplified by peR using forward DEFB103F and
reverse DEFB103R primers (Table 8) in a lOX Ld PCR mix reaction (section
2.2.1.1) to produce a 1.8 kb product. Amplification was carried out for 37 cycles of
950C for 1 minute, 590C for 1 minute and 720C for 1 minute. The amplification
was finalised with a single "chase" phase of 720C for 20 minutes. The PCR
products generated by the primary PCR were subsequently amplified in a
secondary PCR using two pairs of internal primers, forward DEFBI03F2 and reverse
DEFBlO3R3 or DEFB103R4, as described in Table 8. PCR amplification was
carried out for 37 cycles of 950C for 1 minute, 530C and 570e for 1 minute and
720C for 1minute; and finalisedwith a Single"chase" phase of 720C for 20 minutes.
Table 8: Primer sequences used for PCR and sequencing of the DEFBJ031ocus.
Primer name Primer sequence (5'-31 SJze resolved in asarosegel electrophores18
Forward:
DEFB103 CCAAGAGAGTGAAGAGTCCAACTT 1832 bp (human)
Reverse: GCAAAGTACGGACAAGTCAGC
DEFB 103F2jR3 Forward: TTTCTTCGGCAGCA TT 591 bp (human)
Reverse: CTTTCCCCAACTCTTCAAGG
DEFB103F2jR4 Forward: TTTCTTCGGCAGCATT 1007 bp (human)
Reverse: TTGGTCCAAAGCACTCTG
2.2.8.3 Allele-specific peR at DEFB103 locus
Allele-specific primers were designed for mixed allelic positions of interest
(fable 9) found by sequence analysis at the gorilla DEFBJ031ocus.
peR amplification of the target locus was performed using the appropriate
allele specific primers, as described in Table 9, in a lOX Ld PCR mix (section
2.2.1.1). Amplification was carried out for 37 cycles of 95 0e for 1 minute, 540C
to 620C for 1 minute and 700C for 1 minute, fmishing with a single "chase"
phase of 720C for 20 minutes.
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Table 9: Allele-specific primer sequences used for sequencing variant positions found at the
DEFBJ03locus inJ79, Tomoka and Sylvia.
Primer name Primer sequence (5'-31
DEFBI03RJ79_A
DEFBI03RJ79_G
DEFB103F _To.Sy_C
DEFB103F_To.Sy_T
CATTGGAATGATGCATCA
CATTGGAATGATGCATCG
GCATTTTCGGCCACGC
GCATTTTCGGCCACGT
2.2.8.4 Sequencing strategy
Before sequencing, PCR products were purified using the Agencourt
AMPure XP PCR Purification system (Beckman Coulter), to remove dNTPs
and unincorporated primers. To check that the correct products were
amplified, products were separated on a 1.5% agarose gel electrophoresis
(section 2.2.2.1). Sequencing reactions were set up in a 1O/l1total volume with
the purified DNA products in a mix with final concentration of 0.5/lM primer,
5X sequencing buffer (25OmM Tris (pH 9.0) and IOmM MgCI2), standard
BigDye® Terminator v3.1 (Applied Biosystem, UK). For each DNA product
two sequencing reactions were set up, each with one of the two primers
described for each locus, in a high-profile 96 well microplate. DNA products
were amplified for 25 cycles at 960C for 30 seconds, 50 to 580C for 15 seconds
and 60· C for 4 minutes. The conditions applied for amplification, as cycle
temperatures and times, were adjusted according to the primers used and the
expected products. Finally, products were subject to purification using
Agencourt CleanSEQ (Beckman Coulter). Capillary electrophoresis of sequence
products was performed at DBS Genomic (Durham University, School of
Biological and Biomedical Sciences) using Applied Biosystems 3730 instrument
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CHAPTER 3: DEVELOPMENT OF A MULTIPLEX PRT
BASED SYSTEM TO MEASURE THE
(3-DEFENSIN MULTIALLELIC CNV
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In human genetics the identification of genetic variants that contribute to
disease has long been a primary aim. The genetic methods used until recently,
such as standard cytogenetic methods, Southern blotting and peR based
approaches, were able to identify large heterochromatin polymorphisms (large
deletions and duplications) and single nucleotide polymorphisms. Even though
many genetic determinants have been identified for common and complex
disorders, little was known about intermediate variants, their frequency in the
human genome and their importance for disease and human evolution.
With the development of micro array technology, SNP genotyping arrays
and next generation sequencing in the last five years, our knowledge of human
genetic variation was extensively improved with the discovery of several
copy-number variants including some with important roles in disease
phenotypes (Iafrate et al. 2004; Redon et al. 2006; Korbel et al. 2007; Kidd et
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aJ. 2008; Conrad et aJ. 2010; Handsaker et aJ. 2011). These discoveries
presented a completely new perspective on the structural organization of the
human genome, highlighting copy number variation as a frequent type of
genetic variation with phenotypic consequences, considered as important as
Single nucleotide polymorphisms (SNPs) (Iafrate et aJ. 2004; Sebat et aJ. 2004;
Feuk et aJ. 2006). Copy number variation has been recognized to have an
important role in human evolution, genetic diversity between different human
populations and in conferring susceptibility to complex disease traits (genomic
disorders) (McCarroll and Altshuler 2007; Wain et aJ. 2009; Lee and Scherer
2010; Stankiewicz and Lupski 2010).
Established technologies for copy number typing, such as FISH, array-
CGH (Comparative genome hybridization) and QMPSF (Quantitative
Multiplex PCR of Short Fluorescent fragments) have been extensively used for
CNV detection encompassing between 0 and 3 copies, showing a good level of
accuracy (Armour et aJ. 2002; Vaurs-Barriere et aJ. 2006; Carter 2007).
However loci highly polymorphic in copy number, such as the ~-defensin
locus, pose a technical challenge for accurate copy number typing. Other
methodologies, such as MLPA and MAPHfREDVR, have been frequently
used and proved to be able to determine the copy number of highly
polymorphic loci, but they use large amounts of genomic DNA (between lug
and l00-25Ong of DNA, respectively) and are expensive and/or laborious
(Hollox et aJ. 2003; Hollox et aJ. 2005; Groth et aJ. 2008). On the other hand,
real-time PCR, which has been one of the most extensively used methods for
copy number determination in large scale studies, did not demonstrate enough
accuracy to distinguish between high copy number values. This led to
contrasting results in two independent association studies where the ~efensin
copy number was investigated in Crohn's Disease patients (Fellermann et aJ.
2006; Bentley et aJ. 2010). So far, none of the technologies available seems to
be an inexpensive, accurate and high-throughput method to measure copy
number in large case-control association studies. In order to address copy
number variation and the biological importance of ~efensin copy number
variation, a new methodology was developed taking into consideration
accuracy, cost and applicability to large cohorts.
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In this study, a new comparative peR based approach was developed to
measure the copy number of jH:lefensin at the 8p23.1 locus. Initially adapted
from paralogue sequence quantification (PSQ), used for the detection of
chromosomal aneuploidies (Deutsch et al. 2004), the paralogue ratio test (PRT)
uses paralogue sequences located both in the reference and test locus to
comparatively measure the copy number of the test locus (Armour et a1. 2007).
The PRT is a quantitative multiplex PeR-based approach that uses a unique
pair of primers to amplify from a copy of the paralogue sequence within the
variable repeat unit and from a copy on the reference locus, which does not
vary in copy number. The resultant peR products are subsequently
discriminated according to size differences in internal sequence. Using a unique
pair of primers to amplify test and reference locus reduces problems of
accuracy and reproducibility frequently observed in multiplex peR. Due to the
different thermodynamic properties of primers and amplicons, differences in
amplification rate between test and reference locus can be observed in multiplex
peR, as for example in real-time peR, and compromise the accuracy of the
measurement. As such, the PRT system should create a great advantage over
any multiplex PeR-based method, in particular real-time peR. Moreover, the
use of only a small amount of genomic DNA (1O-20ng) and the Simple and
inexpensive methodology design of PRT, should allow an accurate, rapid and
high-throughput copy number typing of jH:lefensin in large-scale studies.
In the first developed PRT method, HSPD5.8 PRT, the primers were
designed to amplify from a heat-shock protein pseudogene (HSPDP3), just -2
kb upstream of the DEFB4 gene on chromosome 8, and from a reference
copy on chromosome 5 (section 2.2.3.1) (Armour et al. 2007). Additionally,
this heat-shock protein pseudogene of -2 kb is found at 10 other locations
elsewhere in the genome. However, HSPD5.8 primers show several
mismatches with the other copies of the HSPDP3 pseudogene as shown in
Figure 10. Therefore, following careful and precise primer design, a single
pair of primers was designed to amplify exclusively the test and reference
loci. The method was validated for the copy number measurement of
jH:lefensin by comparison of its results with measurements previously
obtained from MAPHjREDVR, MLPA and array-eGH for the same samples
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(Armour et al. 2007). The HSPD5.8 PRT was comparable in accuracy to
these alternative methods and showed a high reproducibility in determining
the copy number (-89-95%correct calling) (Armour et al. 2007). Moreover,
due to its simple format, PRT is a suitable method to apply in large cohorts,
showing clear advantages relative to other methodologies frequently used to
measure copy number. However, for highly polymorphic copy number loci,
as the ~-defensin cluster at 8p23.1, the development of further assays that
include the multiplex of several systems will improve the accuracy of the
copy number measurements.
SOOkb repeat
8p23.1
8p23.1 ------
chr8 (OEFB4) CCAGATG OACC GTGTC .. 443 bp " OCTOT ATTG TGAA 'TTAAAA
chr5 CAGATGAGAC AGTGTC .. 447 bp .. TGTAATTG TGAACTIAAAA
hSIJdcOl A gcagatgagaccggtgtcc . (2 introns) , gc 19 t a a t tgc tga a c tta a a a
chrl2A CCAGATGAG n. ,TGTC .. " OCTGTA TTG TGAACTTAAAA
chr3 --AGAT \AGAC AlTGTC .. ., GCTGTAAT\GCTGAAC< TAAAA
chr4 CAGAT AGAC 'AGTGTCC.. ..0 THAATfG TGAAC( \AAAA
chrBA C IAGATGAGA \ 1GT T C" " CTGTAATTG TGAACTI(.AAA
chr21 I CAGATGA( AC AGTOr <... . .0 TGT AlTO TOAAClTAAAA
chr6 CCAGATGAG CC(,GTGTC .. " G'IT\TAATT T ,AA TTAA<.A
chrBB CA T AGAC I <.GTGTCC . . __ \ TGTAATTGCTGA CTrAC,( A
Figure 10: Principle of the HSPD5.8 PRT assay at the 8p23.1 locus. The top line shows the
structure of the repeat unit with the black arrows representing two inverted repeats
(March 2006 assembly). The middle panel shows the location of the seven different
~defensin genes (SPAGIJ, DEFB4 and DEFBI03-10?j in each of the inverted repeat
units. The bottom line shows the location of the primers used for this assay, just 2-3
kb upstream of DEFB4 gene, and the amplified peR products on chromosome 8
(test locus) and chromosome 5 (reference locus), as well as the multiple mismatches
with other copies of the HSPDP3 pseudogene in other locations in the genome.
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To improve the accuracy and efficiency of the copy number measurement,
a Triplex assay composed of two paralogue ratio tests, PRTI07 A (section
2.2.3.3) and HSPD21 (section 2.2.3.2), and an indel system, 5DEL (section
2.2.4.1) was developed to measure the copy number of the ~-defensin cluster at
8p23.1. The idea behind the development of a multiplex system relies on the
assumption that typing the copy number of a given sample by more than one
method at the same time should improve the results without compromising the
time, cost and efficiency of the method. The Triplex assay should consequently
increase the accuracy and precision of the copy number measurements and
represents a new high-throughput method to apply in large-scale studies. Similar
to the HSPD5.8 PRT described earlier, the PRT107A and HSPD2I PRT
followed the same principle, which relies in the simultaneous amplification of test
and reference locus with just one pair of primers. At -20.6 kb upstream of
DEFBJ07 gene lies a dispersed repeat region, which can also be found in other
locations in the genome. The PRT107A primers were designed to uniquely
amplify from the dispersed repeat region of the test locus on chromosome 8 and
from a reference locus on chromosome 11, showing several mismatches with
other loci (Figure l lb). Similarly, the design of the HSPD21 PRT primers relied
on the presence of the heat-shock protein pseudogene (HSPDP3) near DEFB4.
As such, primers were designed to amplify each copy of the pseudogene
present in the test locus on chromosome 8 and in only one other locus on
chromosome 21 (reference locus) (Figure Ila). The primers showed
mismatches with other locations in the genome which were sufficiently different
in sequence to not interfere with the expected products (Figure 11b). The third
component of the triplex system, 5DEL, compares indel alleles from different
repeats and works as a verification assay for copy number measured from PRT
analysis (section 2.2.4.l.). Taking advantage of a 2 bp and 5 bp deletion only a
few base pairs apart and located within the copy number variable region on
8p23.1 10 kb upstream of DEFBJ07 gene, the primers were designed to include
these two variants. Therefore, three possible alleles can be obtained
corresponding to the full repeat (128 bp), the repeat with a 2 bp deletion (126
bp) and the 5 bp deletion sequence (123 bp), and the ratio between the 3
alleles can be used to predict the copy number (Figure Ha). As a result, the
triplex trace obtained for each sample showed the peR products of each
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assay as shown on the bottom panel of Figure l1a. Since the products from
each assay have different length sizes, the three assays can be multiplexed in
the same capillary and analysed without any interference between each other.
In the example shown in Figure 11a, an individual with 4 copies of the
~-defensin repeat unit is represented. The PRTs show a ratio between reference
and test locus of 2:4 and the 5DEL indicates a ratio of 1:1:2. All three assays
agree between each other indicating a copy number of 4. Moreover, the results
for each sample provided by the three assays were combined and analysed by
a likelihood analysis that determines the most likely copy number from 2 to 9
(section 2.2.7.2). The Triplex assay described here was applied to a large
cohort of control samples (ECACC panel 1) and the results were compared
with previous results obtained with other methodologies for the same samples,
to test the accuracy of the method.
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a) Triplex Assay
Dispersed
repeat DEFBI07 DEFBI05 DEFBI06 DEFBI04 5PAGll DEFBI03 DEFB4 DEFBI09
...
M
N
C-
oo
-
..,
HSPDP3
pseudogene
1I PRT: compare signalbetween test and referencelocus
Single pair of primers
Forward' AGCCTCATTTAACTTTGGTGC
Reverse GGCTATGAAGCAATGGCCTA
Single pair of primers
Forward- GAGGTCACTGTGATCAAAGAT
Reverse: AACCTTCAGCACAGCTACTC
Compare indel alleles
from different repeats
1 1 1
Indel rsS889219 PRTl07A PRTHSPD21
• ratios
approx. 1:1:2 DEFB DEFB
b)PRT107A
Prl.mer.s
DEF!31 7A
JEf31073
Chrll
Chr2
Chr~B
Chr13
ChI' 5
9ll!
ChI'~A
Chr'lC
c) HSPD21
Prl.lller~
Chr8
Chr2
Chr 3A
Chr'lA
ChrS3
Chr12
Chr3
ChrS
Cbr2
Chr6
reference
chrll
reference
chr21
AGCCTCATTTAACTTTGGTGC TAGGCCATTGCTTCATAGCC
AGCC7CA7TTAACTTTGGTGCctatqctctqa 157bp tq4qtaTAGGCCATTGCTTCATAGCC
AGCC7CA7TTAAC7TTGGTGCctatqctctqa 157bp tqaqtaTAGGCCATTGCTTCATAGCC
AGCCT ATTTAAC7T7GGT Cctatgctctga 55bp qqattqTAGGCCATTGCTTCATAGCC
AGCC7CA77TAACTTCGGTGCctqtgctctga lS7bp qgattgTAGGCCATTGCTTCATAGCC
AGCC7CA7T7AAC7TCTGTGTctgtqctctqa gqattaTAGGCCATTGC7TCATAGCC
AGCCTCATTCAACTTTGGTGCctgtgctttga ggattgCAGGTCACTGATTCATAGCT
AGCC7CA777AACT7CGGTGCctgttctctga qoactqTAGACCAT-GCTTCATATCC
AGCC7CA7T7AACTTCGCGGTgcctgggctctga ggattgTAGGCCA:TGCTTCATAGCC
AGCCTCATTTAACTTCAGTACctgtqCtcta4 ggattqTAGGCCAITGCICCATAGCC
AGCCTCAT7TAACTTCGGTGTctgtgctctga ggatcaIAGGCCAITGCAITOTAGCC
~GGTCACTGTGATCAAA~T ......................• GAGTAOCTGTGCTGAAGGTT
GAGGTCACTGTGA:CAAAGATtatgcc ... 72bp cagatgGAGTAGCTGTGCTGAAGGTT
GAGG:CACTGTGA: AAAGAIgatgct ..• 180bp cagatgGAGLAGCTGTGCTGAAGGTT
GAGGTCATTGTGACTAAAGAItatgct .........• . cagatgGAGTAGCTGTGCTGAAGGTI
GAGG:CA~G:GACCAAAGACgatgcc ...• ......• cagatgGAGTAGCTGTGCTGAAGGTI
GAGGTCATTGGGACCAAAGGTgatgct aaaatgGAGTAGCTGTGCTGAAGGTI
CAAGTC~CCGOGCCCAGCCgatgcc • ...• • ....• cagatgGAGTAGCTGTGCTGAAGGTT
GAGGTCATTGTGACCAAAGATgatgcc ...• ....• .. cagatgGGATAGCTAIGOCAAAGGTT
GAGG:CATTGTGACCAAAGACgatgcc ..• ........ cagatgGAGTAGTTGTGCTGAAGTTI
GAGG:CATTGTGACCAAAGACgatgcc cagatgGAGTGGCTGTGCTGAAGGTA
GAGG:CAT':TTGACCAAATATaatac~ ...• • ....• . caaataGAGTAGCAGTGCTGAAGGCT
Figure 11: Principle of the Triplex assay at the 8p23.1 locus. Schematic representation of the
Triplex assay (a), showing on the top line the structure of the repeat unit (March
2006 uese assembly) with the seven I>-defensin genes (SPA GIl, DEFB4 and
DEFBI03-10lj, the dispersed repeat region just upstream of DEFBI07 and the
heat-shock protein pseudogene (HSPDP3) -2 kb upstream of DEFB4. The bottom
panel represents a typical capillary electrophoresis trace for Triplex assay. Each trace
shows the SDEL, PRT107A and HSPD21 peR products in two labelled dyes.
PRT107A (b) and HSPD21 (c) amplification details showing the amplified peR
products on test (chromosome 8) and reference locus (chromosome 11 and 21), as
well as the multiple mismatches with other copies of the dispersed repeat region and
the HSPDP3 pseudogene, respectively, elsewhere in the genome.
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3.2.1 Quality control, accuracy and validation
The Triplex assay was firstly applied to a cohort of 96 control samples
from ECACC HRC panel I, which have been previously genotyped by other
methodologies, such as MAPH (multiplex amplifiable probe hybridization),
REDVR (restriction enzyme digest variant ratio), MLPA (multiplex ligation
probe amplification) and array-CGH (comparative genomic hybridization)
(Armour et al. 2007). The use of samples with known copy number allowed a
comparison between the results produced by the Triplex assay and the copy
number values established by the previous methodologies. By using this
comparison it was possible to test the accuracy of the Triplex assay for copy
number measurement. The Triplex assay showed a miscalling rate of just
5.26%, meaning that in - 95% of the samples the Triplex yielded the correct
integer copy number value. To undertake the genotyping of this cohort, four
reference samples selected from the ECACC HRC panel I (Cll, CI8, C62
and C66) were used as internal controls to calibrate each experiment. The
reference samples were selected not only because they showed reproducible
results for multiple assays, including PRT assay, but also they represent copy
numbers of 3 (CII), 4 (CI8), 5 (C62) and 6 (C66). For these samples, which we
had prior knowledge of the copy number using other methods, such as MAPH,
and concordance of PRT data with other results demonstrated that the
reference locus was not variable in copy number, showing a constant diploid
copy number of 2 (Figure 7, section 2.2.3.4). The remaining ECACC HRC
panel I samples (92 samples) were genotyped several times, to test the
reproducibility of the method, in 96 well plates that included the reference
samples and blanks. For each samplejrepeat the peak area of each allele was
used to calculate the PRT ratios obtained for FAM- and HEXjNED-labelled
products. PRT ratios were then calibrated against the ratios of reference
samples to predict the copy number of those samples.
To test the concordance and accuracy of the Triplex assay, the unrounded
copy number values from PRT107A and HSPD2I were plotted in a scatter plot
and the level of clustering was used to evaluate the performance of the PRT
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systems. As shown in Figure 12, different copy number clusters were formed
around integer values. These clusters correspond to different copy number
groups and are clearly separated from each other, showing the ability of this
assay to accurately measure copy numbers up to 10 copies. On the other hand,
the clusters centred at integers also demonstrate the concordance in the copy
number measured by each PRT for the same sample, giving a clear perspective
of the extent of variation between independent measurements of the same
sample with different PRT systems.
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Figure 12: Unrounded copy number values of PRTI07 A and HSPD21 for ECACC panel 1
samples typed by the triplex assay. The scatter-plot shows clear clusters centred in
integer values, highlighted by the red circles (drawn by hand), that correspond to
different copy numbers classes. In this plot, the PRTI07A values are more spread
than the HSPD21 copy number values. (The 96 ECACC panel 1 samples were
typed several times with the Triplex assay making a total of 237 different repeats).
The same degree of clustering is also demonstrated by the mean copy
number distribution of PRTs and the HSPD2l PRT alone (Figure 13b and c).
In the histograms b) and c) of Figure 13, the unrounded copy numbers are
distributed around integer values showing either a gap or a very low frequency
between the different copy number classes. The degree of clustering observed
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for HSPD2l and the mean of PRTs was not reproduced for PRTI07 A (Figure
13a). Although the unrounded copy number values of PRT107 A tend to
approximate to integer numbers, the clustering for 4, 5 and 6 copies is not so
defined, with higher than expected frequencies of intermediate values. The
mean copy number data (c) shows the lower standard deviation (0.046),
calculated from the normalized mean unrounded copy number values, which
support the accuracy of the measurements obtained from the Triplex assay and
shows that the combination in Triplex of different systems is the most accurate
way to measure the beta-defensin copy number variation.
The analysis of copy number values is based in the assumption that only
integer values represent the real biological copy number. This assumption
disregards the existence of any somatic mosaicism, and therefore the
differences observed between the measured values and the closest integer
values (ML CN), denoted copy number residuals, should represent the error
of the method and can be used to evaluate the accuracy of the Triplex assay.
To test this hypothesis the copy number residuals for PRT107A and HSPD21
were calculated from the fmal copy number value given by the likelihood
analysis (ML eN) and plotted in a scatter plot as shown in Figure 14. The
residuals of both PRTs tend to be close to zero, which indicates that the
majority of the copy number values obtained from the Triplex assay were
correctly called and the lack of correlation suggests that no mosaicism was
observed. The closer the copy number residuals are to zero, the more accurate
the measurements and the system. In the presence of somatic mosaicism, the
residuals would have correlated distributions, instead of independent
distributions, indicating a correlation between the PRT107A and HSPD21
residuals. In this case no Significant correlation was found between the
PRTI07A and HSPD21 residuals (p-value=O.6719, Pearson's correlation test),
which provides no evidence for somatic mosaicism. The PRT107 A residuals
vary between -0.51 and 1 (average residual 0.126) from the rounded copy
number given by the ML CN, while the residuals from HSPD21 vary between
-0.91 and 0.75 (average residual -0.15). The range of variation for the HSPD21
residuals is wider than for PRTI07 A, but the HSPD21 frequently gave more
copy number residuals closer to zero as shown in the histogram (Figure 15).
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a) ECCAC Panel 1 samples: PRT107 A (N=237)
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Figure 13:Histogram of unrounded copy number distribution of PRTI07A (a), HSPD21 (b)
and the mean of PRTI07A and HSPD21 (c), showing a clustered distribution
centred in integer values (the 96 ECACC panel 1 samples were typed several times
with the Triplex assay making a total of 237 different repeats). The standard
deviation shown for each assay was calculated using normalized copy number values
from PRTl07A, HSPD21 and the mean PRT, respectively.
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PRT residuals from the ML CN (N=94)
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Figure 14: Comparison of copy number residuals of PRTl07A and HSPD21 from ECACC
HRC panel 1 data. The residuals were calculated from the difference between the
measured unrounded copy number value of each PRT and the integer copy
number (ML CN) given by the maximum likelihood program for 94 samples.
Residuals of each PRT system from the ML CN value (N=94)
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Figure 15: Histogram showing the frequency distribution of copy number residuals from
PRTl07 A and HSPD21 performed in Triplex assay for the ECACC panel 1 HRC
panel I samples. The residuals were calculated from the difference between the
measured unrounded copy number value of each PRT and the integer copy
number (ML CN) given by the maximum likelihood program.
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Further validation of the Triplex assay was carried out through an extensive
comparison with the publicly-available data generated from a hybrid genotyping
array featuring more than 1.8 million genetic markers (Affymetrix SNP 6.0) and
tiling oligonucleotide micro arrays comprising 42 million probes, by McCarroll et
a1 (2008) and Conrad et a1 (2010), respectively. This data comprises three
HapMap collection cohorts, CEU (CEPH individuals with northern and western
European ancestry from Utah, USA), YRB (Yoruba from Ibadan, Nigeria) and
CHBLJPf (Chinese from Beijing, China and Japanese from Tokyo, Japan). The
table below shows the number of samples typed and the percentage of
agreement between the copy number values generated for the three Hap Map
cohorts by the Triplex assay and by the two other studies (Table 10). From a
initial comparison of either Triplex assay or McCarroll et al. (2008) data with
Conrad et a1 (2010) copy number values, a very low degree of agreement was
observed for any of the populations (between 0010 and 3.80%).This suggested that
copy number values were systematically called with a one copy number value
offset due to an original copy number miscalling of the reference genome used in
the array-CGH based approach by Conrad et al. (2010). Therefore, further
comparisons were carried out based in this assumption and Conrad et al. (2010)
data referred as Conrad +1. As such, the Triplex assay showed a high percentage
of agreement for any of the three populations (between 86.08%and 93.51%)with
both of the studies, McCarroll et a1 (2008) and Conrad +1 (Conrad et al. 2010).
Table 10: Comparison of copy number data from Triplex assay with data generated by
McCarroll et al. (2008) and Conrad et al. (2010) for three HapMap collection
cohorts: CEU (CEPH individuals with northern and western European ancestry from
Utah, USA), YRB (Yoruba from Ibadan, Nigeria) and CHBLJYf (Chinese from
Beijing, China and Japanese from Tokyo, Japan). Number of samples typed in
common between studies and percentage (%) of agreement is indicated for each
population. Conrad +1 refers to the Conrad et al. (2010) data with the increment of
one copy number value for each sample.
CEU YRB CHBBPT
Total % of Total % of Total % of
typed agreement typed agreement typed agreement
McCarroll vs. Conrad 80 0 74 0 69 1.45
McCarroll vs. Conrad +1 80 100 75 93.33 70 97.14
McCarroll vs. Triplex 84 92.86 84 89.29 77 93.51
Conrad vs. Triplex 86 1.16 79 3.80 82 3.66
Conrad + 1 vs. Triplex 86 93.02 79 86.08 82 90.24
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The frequencies obtained for each copy number class for these HapMap
cohorts were also compared with frequencies previous published by different
studies. The first histogram (Figure 16a) reports the ~-defensin copy number
frequency distribution from seven independent studies carried out in the
European HapMap cohort, CEU. f3--defensin copy number frequency
distributions were very similar between studies, with the exception of the
frequencies observed for 3 copies, in which Bentley et al. (2010), Fellermann et
al. (2006) and Aldhous et al. (2010) showed higher frequencies than the other
studies. Regarding the Yoruba and ChineseLJapanese HapMap cohorts (Figure
16b and c), copy number frequency distribution given by Triplex assay was
plotted together with frequency distributions obtained from McCarroll et al.
(2008) and Conrad et al. (2010). In Yoruba, similar frequency distributions
were shared between the three studies for copy numbers of 3 and 4 and
between Triplex assay and McCarroll et al. (2008) for copy numbers of 5 and
6. Comparable frequencies were also observed between all studies for copy
numbers of 2, 3 and 4 in the CHBLJYf cohort, but only Triplex assay showed
frequencies for high copy number values up to 7 copies.
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Figure 16: [3-defensin copy number frequency distribution in CEU (CEPH individuals with
northern and western European ancestry from Utah, USA) (a), YRB (Yoruba from
Ibadan, Nigeria) (b) and CHBLJPT (Chinese from Beijing, China and Japanese from
Tokyo, Japan) (c) HapMap collection samples. All histograms show frequency copy
number distribution given by McCarroll et al. (2008), Conrad + 1 (Conrad et al.
2010) and the Triplex assay. Additionally, in the CEU histogram copy numbers
frequencies from Aldhous et al. (2010), Fellermann et al. (2006) and Bentley et al.
(2010) are also represented.
3.2.2 Data characterization
To analyse the data, given by the Triplex assay, a likelihood function was
used to calculate the probability of each copy number given the measurements
obtained, assuming a normal distribution for PRT data (section 2.2.3.4).
Therefore, here it was tested if the copy number values given by the Triplex
assay PRT results followed a normal distribution using quantile-quantile plots
(Q-Q plots). A Q-Q plot is a probability plot, which allows the comparison of
two probability distributions by plotting their quantiles against each other. In
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this case, the normalized CN data set was plotted against a standardized
normal distributed data, to determine how well the CN data set of values fitted
a normal distribution (theoretical model) (Figure 17).
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Figure 17: Quantile-quantile plots of PRTI07A (a), HSPD21 (b) and arithmetic mean of PRTs
(c) comparing normalized eN distribution on the Y-axis to a standard normal
distribution on the X-axis (theoretical normal distribution). The linearity of the
points suggests that the data are normally distributed.
101
DEVElOPMENT OF A MULTIPLEX PRT BASED SYSTEM TO MEASURE THE P-DEFENSIN CNV
1) h 1<
Therefore, if the two distributions being compared were linearly correlated, the
points in the QQ plot would approximately lie on the linear regression line, as
shown in the plots for PRT107A, HSPD21 and the mean of PRTs.
To further evaluate the performance of each PRT system in measuring
different copy numbers, the standard deviation and "integer error" (incorrect
classification of an integer) of PRT107A, HSPD21 and the mean of both PRTs
were calculated for each copy number value (Table 11). The "integer error"
described here represents, for each copy number class, the cumulative
probability of an observed value occurring below or above ±O.S decimal points
around each integer value, taking into account its mean and standard
deviation. As a result, it gives the predicted probability of the method assigning
the wrong copy number. As shown in the table below, the standard deviation
and "integer error" of 6 copies is the highest in any system. Moreover, the
PRT107 A is the system that exhibits the highest standard deviation and
"integer error" for almost all the copy number groups. On the other hand, the
mean PRTs showed the lowest standard deviation and "integer error" for all copy
number values analysed.
Table 11: Standard deviation (std. dev.) and "integer error" of each copy number from 3 to 6
for PRTl07A, HSPD21 and the mean PRTs. The values were calculated from the
copy number values obtained from Triplex assay for ECACC HRC panel 1 cohort.
CN PRTI07A HSPD21 MeanPRTs
std. dev. integer error std. dev. integer error std. dev. integer error
3 0.29 0.16 0.27 0.07 0.24 0.04
4 0.40 0.22 0.35 0.16 0.28 0.08
5 0.34 0.18 0.25 0.06 0.23 0.03
6 0.60 0.41 0.47 0.32 0.48 0.31
Finally, the unrounded copy number of each PRT system (PRT107A and
HSPD21) and the peak area of each allele from the SDEL assay were analysed
by a likelihood function which gave the most likely copy number along with a
index of confidence (minimum ratio) for each sample (section 2.2.7.2). If
samples were typed more than once, the integer copy number was selected
based on the higher minimum ratio. The JHlefensin copy number for 94
samples from the ECACC HRC panel 1 cohort is shown in Figure 18. As
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shown in the histogram, the ~-defensin copy number varied between 3 and 10
copies with a mean copy number of 4.43 copies. The copy number of 4 is the
most common and is present in about half of the samples typed.
p-defensin copy number distribution in UK (N=94)
60
50
40
10
1 2 3 4 5 6 7 8 9 10
copy number value
Figure 18: J3-defensin frequency copy number distribution in a UK population cohort (ECACC
HRC panel 1). The histogram shows integer copy numbers obtained from the
Triplex assay. The copy number for each sample was defined by the result with a
higher minimum ratio.
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3.3 DISCUSSION
The present study aimed to develop an accurate and robust methodology to
measure j3-defensin copy number variation in large case-control association
studies. The PRT-based Triplex assay, developed here, was able to consistently
distinguish between different copy number classes, as demonstrated by the
analysis of clustering from the repeated typing of reference samples (Cll, CIS,
C62 and C66 from the ECACC HRC panel I). The formation of clusters around
integer values, separated by gaps, was observed both for the reference samples
and for all other ECACC HRC panel I samples and was a clear indication of the
accuracy of the Triplex assay. This clustered distribution of the unrounded copy
number values suggested that the copy number values measured by the Triplex
assay represented the real copy numbers and the outlying measurements
represented the error of the method. The hypothesis presented here was also
supported by the analysis of residuals, which showed no Significant correlation
between PRT107A and HSPD2I residuals suggesting that either mosaicism is not
frequent or is not very extensive. As such, if two independent measurements of
the same sample give a different outcome, this would be more likely due to a
random error than due to somatic mosaicism. Nevertheless, a small degree of
mosaicism cannot be ruled out, since the analysis used here is not able to detect
this degree of mosaicism. To achieve that, it would be necessary to use
mathematical modelling to predict the amount of mosaicism that would be
represented by a Significantp-value. Finally, to overcome any possible difference
in accuracy between experiments, the calibration of the copy numbers given for
each sample was carried out against internal reference controls, thus
guaranteeing an overall uniformity along different experiments.
The Triplex assay was validated by comparisons with results from three other
established methodologies for the ECACC panel 1 cohort, showing a low error
rate of 5.26%.Further validation, carried out in three HapMap collection cohorts,
comparing the Triplex assay with array-CGH based approaches again confirmed
the accuracy of the Triplex assay due to the high level of agreement observed on
this analysis (>86%). The Triplex assay therefore proved to have comparable
accuracy to very well established methods, such as MAPHjREDVR, MLPA and
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array-CGH. The Triplex assay combines the ability of a high-throughput method
with the advantages of a low cost and simple methodology, a combination of
characteristics that is not present in any of the other methodologies.
The calculated standard deviation and the estimated rates of "integer
error" of each copy number class indicated that highest copy numbers (6
copies) presented the greatest "integer error"; a result already expected for a
method that relies on the measurement of ratios. These parameters were
independently calculated for each PRT system (PRTl07A and HSPD2l) and
for the mean of the two PRTs. The values obtained for standard deviation and
rates of "integer error" for each system demonstrated that PRTl07 A was the
less accurate. A possible explanation for this is the co-amplification of the
reference locus with a further locus on chromosome 2 that has only one
mismatch with the forward primer sequence. In this case, the reference locus
shows a higher yield resulting in an apparent lower copy number from the
PRT107 A system. However, this phenomenon did not affect the other two
assays (HSPD21 and 5DEL). On the other hand, the combination of two PRTs
provided the higher accuracy and precision in the measurement of f3-defensin
copy number variation, demonstrated by the lowest values of standard
deviation and rates of "integer error". Moreover, as it would be expected from
the multiplex of PRT systems, the PRT-based Triplex system developed here
showed a lower error rate (5.26%)when compared with a single PRT system
(HSPD5.8, -7%) (Armour et al. 2007), which supports the initial idea for the
development of a multiplex system. The Triplex assay increased the power of
copy number measurement, which is especially important in studying
multiallelic copy number loci. A Multiplex PRT, combining three different
PRT systems was first used to measure the CCL3LJjCClALJ copy number
variant genes (Walker et al. 2009). In this study the multiplex PRT also showed
accurate and reproducible data in large scale genotyping, assigning all samples
to discrete copy number classes (Walker et aJ. 2009).
Amplification failure of any of the two copies of the reference locus, due to
primer mismatch or a copy number variant, would lead to an apparent increase
in copy number of test locus for the system affected (Armour et al. 2007). The
failure to amplify a variant sequence from either test or reference locus or the
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possible variation in copy nwnber of the reference locus would lead to the
disagreement of a particular system with the other two assays that compose the
Triplex assay. However, this effect was not observed, as neither of the PRT
systems showed a copy nwnber difference of exactly twice the value of
consensus copy number, so there is no evidence to suggest lack of amplification
of one or more copies of the reference locus. The degree of concordance
between the systems also suggests that the presence of SNPs and/or copy number
variants in the reference loci is not frequent among the European population.
The Triplex assay has now been successfully applied by other groups to
investigate the lHlefensin genomic copy number variation in different
populations (Fode et al. 2011). In this study the Triplex assay was used
alongside real-time peR and pyrosequencing-based paralogue ratio test
(P-PRT) to type lHlefensin copy number. Interestingly, the triplex assay
appeared to be the most precise and accurate method shown by the improved
clustering of this assay when compared with the other two methods.
The applicability of PRT and of a PRT-based Triplex assay can be
expanded to other loci. Though the design of PRT is dependent on the
existence of paralogous sequences, these can be often found in the human
genome and used to design PRT assays to investigate other copy number
variable regions. PRT systems have been used to measure the copy number
variation of the DEFAI/DEFA3 genes (a-defensins) at the 8p23.1 locus (Fayeza
Khan, personal communication), the CCL3Ll/CClALl copy number variant at
the 17q12 (Walker et al. 2009), the complement C4 gene (in the class In region
of the major histocompatibility complex, MHC) on the short arm of
chromosome 6 (Fernando et al. 2010) and the immunoglobulin-receptor genes
FCGR3A and FCGR3B on chromosome lq23.3 (Hollox et al. 2009). Apart
from these loci many others have closely linked paralogous sequences, which
are present at constant copy nwnber, that can be used as reference loci in PRT
systems to measure for example the RHD, CYP2D6 and PRB} copy number
variable genes (Armour et al. 2007). Another possibility is the use of an
unlinked reference locus, as described previously for HSPD5.8 and HSPD21
PRT which rely on the presence of a pseudogene (HSPDP3) near DEFB4 gene
to allow the design of these PRT systems. In addition to DEFB4, 18 other copy
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variable loci were found to harbour an unlinked reference locus which allows
the design of a specific PRT assay, such as for UGT2B17 or SMN2 genes
[Armour et al. 2(07). The PRT applicability is relatively broad and it was
suggested that at least 50% of copy number variable genes allow the design of
PRT systems (Armour et al. 2007).
The PRT-based Triplex assay described here showed accurate and
reproducible results for about one hundred European control samples
(ECACC HRC panel 1) and concordance between independent PRTs
confirms that the reference loci are not variable in copy number, supporting
the idea that this is a high-throughput system suitable to apply in large-scale
case-control association studies. However, the accuracy described here for the
PRT-based Triplex system needs to be demonstrated in larger genotyping
studies, an essential requirement to evaluate the performance and reliability of
a copy number measurement methodology. Recently, this was demonstrated in
two studies carried out in large case-control association studies using the PRT-
based Triplex assay to measure jHlefensin copy number variation in Crohn's
Disease (Aldhous et al. 2010) and psoriasis, which will be reported in chapter 4.
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CHAPTER 4: APPLICATION OF THE TRIPLEX SYSTEM
4.1 ~-DEFENSIN CNV AND PSORIASIS: A CASE-
CONTROL ASSOCIATION STUDY
4.1.1 Introduction
The human j3-defensins are secreted antimicrobial peptides with cytokine-
like properties (Ganz 1999b; Yang et al. 1999; Niyonsaba et al. 2004). The
j3-defensins are secreted by leukocytes and a variety of epithelial tissues, such as
skin, lung, gastric antrum, oral and nasal mucosa, cornea and urogenital tract
(Schutte and McCray 2002; Ganz 2003). They are part of the innate immune
system acting as the first line of defence against several pathogens, such as
bacteria, virus and fungi (Ganz 2003; KIotman and Chang 2006). Taking into
consideration the role of j3-defensins in innate immunity, the variation of
(3-defensingene copy number suggests variability in gene dosage that ultimately
could contribute to the susceptibility to infectious and inflammatory diseases
(Fellermann et al. 2006; Bentley et al. 2010).
In 2005, Hollox et al. investigated association between (3-defensin copy
number variation and severity of cystic fibrosis, an autosomal recessive genetic
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disease associated with a frequent lung infection caused by chronic bacterial
colonisation of the lungs. The human !}-defensin 2 peptide (encoded by the
gene DEFB4) is expressed in the lung airway and due to its antimicrobial
activity, the DEFB4 gene was identified as a possible candidate gene for
modifying cystic fibrosis severity. However, the study revealed no Significant
association between severity of cystic fibrosis and j3-defensin copy number
variation in 355 patients with the disease (Hollox et al. 2005).
The j3-defensin genomic copy number, in particular of the DEFB4 gene,
has been associated with Crohn's disease. However, this is not without
controversy (Fellermann et al. 2006; Bentley et al. 2010). While in the
Fellermann et al. study in 2006, Crohn's disease of the colon was associated
with low DEFB4 copy number, a more recent study by Bentley et al. (2010)
found an opposite association with higher DEFB4 copy number. The first study
suggests that the antimicrobial properties of defensins protect the intestinal
mucosa against bacteria. As such, a low copy number of these defensins could
provide a lower level of protection against microorganisms and cause chronic
inflammation, characteristic of Crohn's disease (Fellermann et al. 2006). Bentley
et al. (2010) on the other hand suggest that Crohn's disease has an autoimmune
effect and that the high copy number of j3-defensins could increase the
expression of antimicrobial pepndes resulting in inflammation of the intestinal
epithelium (Bentley et al. 2010). Even though it has been proposed that
J3-defensin genes play a role in susceptibility to Crohn's disease, a recent study
carried out with PRT-based methods failed to replicate any association with
J3-defensin copy number variation (Aldhous et al. 2010; The Wellcome Trust
Case Control Consortium 2010).
Although the studies mentioned above did not clearly report any disease
associated with ~-defensin copy number variation, other inflammatory diseases
have also been investigated. Among these was psoriasis, an inflammatory skin
disease with a strong genetic aetiology and associated with high j3-defensin
copy number (Hollox et al. 2008b). Many different susceptibility loci have been
described to influence and increase the risk of the disease, with the HLA-Cw6
allele, of MHe locus on chromosome 6p21.3, being described as the major risk
allele for psoriasis (Russell et al. 1972; Tiilikainen et al. 1980; Gudjonsson et al.
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2003; Karason et aI. 2003). Some histological evidence acquired from the
examination of psoriatic lesions, where considerable amounts of the hBD-2
protein encoded by DEFB4 gene have been detected, support the hypothesis
that j3-defensins could be implicated in the susceptibility to psoriasis (Harder et
al. 1997a; Hollox 2(08). Moreover, a study from Hollox et aI. (2003) correlated
the lymphoblastoid mRNA expression level variation of DEFB4 with j3-defensin
genomic copy number (Hollox et al. 2003). This suggests that mRNA and
consequently the protein levels of these peptides may reflect the number of
DEFB4 gene copies, and therefore may be dependent on gene dosage. Finally,
taking into consideration the chemokine and cytokine-like properties of hBD-2,
which lead to the recruitment of immature dendritic cells to the site of
inflammation, it is possible that high amounts of this protein may cause an
atypical inflammatory response in the skin, ultimately leading to the formation
of psoriatic plaques. Therefore, is appropriate to highlight DEFB4 copy
number as a candidate gene for psoriasis.
To investigate the relationship between p-defensin genomic copy number
and susceptibility to psoriasis, two independent case-control association
studies were performed. In the first study, a Dutch cohort was genotyped
using HSPD5.8, the first developed PRT. These samples were Simultaneously
genotyped by Hollox et al., using MAPHJREDVR in order to confirm the
copy number. Alongside this, a German cohort of psoriasis patients and
controls was genotyped using HSPD5.8 by our collaborators in Erlangen
(Gennany), using patients from Mttnster (Hollox et aI. 2008b). In the second
(follow up) study a PRT-based triplex assay was used to re-type the Dutch
cohort only. The study presented here aims to contribute to the
understanding of how copy number variation can influence disease
development, focusing in particular on the consequences of the j3-defensin
copy number variation in psoriasis. Hopefully the clarification of such
mechanisms will be a step forward for the understanding of psoriasis and may
lead to the development of improved therapies.
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4.1.2 Results
4.1.2.1 Quality control and accuracy
To carry out the genotyping of psoriatic and control samples in the two
independent case-control association studies, four reference samples, with known
jklefensin copy number, have been used as internal controls to calibrate each
experiment (Figure 7, section 2.2.3.4). The reference samples Cll, CIS, C62 and
C66 were selected from ECACC HRC panel 1, corresponding respectively to
copy numbers of 4, 3, 5 and 6. The samples have not only showed reproducible
results with multiple PRT assays but their copy numbers had been also confirmed
by other methodologies such as, MAPH (multiplex amplifiable probe hybridization)
and REDVR (restrictionenzyme digest variant ratio) tests (Armour et al. 2(07).
In the first study carried out using only one PRT system, HSPD5.S, the peak
area of each test and reference product were recorded in order to calculate the
relative ratio (section 2.2.3.l). Alternatively a PRT based triplex assay was applied
in the second (replication) study and in this instance the peak heights were
recorded instead to avoid the presence of a NED "dye peak", that CO-migrated
together with the test peak of the HSPD21 PRT system (Figure 19) (section 2.2.3.2).
FAM and HEX dyes also exhibited dye peaks, but these did not interfere with any
of the peaks corresponding to the test or reference locus of any system used in the
triplex assay (section 2.2.7). Moreover, it was possible to observe in some samples
a shift of "dye peaks" from their original position showing that they have variable
mobility (Figure 19). Once the NED "dye peak" overlaps the HSPD21 test peak,
the peak area will not correspond to the real area of the test peak because it will
include extra material from the "dye peak". As such, data from the peak area of
NED dye products will not be accurate, as demonstrated in the histograms below
(Figure 20b). However, when using peak height both FAM and NED unrounded
ratios are clustered, as shown by the histogram of Figure 20a. In the second
histogram (Figure 20b), the values obtained from peak area for NED dye are
spread along the Y-axis, indicating the addition of extra material from the "dye
peak" and consequently giving inaccurate copy number measurements.
Therefore, these results supported the use of peak heights as a better indicator of
copy number variation to be used in further analysis (Figure 20a).
111
APPLICATION OF THE TRIPLEX SYSTEM
4 1 ~-defensin CNVAND PSORIASIS: A CASE-CONTROL ASSOCIATION STUDY
a) Control Sample
IOOOr-~IW~ ~I~W~ ~140~ ~I~~ ~I~~ ~1~70~ ~I~~
900 HEX dye peak
seo "173bp"
700
eoo
500
32'1:: !l\ ~FAM dye peak"124bp"
o~~~~~~~==~~~~~~~~~~~~~~~~~~~~
ROXmarker
150bp
ROXmarker
139bp
NED dye peak
"168bp"
~
b) Sample 1
4000r- __ ~1W~ ~1W~ 1~40~ ~1~~~ ~1~=- ~1~70 ~1~~
3000
HEX dye peak
"172bp"
NED dye peak
"167bp"
FAM dye peak
"123bp"
c) Sample 2
120 160 170130 140
5000
4000
NED dye peak HEX dye peak
"170bp" "174bp"
FAM dye peak
3000 "125bp"
Figure 19: Location of dye peaks generated from FAM, HEX and NED primers on a triplex
PRT-based assay. The blank control shows the position of dye peaks from FAM,
NED and HEX with apparent sizes of 124 bp, 168 bp and 173 bp, respectively (a).
Location of the three dye peaks in sample 1 (b) and sample 2 (c) is slightly shifted,
approximately 1 to 2 bp, when compared with the original location in the blank
control. On both samples 1 and 2, the variable mobility of the dye peaks is shown.
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Figure 20: Results produced by HSPD21 PRT system in Triplex assay given by the data
analysis of peak areas and peak heights for FAM and NED dyes. a) Scatter-plot of
unrounded ratios from peak height for FAM and NED dyes showing a high
concordance between the two data sets and clustering of values, presumably
corresponding to integer values. b) Scatter-plot of unrounded ratios from peak area
for FAM and NED dyes showing a poor concordance between the two data sets.
Analysis of peak areas produced consistently higher ratios for NED dye products
due to the introduction of extra material from the "dye peak".
The HSPD21 NED peaks frequently showed a lower signal when
compared with FAM peaks, and were consequently more prone to error. For
this reason, a comparative analysis was carried out to test if the unrounded
copy numbers given by FAM and NED dyes were equivalent. The
histograms (Figure 21) show the HSPD21 copy number distribution given by
FAM only, the mean of FAM and NED and the weighted mean of the two
dyes. Clearly, either the use of the FAM dye by itself or the weighted mean
of PRTs showed more distinct clusters when compared with the use of the
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arithmetic mean of PRTs. To calculate the weighted mean ratio a proportion
of 2:1 (FAM, NED dyes, respectively) was used to determine the HSPD21
mean ratio of each sample. Decreasing the influence of the results from NED
dye in the mean ratio improves the final copy number results. When
compared with the arithmetic mean, the weighted mean improved the copy
number measurements, especially for high copy numbers, suggesting that
NED dye actually introduced greater error into the measurement. As such,
using a weighted mean ratio of FAM and NED gave a more accurate
outcome, as shown in the histogram by the formation of clear clusters
separated by deeper gaps (Figure 2Ic). For the PRT107A, an arithmetic mean
of the two dyes, FAM and HEX, was calculated since the two dyes gave
constantly equivalent outcomes.
To confirm the accuracy of the triplex measurement on the reference
samples, the degree of clustering of the unrounded copy numbers for
PRT107 A and HSPD21 was analysed. As illustrated by the scatter plot (Figure
22), the two PRT systems show clusters around integer numbers corresponding
to 3, 4, 5 and 6 diploid copies of the four reference samples used, C18, CII,
C62 and C66, respectively. Although the unrounded copy numbers are still
clustering around the integer numbers for the majority of the cases, the clusters
corresponding to the CII (4 copies) and C62 (5 copies) are not exactly centred
at 4.0 and 5.0 by the PRT107A method. The CII cluster is shifted towards a
slightly lower unrounded copy number (-3.8 copies) while the C62 cluster is
shifted towards a higher unrounded copy number (-5.2 copies), possibly due
to the mismatch in the primer that allows simultaneous amplification of a third
locus on chromosome 2.
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Figure 21: Histogram of HSPD21 unrounded copy number distribution of Nijmegen samples
typed in the second case-control association study. a) HSPD21 copy number
distribution for FAM dye only. b) HSPD21 copy number distribution for the mean.
c) Weighted mean copy number of FAM and NED dyes. The weighted mean ratio
was calculated as: (2 x FAM ratio + NED ratio);3 and then used to calculate the
weighted mean copy number of each sample.
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Figure 22: Unrounded copy number given by PRTl07A and HSPD2I PRT systems in the
triplex assay for multiple typing offour reference samples, CI8, Cll, C62 and C66.
The scatter-plot shows clear clusters around integer numbers 3, 4, 5 and 6,
corresponding, respectively to the four reference samples above.
4.1.2.2 Typing details} strategies and results concordance
4.1.2.2.1 FIRST CASE-CONTROL ASSOCIATION STUDY (HOLLOX ET AL. 2008B)
The initial study to investigate the relationship between p-defensin genomic
copy number and susceptibility to psoriasis disease was carried out on a Dutch
cohort consisting of 493 samples, 303 of which were controls and 190 psoriasis
cases. However, for 42 Dutch samples no PRT data was available (8.52%
failed), lowering the total number of samples actually typed with PRT to 451
(272 controls and 179 cases). These samples were genotyped in 96-well plates,
which included a mix of cases, controls, reference samples and blanks
allocated at random to a well position in each 96-well plate. This proceeding
minimizes any batch-related error that could cause differential bias between
cases and controls. Several case and control samples (267 samples in total)
were replicated twice or more (maximum four times) between the 10 different
96-well plates used.
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The PRT ratios obtained for HEX- and FAM- labelled products were
selected and accepted for use in copy number determination if the ratios of the
two-labelled products differed by less than 15%of their mean. For the results
accepted, the average of the two ratios was calculated and used to determine
the copy number of each sample. Unrounded copy number values given by
HSPD5.8 PRT were plotted on a histogram and the analysis of integer
clustering was carried out to test the accuracy of PRT to measure B-defensin
copy number (Figure 23). In the histogram, different clusters were formed
corresponding to distinct copy number classes. While lower copy numbers,
from 2 to 5 copies, showed good clustering with deep gaps, higher copy
numbers were more difficult to distinguish and measure accurately. However,
this was already expected from a method based on ratios, which normally
determines lower copy numbers more accurately.
Nijmegen samples: HSPDS.8 PRT
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Figure 23: Histograms of unrounded copy number distribution of Nijmegen samples using
HSPD5.8 PRT. The copy number distribution shows clusters around integer
numbers, with low copy numbers showing an improved clustering when compared
with high copy numbers (from Hollox et al. 2008).
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The cumulative frequencies of residual values from PRT are shown below
(Figure 24). Since residual values are the difference between the measured
unrounded copy number and the integer value, they can actually demonstrate
how well the method performed. In other words, the residuals represent the
error of the method, if we assume that the biological meaning of copy number
can only be represented by integer values. In the histogram, Figure 24, the
frequency distribution of copy number residuals from cases (mean -0.055) and
controls (mean 0.038) were comparable. Although the frequency of cases was
slightly increased for negative residuals, overall the frequencies for cases and
controls were very similar. The standard deviation observed for cases (std.
dev.=0.25) and controls (std. dev.=0.24) indicates that the unrounded copy
number values given by PRT are normally close to the integer value
demonstrating the accuracy of the method.
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Figure 24: Comparison of cases and controls cumulative frequency distributions of residuals
from HSPD5.8 PRT data. The residuals were calculated from the difference between
the measured unrounded copy number value of PRT and the integer copy number
(from Hollox et aJ. (2008b)).
To increase the accuracy of the copy number estimates, this cohort was
also retyped by other methods, MAPH and REDVR, and a consensus
integer copy number was established for each sample using the information
given by the three methods together, as described in Hollox et al. (2008b).
The comparison of integer copy numbers showed that 78% of samples
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agreed between first-pass PRT and MAPHjREVDR and a further 11%
agreed when a repeat typing PRT was performed on the discordant samples
(Hollox et al. 2008b). Overall, 89% of samples agree in a copy number value
between the different methods, which confirms the accuracy of the HSPD5.8
PRT to measure the ~-defensin copy number, even in large case-control
association studies.
4.1.2.2.2 SECOND CASE-CONTROL ASSOCIATION STUDY
The study described here is an independent case-control association study
carried out in the same Dutch cohort from Nijmegen, Netherlands. Here,
samples were genotyped using a PRT-based Triplex assay to measure the
~-defensin genomic copy number variation. The ~efensin copy number
variation was analysed in a total of 475 samples, of which 279 were controls
and 196 were psoriatic cases (Table 12). From those samples, 33 controls and 7
cases were excluded either because they failed to give any genotype (20
controls) or because no copy number was determined (13 controls and 7
cases). The genotyping failure was mainly due to the low amount of DNA
available while the inability to determine copy number was due to the
disagreement between different systems and the low quality of results. Further
analysis was carried out on the remaining 246 controls and 189 cases. To
genotype the ~efensin copy number variation, cases and controls were
arranged at random in 96-well plates, which also included blanks and reference
samples. Some of these samples were replicated more than once among the
seven 96-well plates used. As described earlier, this procedure reduces any
batch-specific error associated with technical handling that could affect cases
and controls differently.
Table 12: Numbers of cases and controls successfully typed and failed.
Successful Data Teatl attempted No data available
Dutch controls
Total
246
189
435
279
196
475
33
7
40
Dutch cases
119
APPLICATION OF THE TRIPLEX SYSTEM
4 1 G defpn'ill CNV ;,':' I/" r
The main advantage of the Triplex assay is to provide three independent
measurements of the same sample simultaneously, two from PRT systems and
one from an indel assay. In comparison to a Single PRT, the Triplex assay
offers much more information about the copy number of a given sample.
However, to accept the results, concordance between the copy number
measurements derived from each system that composed the triplex assay was
taken in consideration. Such combination of all results increases the confidence
of the copy number measurement.
The criteria to accept the results required the analysis of the "minimum
ratio", a confidence index of the copy number given for each sample by a
likelihood function (maximum likelihood copy number, ML eN) (section
2.2.7.2). From the 435 samples successfully typed, 47 samples showed a
minimum ratio less than 20 and were therefore retyped. All samples with a
higher minimum ratio were selected for further analysis. Then the copy
numbers for every sample given by each system were compared. The ML eN
was accepted if at least two systems agreed between themselves and with the
ML eN (329 samples). In case of disagreement a careful analysis of the
information from 5DELR4 peaks was carried out to investigate if the 5DELR4
system supported any of the PRT systems or the ML eN given by the
maximum likelihood program. When the allele ratios obtained from 5DELR4
showed evidence of agreement with any of the PRT systems or the ML eN,
the fmal copy number was dictated by 5DELR4 and if necessary the ML eN
would be changed (3 samples). When neither of these conditions applied (56
samples), samples were retyped using either the Triplex assay or micro satellite
analysis. From the total of 103 samples that did not pass the criteria or failed to
give any outcome, only 98 samples were retyped, as DNA was no longer
available for 5 samples. Samples were retyped using the Triplex assay if the
initial typing failed or results were only obtained for just one system (59
samples). In this case samples were subjected to the same criteria of selection
used in the first Triplex assay. If the ML eN given by each Triplex assay were
not in agreement, then the copy number selected was the one that passed all
the criteria or the one with higher minimum ratio. However, in case of
disagreement between the three systems of the Triplex assay, rnicrosatellite
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analysis (EPEVI and EPEV3) was applied to further clarify the sample copy
number (section 2.2.5) (39 samples). The examination of allele ratios from
rnicrosatellite analysis allows the determination of the number of different
alleles and can be used to support any of the results given by the PRT systems,
5DELR4 or ML CN. In case of strong support by microsatellites to any of the
results from the systems mentioned above, the ML CN would be changed to a
final copy number that was determined by the rnicrosatellite analysis
(6 samples). Finally, if the microsatellite analysis did not add any further
information, the ML eN was maintained.
The analysis of integer clustering of PRT unrounded copy number data
was carried out to verify the accuracy of the copy number measurements
obtained by the Triplex assay. The unrounded copy number values from
PRTI07 A and HSPD21 tend to cluster around integer values corresponding to
copy numbers of 2, 3, 4, 5 and 6, as shown in Figure 25a. Although clustering
around integer numbers can confirm the accuracy of the Triplex assay to
measure the P-<lefensin copy number variation, clusters from PRT107 A were
not precisely centred on integer numbers and were shifted slightly towards
lower values, possibly due to the amplification of an additional locus on
chromosome 2. The chromosome 2 locus had only one mismatch with the
reference locus and showed products sizes very similar to the reference locus
products. Such similarity could be responsible for variation in the amplification
of the reference locus for PRT107A giving rise to the anomalous calibration of
PRTI07A as described in section 4.1.2.1. As a consequence, the mean copy
number of reference samples differs for PRT107A. To avoid the propagation of
error, a linear transformation (adjustment) was applied to the entire cohort
(cases and controls) to adjust the copy number values and improve the quality
of the results (Figure 25b).
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b) Nijmegen samples after adjustment: PRT (N=411)
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Figure 25: Copy number values from PRTI07A and HSPD21 resulting from a triplex assay.
a) Scatter-plot of unrounded copy number values of PRTl07A and HSPD21
showing clear clusters corresponding to different copy numbers classes. In this plot
PRTI07A values are shifted down from the integer copy numbers when compared
to HSPD21. b) Scatter-plot showing the unrounded copy number values after
PRT107A adjustment. Clusters are placed more exactly around integer values.
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In a different analysis copy number values have been represented in a
histogram (Figure 26) that shows the accuracy of the method but also the
frequency distribution of the different copy number classes measured by the
Triplex assay. To analyse each PRT independently, a histogram was
separately plotted for PRT107A (Figure 26a) and HSPD21 (Figure 26b), while
a third histogram was plotted with the weighted mean values from the two
PRT systems (Figure 26c). These three histograms show a copy number
distribution characterized by the formation of clear clusters, which are placed
around integer numbers. Although none of them show clear gaps between
each copy number group, the clustering remains evident in the three
histograms. The PRTI07 A copy number values showed a wider distribution
when compared with HSPD21 or PRT weighted mean copy number
distribution (section 2.2.7). Both HSPD21 and PRT weighted mean copy
numbers presented tighter clusters divided by clear gaps showing an
improved distribution of the different copy numbers, ultimately confirming
the precision of the method. Even if none of the histograms showed a clear
separation between the clusters, the weighted mean copy number distribution
of the two PRT systems illustrates a remarkable clustering for l3-defensin copy
number variation. The PRT weighted mean values were then plotted
according the final ML eN, which takes in consideration all the Triplex data
obtained for each sample (Figure 27). Each copy number was represented in
the histogram by a distinct colour, allowing the definition of the different
copy number clusters. As shown in Figure 27, the edges of some copy
number clusters of PRT values, such as the ones corresponding to 2, 5 and 6
copies overlap between each other, demonstrating the importance of the
5DELR4 analysis in the final copy number determination, mainly when
measuring high copy numbers. Finally, to better illustrate the Triplex
performance, unrounded copy number values obtained from the weighted
mean of PRTs were normalized as shown in Figure 28 by dividing by the
nearest integer value, so that a mean value of 1.0 is expected. The data tend
to cluster around the mean showing a low standard deviation, which is
indicative of the high quality of the results and the accuracy of the
measurements obtained by the Triplex assay.
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a} Nijmegen samples: PRTI07A {N=422}
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b) Nijmegen samples: HSPD21 (N=479)
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c) Nijmegen samples: PRT weighted mean copy number ( N=490)
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Figure 26: Histograms of unrounded copy number distribution from PRTI07A, HSPD21 and
weighted mean of PRT systems. PRT107A (a) and HSPD21 (b) copy number
distribution showing clusters around integer numbers. The HSPD21 histogram
illustrates a copy number distribution where clusters are better separated when
compared with PRTl07A. PRT weighted mean (c) copy number distribution
showing an improved clustering of the copy number values compared with the
individual PRT systems.
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Nijmegen samples: PRTweighted mean copy number (N=490)
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Figure 27: PRT weighted mean copy number distribution according to the fmal ML eN. Each
colour represents a different copy number given by the analysis of the Triplex data
on a maximum likelihood program.
Normalized eN distribution (N=490)
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Figure 28: Distribution of the normalized unrounded copy number values obtained from the
PRT weighted mean, showing a low standard deviation.
The analysis of clustering allows us to assess the accuracy of the
measurement methods, using the assumption that only integer copy numbers
have biological meaning. Therefore, differences obtained between the
measured values for each individual system and the final integer copy
number, ML CN, should represent the error of the measurement, which can
be used as an indicator of the method accuracy. Figure 29 shows the copy
number residuals for each PRT, calculated from the difference between the
measured unrounded copy number and the obtained ML CN for each
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sample. The graph shows how PRTI07 A residuals have a wider distribution
than HSPD21 residuals. PRTI07A residuals vary between approximately -l.6
and 1.6 from the rounded copy number given by the ML eN, while residuals
from HSPD21 are more frequently close to zero, varying between
approximately -2 and 0.9, indicating a higher accuracy. Overall, PRT
residuals tend to congregate around zero (average residual: PRT107A=-0.0048
and HSPD21=0.0069) forming a spherical distribution indicating that the
majority of the results from either of the PRT systems gave a correct outcome
that was very close to the integer copy number value. A non-Significant
correlation (p-value=0.1758, correlation test) was found between PRTI07A
and HSPD21 residuals indicating the absence of somatic mosaicism or if
present infrequently or at low level.
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Figure 29: Comparison of copy number residuals from PRT107A and HSPD21 data. The
residuals were calculated from the difference between the measured unrounded
copy number value of each PRT and the integer copy number (ML CN) given by
the maximum likelihood program.
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4.1.2.2.3 CONCORDANCE BETWEEN THE TWO STUDIES
Considering the first and second case-control association study together,
516 samples from Nijmegen, Netherlands, were typed in total. From these, 446
samples were typed in both studies that after removing the samples that failed
become a total of 407 samples successfully typed, from which 240 and 167
were controls and cases, respectively. The copy number values described here
for the first case-control association study, result from a consensus copy number
of PRT (HSPD5.8), MAPH and REDVR, as described in Hollox et al. (2008b).
The agreement between the copy numbers given by each association study was
analysed for the samples replicated on both studies (407 samples). For 87.96%
of samples (358 samples) the integer copy number agreed between studies,
while for 12.04%of samples (49 samples) the copy number value differed. From
those 49 samples that disagreed, the copy number values given by the second
study were higher for the majority of the samples, either for cases or controls
(29 samples), when compared with the first study (Table 13). Since cases and
controls showed concordantly higher copy number values in the second study,
the disagreement observed between the two studies was not biased for cases or
controls. Overall, the net difference in copy number repeat units between the
two studies differed by just 11 repeat units. The control samples were the ones
that varied the most between the two studies, contributing 10 repeat unit
differences. The disagreements observed in the copy number measurements
between the studies (44 samples) were mainly in the order of one copy number
repeat unit with the exception of 5 samples, in which the outcome differed by 2
(4 samples) or 3 copies (one sample).
Table 13: Dutch samples for which the final copy number value differed between the two
association studies. The first column shows the number of cases, controls and total of
samples that disagreed. The second and third columns indicate the number of
samples in which the copy number was higher (UP) or lower (DOWN) in the
second study compared with the first association study. In the last column the net
difference in terms of copy number repeat units is represented.
Number of samples that
disagree Up Down
Net difference of
repeat unitB
Total
31
18
49
19
10
29
12
8
20
10Controls
Cases
11
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4.1.2.3 Psoriasis disease association results
To investigate the relationship between l3-defensin genomic copy number
and susceptibility to psoriasis disease, the copy number variation was analysed
and the association with psoriasis was tested in two independent case-control
association studies using PRT based assays. As reported previously, the copy
number variation at the 8p23.1 l3-defensin cluster commonly varies between 2
and 7 copies.
In the first case-control association study the JHlefensin genomic copy
number was analysed in 272 controls and 179 psoriasis cases from Nijmegen,
Netherlands. The l3-defensin copy number reaches higher values in cases than
in control samples, with controls varying between 2 and 7 copies and cases
varying between 2 and 8 copies. Comparison of PRT results from cases and
controls suggested an association of high JHlefensin copy number with
psoriasis, confirmed by a p-value of 0.01 (ttest) (Hollox et al. 2008b). To
improve the overall accuracy of the copy number measurements the data from
PRT was combined with the data from MAPH and ratios of multisite variants
(MSVs) in a consensus copy number. This consensus copy number showed,
once again, a Significant difference (p-value=7.8 x 10-5, ttest) between cases and
controls, confirming the association between high p-defensin copy number and
susceptibility to psoriasis (Figure 30) (Hollox et al. 2008b). Alongside this
cohort our collaborators in Erlangen, Germany, typed a German cohort with
624 samples, 305 controls and 319 psoriasis cases from Mtinster using the
HSPD5.8 PRT alone. In this independent test of association they also found a
Significant association between JHlefensin copy number and psoriasis
(p-¥alue=2.95 x 10-5, Hest) (Hollox et al. 2008b).
In the second association study carried out, 246 controls and 189 psoriatic
cases were analysed for JHlefensin copy number variation by a PRT-based
Triplex assay. Overall, the JHlefensin copy number varied between two and
nine copies per diploid genome with a mean copy number of 4 (Figure 31).
Considering each group separately, the copy number varied between two and
seven copies for controls and between two and nine copies for cases. The cases
showed a wider range of copy number variation with a higher mean copy
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number (mean CN cases=4.52381) compared with controls (mean CN
control=4.252033). The difference in the mean copy number observed
between cases and controls proved to be significantly different using at-test
showing a p-value of 0.0058.
Nijmegen samples: HSPDS.8 PRT (controls,N=272 and case, N=1879)
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Figure 30: Frequency distributions of Il-defensin genomic copy number in the Dutch cohort
from Nijmegen. Copy number distribution of 272 controls and 179 psoriasis cases,
where cases showed on average higher copy numbers (Hollox et aJ. 2008b).
Nijmegen samples: Triplex assay (controls, N=246 and cases, N=189)
0.5
p-value = 0.0058
0.4 .Controls
Cases
> 0.3u
c:
AI
::::s
C"
AI 0.2...
-
0.1
0
0 1 2 3 4 5 6 7 8 9 More
copy number value
Figure 31: Frequency distributions of Il-defensin genomic copy number from 435 samples, 246
controls and 189 psoriatic cases, separately. The histogram illustrates the Il-defensin
copy number variation for cases and controls in a European population from
Nijmegen, Netherlands with cases showing clearly higher copy numbers (8 and 9
copies) compared with controls.
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In a case-control association study is important to assure that no differential
bias in genotyping is observed between cases and controls, which could
increase the false-positive rate and lead to spurious associations (Clayton et al.
2005; Plagnol et al. 2007). IfDNA preparation methods are sufficiently different
between cases and controls this could be a source for genotyping bias which
ultimately could lead to an apparent association (Clayton et al. 2005). When
measuring copy number, particularly high copy numbers, this matter is
especially important. Since higher copy numbers are more difficult to measure,
they are more likely to produce unsuccessful results that will consequently be
rejected. Thus, differential drop-out of samples is more likely to affect samples
with high copy numbers. To avoid this, the DNA preparation methods used in
these studies were the same for all Dutch samples. In addition, cases and
controls were randomly interspersed throughout the 96-well plates used for PRT
analysis, thus minimizing any genotypmg error favouring either cases or controls.
However, to test for differential biases, cumulative frequencies of the set of
copy number values obtained for cases and controls were plotted in a graph
that shows the cumulative totals of the set values. In the case of differential bias
caused by systematic experimental error affecting just one of the sample sets,
the effect should be detected through the analysis of cumulative frequencies of
each copy number group separately. The cumulative frequency plots for cases
and controls with 3 (N=73), 4 (N=207) and 5 (N=124) copies were very Similar,
with p-values (Hest; 0.995, 0.985 and 0.948, respectively) showing no Significant
difference between cases and controls (Figure 32). Thus, the significant
correlation reported here cannot be attributed to differential bias between the
two groups studied but instead to real frequency differences of integer values.
Combining the two studies together, using all samples for which reliable
measures are available, the association between p.d.efensin copy number and
psoriasis susceptibility was once again tested for a total of 516 samples, 314
controls and 202 psoriasis cases. The copy number distribution was very similar to
the one previously reported, with mean copy number for controls at 4.24 and for
cases at 4.55. The results confirmed the association of p.d.efensin copy number
with psoriasis susceptibility, but at a higher Significance (p-value=9.44xlO-4,stest)
(Figure 33), which strongly confirms the association previously reported.
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1
0.9
p-value= 0.9482
> 0.8 -controls
...
c 0.7 -casesQj
~
eT 0.6Qj
...
- 0.5Qj
>
.... 0.4
~
~ 0.3E
~ 0.2...
0.1
0
0 1 2 3 4 5 6 7 8
unrounded copy number
Figure 32: Cumulative frequency graphs of cases and controls for 3 (a), 4 (b) and 5 (c)
~-defensin copies, representing the cumulative totals of the set values. The
cumulative frequency plots of cases and controls do not show much difference for
any of the copy number groups, confirming the absence of large differential bias
between cases and controls.
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Nijmegen samples: Triplex assay (controls, N=314 and cases, N=202)
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Figure 33: Frequency distributions of ~-defensin copy number for 314 controls and 202
psoriatic cases, separately. The histogram illustrates the j3-defensin copy number
variation in a European population from Nijrnegen, Netherlands, where cases show
higher copy numbers (8 and 9 copies) than controls.
4.1.3 Discussion
Variants such as SNPs have long been studied and associated with disease
(The International HapMap 3 Consortium 2010). On the other hand, little is
known about the consequences of copy number variation in disease, but recent
studies have highlighted the importance of CNV in disease susceptibility fY'1ain et
al. 2009; Conrad et al. 2010; Sudmant et al. 20lO). The studies presented here
aimed to investigate the consequences of lHiefensin copy number in disease,
particularly in psoriasis. To investigate the association of copy number with disease
it is essential to measure the copy number accurately, as power to detect a real
association will be reduced with error-prone methods. Here, new PRT-based
measurements methods were used and their accuracy tested in a large case-control
association study to investigate the lHiefensin copy number variation in psoriasis.
The PRT-based methods used in our studies accurately measure the
~-defensin copy number variation in association studies. Moreover, the results
have a high degree of reproducibility shown by the repeat typing of internal
reference samples with known copy number (data not shown). Furthermore,
the internal reference samples were also previously typed by other
measurement methods, such as MAPH and REDVR, which confirmed our
results. From the clustering analysis of internal reference samples, a very good
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clustering around integer values (3, 4, 5 and 6) was obtained. Such clustering
indicates the accuracy and reproducibility of the PRT assays that is emphasised
by a miscalling error rate of -8.1% for a Single PRT test (HSPD5.8) (Armour et
al. 2(07) and 4.85% for the Triplex assay. A similar degree of clustering was
also observed for the Dutch cohort in which five distinct clusters centred on
integer values of 2, 3, 4, 5 and 6 were formed. Considering that only an
accurate measurement method can distinguish different copy numbers,
clustering analysis is without doubt a powerful tool to evaluate the performance
of a CNV measurement method, working as a simple "barometer" for
accuracy. Furthermore, a high concordance from the detailed comparison of
independent typing platforms was shown between the first and second studies
for cases and controls. Once again the reproducibly of the PRT was tested and
confirmed in large case-control association studies.
A multiplex PRT was first described by Walker et al. (2009) to measure
the CCL3LJ/CCL4LJ copy number variation. They demonstrated that
multiplex PRT is an accurate and robust method to measure multiaIlelic copy
number and suitable to use in large scale case-control association studies (Field
et al. 2009; Walker et al. 2009). Taking this into consideration, the combination
of three different systems in our study, two PRTs and an indel assay, provides
more accurate information than a Single PRT. Even knowing that the reference
locus of PRT107A has one mismatch with a locus on chromosome 2, which
could lead to a degree of co-amplification and result in a lower copy number in
this system, the other two systems are not affected and consequently the triplex
assay still improves the power of copy number measurement. Comparing the
data from the Triplex assay versus each of the individual PRTs demonstrates
the higher accuracy of the Triplex assay and its improved clustering when
compared with HSPD2l or PRT107A alone. Although it is clear that the
Triplex assay have an improved degree of clustering than any individual
system, the quality of clustering decreases for more than 6 copies, even for the
Triplex assay. It is then worth thinking if it is meaningful to separate the copy
number classes greater than 6. Previous reports, which measure the beta-
defensin copy number variation using real time PCR, followed a very
conservative analysis separating the copy number values only in three different
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classes, such as: less, equal or higher than 3 or 4 copies (Fellennann et al. 2006;
Bentley et al. 2010). This kind of approach gives little information about the
real copy number of beta-defensins and was one of the motivations for the
development of a method that could actually distinguish the true integer states
of the beta-defensin copy number variation. Moreover, the data also shows a
higher standard deviation and integer error for the 6 copy number class, in all
systems, when compared with lower copy number classes (3, 4 or 5 copies),
indicating that the Triplex assay is probably less accurate in distinguishing copy
numbers higher than 6. However it is still possible, even with a higher degree
of error, to distinguish between copy numbers higher than 6. In the Nijmegen
cohort there are some examples of samples showing a copy number of 8 and 9.
For each of them, the copy number measured between repeats for the same
sample never showed a copy number difference of more or less than one
integer value. The approach used here can, with some degree of error,
measure high copy numbers, giving an accurate or estimated value closer to
the real copy number than previous methods have done for the beta-defensin
locus. This is nevertheless better than pooling all the copy numbers higher than
6 in the same copy number class. For the Nijmegen cohort only 17 samples
showed a copy number higher than 6. Certainly, with access to more samples
with high copy number would be possible to improve the copy number
clustering seen here for 6, 7, 8 and 9 copies.
Recent studies also compared the accuracy of the Triplex assay with other
methodologies. In a side-by-side typing, Triplex assay and real time PCR were
used to measure j3-defensin copy number variation in a large case-control
association study of Crohn's disease (Aldhous et al. 2010). This study strongly
supports the Triplex assay as a reliable and robust method for copy number
typing. The real time PCR showed very poor clustering which suggests
reduced accuracy and reproducibility when compared with the Triplex.
Therefore, the Triplex assay appears to be the most accurate measurement
system, so far, to be used in measuring multiallelic copy numbers.
Our fmdings cannot be attributed to differential genotyping bias, since
different genotyping parameters were closely matched between cases and
controls. Important parameters such as DNA preparation, integer clustering
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and independent replication were carefully taken in consideration in these
case-control association studies. As such, the difference between the means of
cases and controls can only be attributed to the real difference of integer
values, which indicates an association between high ~-defensin copy number
and susceptibility to psoriasis.
The results found in the replication study strongly supports the association
previously found using HSPD5.8 PRT alone (Hollox et a1. 2008b). Even given
that the differences observed in copy number values were few between the
studies for cases or controls, and that both showed a Significant association
between jHiefensin copy number and susceptibility to psoriasis, the pvalue
obtained in the replication study was higher than the one obtained in Hollox et
a1. (2008b). However, combining the two studies decreases the resultant p-value
when compared with the pvalue obtained for the replication study alone. This
increased level of Significance could possibly reflect the importance of sample
size in case-control association studies, since the combined analysis of the two
studies included more samples.
Another comparison between cases and controls for the same Dutch cohort
(179 cases and 272 controls) was performed using a consensus integer copy
number given by PRT (HSPD5.8) and MAPHjREDVR. This study also showed a
Significanthigher copy number among cases (p:value=7.8xlfr5, stest) (Hollox et al.
2008b). Finally, the association between ~efensin copy number and psoriasis was
once again tested and confirmed (p:value=2.95xlfr5) in an independent association
study carried out in a German population using PRT alone (HSPD5.8) (Hollox et
al. 2008b). These studies once again confirmed the association previously
described, and together with our findings give a strong argument that high copy
number of ~efensin increases the susceptibility for psoriasis.
The statistical analysis proposed here to test for significant differences
between the means of two groups (cases and controls) was carried out using the
t-test for independent samples. The t-test has traditionally been used when only
two groups are involved, while the analysis of variance (ANOV A) can be used
when two or more groups are being tested. A t-test shows the differences in the
means between two groups assuming that the variances in the populations from
which the two sample groups were taken are identical. Similarly, analysis of
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variance (ANOV A) measures the overall difference among the means of two
or more groups comparing the variability within the groups to the variability
between the groups to determine if there are any significant differences among
the means. In the study presented here, as the variances between the groups are
similar we used the Hest to determine if the difference between means was
significant ANOV A could be expected to detect differences in distribution
between copy number classes if analysed separately, but in testing the mean of
the entire distribution, the use of ANOV A in this case is mathematically identical
and would produce the same conclusions as the t-test for independent samples.
In the replication study described here, performed with the Triplex assay, a
0.272 mean increase in copy number among individuals affected with psoriasis
vulgaris was observed. These findings support earlier work showing higher
concentrations of jHiefensin proteins, particularly hBD-2 (DEFB4 gene), in
psoriatic lesions (Hollox et al. 2003). Previous studies had indicated hBD-2 as the
main beta-defensin with a role in psoriasis susceptibility (Harder et al. 1997a;
Hollox et al. 2003). However, is important to not rule out other beta-defensin
genes included in the copy number variable region at 8p23.1. hBD-3, was also
isolated from human psoriatic lesions and is expressed in different tissues,
including skin (Harder et al. 2001). The particular contribution of each beta-
defensin gene of this copy variable region in psoriasis risk is not known, but is
likely that the ones expressed in skin, such as DEFB103 and DEFB4, have a key
role in skin immunity and therefore in the psoriasis aetiology. Moreover, the
increase in copy number is also concordant with the fact that jHiefensin shows
cytokine-like properties that activate different iIrunune and inflammatory cells and
promote keratinocyte migration and proliferation that could lead to psoriasis
(Niyonsaba et al. 2007). The involvement of jHiefensin in skin immunity
(cutaneous inflammation) and wound healing suggests that a higher copy number
of these defensins may cause an atypical inflammatory response in the skin,
ultimately leading to the formation of psoriatic plaques. Even though the role of
jHiefensin in the psoriasis molecular pathway is not completely understood, our
studies identified a new susceptibility locus for psoriasis that has not been
previously found by linkage analysis, highlighting for the first time the importance
of jHiefensin copy number and their influence in the aetiology of psoriasis.
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4.2 CHARACTERIZATION OF ~-DEFENSIN CNV IN
HUMAN POPULATIONS
4.2.1 Background
Our knowledge of human genetic variation has been to some extent
limited to heterochromatin polymorphisms, sufficiently large to be visualized in
the light microscope, and to genetic markers, such as SNPs (single nucleotide
polymorphisms), microsatellites and minisatellites, conventionally detected by
PCR-based or Southern blot typing. In the last few years new methodologies
with greater resolution, such us micro array technologies, SNP genotyping arrays
and next-generation sequencing, have been able to detect other types of genetic
variation of intermediate scale, such as copy number variation. Among the
regions enriched for CNV are genes involved in chemosensation and immune
responses, which are especially important in adaptation to new environmental
niches, but also genes involved in fertility and reproduction, which were subject
to a rapid evolution in primates due to the expansion of sexual competition
(Nguyen et al. 2006; Voight et al. 2006). This suggests the role of CNVs in
human evolution and adaptation, conferring genetic plasticity for organisms to
evolve in response to external selective pressures (de Smith et al. 2008).
Although purifying selection has been suggested to overcome positive
selection in human copy number variation evolution (Nguyen et al. 2008),
some studies reported that certain human CNV genes are under positive
selection, such as the amylase locus (AMYl gene) (Perry et al. 2007) and
UGT2Bl7 gene (Xue et aI. 2008). Apart from this, neutral evolution has also
been suggested to underlie certain CNV s, mainly those including
chemosensory genes (Nozawa et al. 2007; Young et al. 2008). A positive
correlation was described between the copy number of the salivary amylase
gene (AMYl) and the starch content of diet. Perry et al. (2007) found that
populations with a diet rich in starch have a higher mean copy number than
populations with "low-starch" diets, which consisted mainly of meat, fruit,
honey and milk. This suggests that higher copy numbers of the AMYl gene
had been selected in response to adaptation to "high-starch" diets, but in the
absence of such selective pressure the copy number has evolved neutrally
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(Perry et al. 2007). The human UGT2B17 gene also varies according to the
geographic region, with an increased frequency of the deletion polymorphism
from Africa to East Asia and intermediate frequency in Europe (Xue et al.
2008; Yang et al. 2008; Campbell et al. 2011). UGT2B17 gene encodes an
enzyme that catabolises steroid hormones, androgen and estrogen, which have
important roles in maintaining cancellous bone mass and integrity. Thus,
increased expression of UGT2Bl7, as a consequence of the increased copy
number of this gene, might lead to an imbalance between bone formation and
bone resorption and enhance the risk of osteoporosis. Their findings suggest
that higher UGT2Bl7 copy number is associated with increased risk of
osteoporosis in both Han Chinese and Europeans. Moreover, CNV of
UGT2B17 also showed a strong ethnic difference, with the deletion
polymorphism of UGT2B17 being much more common in Chinese than in
Europeans. This phenomenon is in agreement with the lower levels of
osteoporosis observed nowadays in the Chinese compared with western
populations (Yang et al. 2008). In the past, these populations might have been
exposed to different selective pressures and selection might have favoured
different levels of UGT2Bl7, suggesting positive selection for deletion in East
Asia (Xue et al. 2008).
Another example of notable geographical difference among human
populations, especially between European (0 to 4 copies) and African (2 to 14
copies) populations occurs in the copy number of the CCL3Ll gene (Gonzalez
et al. 2005; Walker et al. 2009; Campbell et al. 2011). CCL3Ll is a chemokine
gene encoding for a potent ligand that binds to several pro-inflammatory
cytokine receptors, such as the CCRS, the principal co-receptor for HIV. Some
studies have suggested a close interaction between low CCL3Ll copy number
and increased risk for HIV infection (fownson et al. 2002; Gonzalez et al. 2005;
Mackay 2005). However, this finding has not been independently replicated
(Shao et al. 2007; Urban et al. 2009) and cannot explain the differences in copy
number of this locus observed between populations. Although, the reason that
accounts for this population diversity is not clear, the role of CCL3Ll in the
CCRS pathway in blocking its signal, suggests the importance of the chemokine
system in modulating immune responses (McKinney et al. 2008).
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The existence of geographical differences in CNV between populations
highlights the fact that certain genes may be under selection, mainly those that
confer a clear adaptive advantage for human populations, such as the ones with
an important role in autoimmunity in humans (perry et al. 2007; Xue et al. 2008;
Schaschl et al. 2009). lHlefensins have an important role in the innate immune
system, acting directly against pathogens or as signalling molecules mediating
inflammatory responses. The role of lHlefensins suggests that their variation in
copy number could affect the susceptibility to inflammatory or autoimmune
diseases, as demonstrated by the association of high copy number with psoriasis
(Hollox et aI. 2008b), or conversely by the association of low copy number and
an increase risk for infectious diseases. The ~-defensin copy number can
commonly vary between 1 and 9 copies per diploid genome with a mean copy
number of 4, but copy numbers up to 12 copies can be found in some
individuals (Hollox et sl. 2003; Armour et al. 2007; Groth et al. 2008; Hollox et
al. 2008a). So far it has been demonstrated that mean copy number of lHlefensin
is higher among individuals with psoriasis than in a healthy population (Hollox
et al. 2008b), although there is no evidence for any geographical variation. The
mean copy number of lHlefensins has been reported to be 4 copies in all human
populations typed by a single PRT assay (Hollox 2(08); however, the triplex
assay with its increased power in copy number measurement should provide a
better evaluation of the copy number variation. Consequently, the triplex assay
was used to type lHlefensin copy number in 6 different human populations to
better understand CNV between populations.
4.2.2 Results
To investigate the geographical variation of the ~-defensin copy number
among different human populations, the Triplex assay was used to type copy
number in 6 different populations: Yoruba from Ibadan, Nigeria (YRB); Dutch
from Nijmegen, Netherlands; British, UK; Utah residents with Northern and
Western European ancestry from the CEPH collection, USA (CEU); Japanese
from Tokyo,Japan (JPT); Han Chinese from Beijing, China (CHB).
Clustering analysis of the unrounded copy numbers from PRT107A and
HSPD21 for each population indicated the accuracy of both PRT systems with
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the distribution of values centred in integer values (scatter-plots not shown).
Moreover, as explained in section 3.2.1, the copy number values obtained from
the Triplex assay for the RapMap CEU, YRB, CRB and JTP cohorts were
validated with data previously published by different studies (McCarroll et al.
2008; Abu Bakar et al. 2009; Conrad et al. 2010). The agreement observed
between copy number values obtained from different studies, range from
86.08%to 93.51%and confirms the accuracy of the Triplex assay.
As shown in the histograms below (Figure 34), the ~-defensin copy number
varies generally between 2 and 10 copies per diploid genome, with copy
numbers up to 7 being the most common. The modal diploid copy number in
all populations is 4 copies (mean for UK=4.43, Dutch=4.36, JPT=4.51,
CHB=4.09, YRI=4.57, CEU=4.42) however, slight differences in copy number
frequencies appear to move the copy number distribution towards higher
values in Yoruba and Japanese populations as compared with European
populations. A one-way analysis of variance (ANOV A) was used to test the
amount of variation that occurs between populations. Despite the slight
differences observed in the copy number distribution, ~-defensin copy number
variation was not Significantly different between the human populations studied
(p-value=0.261, ANOVA).
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c) HapMap CEU (N=60)
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d) HapMap Japanese (N=45)
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e) HapMap Chinese (N=45)
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f) HapMap Yoruba (N=65)
60
50
III
40iU
:l
"0
.s;
30:c
.5
- 200
'* 10
0
1 2 3 4 5 6 7 8 9 10
IJ-defensin genomic copy number
Figure 34: ~defensin diploid copy number distribution in six different populations: British, UK
(a); Dutch from Nijmegen, Netherlands (b); CEPH individuals with northern and
western European ancestry from Utah, USA (c); Japanese from Tokyo, Japan (d);
Chinese from Beijing, China (e) and Yoruba from Ibadan, Nigeria (f). The copy
numbers were typed by the Triplex assay.
4.2.3 Discussion
Several CNV s show large differences in diploid frequencies and
distribution between human populations, but this was not observed for the
~-defensin locus. The data obtained from the genotyping of ~-defensin showed
no Significant differences between the 6 populations studied, although the
mean copy number in Japanese and Yoruba was slightly higher than other
populations. The slight increase in copy number observed for Japanese and
Yoruba populations could be due to genetic drift, different mutation rates or
selective pressures or an artefact due to small sample size. The similarity of
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copy number distribution between the European populations dearly reflects
the geographical proximity between them; nevertheless this does not explain
the similarity between Europeans and Yoruba. Japanese and Chinese
populations showed the most differentiated distributions. In the first case there
is a clear shift towards high copy numbers, for example the frequency for 7
copies was higher than for 2 and even 3 copies. Conversely, the high frequency
of lower copy numbers, such as 2 and 3 copies, makes the Chinese copy
number distribution unusual.
The observation of the same average copy number in all populations
indicates that this locus is not under different strong selective pressures. This
suggests that average copy number of 4 might be a good balance in all
populations. Since the j3-defensin copy number has been correlated with the
DEFB4 mRNA levels (Hollox et al. 2(03), 4 copies represents an intermediate
level of expressed j3-defensin, not too low or too high, which may protect
against the risk of infectious and/or inflammatory diseases. These findings agree
with the previous analysis of the j3-defensin duster at 8p23.1 by Hollox and
Armour (2008), describing the absence of positive selection at this locus in the
last 25 million years.
Finally, the data reported here was carefully analysed and the accuracy of
the Triplex assay was, once again, demonstrated by the direct comparison with
results previously published for the HapMap collection cohorts (section 3.2.1).
The results obtained in this study for those samples showed a high agreement
(>86%) with the published data, thus demonstrating the high performance of the
PRT-based Triplex assay for copy number measurement of j3-defensin.
Moreover, this also demonstrates the vast applicability of the multiplex system
to different human populations, showing the assay is not population dependent.
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4.3.1 Background
Rearrangements in genome structure are an important source of variation
in the human genome. This variation can include deletions and duplications,
and thus variation in copy number, but also orientation and positional
polymorphisms. The implications of such structural variation are known to
induce effects on gene and protein expression, leading to phenotypic and
disease susceptibility variations. A classical example of a region showing
several types of variation is the chromosomal band 8p23.1, the region in which
the defensin genes reside. The olfactory repeat regions (OR), REPP and REPD,
that flank the 8p23.1 locus, predispose to an increased number of chromosomal
rearrangements due to recurrent recombination between the two olfactory
regions, giving rise to large imbalances in the 8p chromosome arm (Giglio et
al. 2(01). Non-allelic homologous recombination (NAHR) occurs frequently
between REPD and REPP and is the mechanism that leads to the deletion or
duplication of the sequence that separates these two olfactory repeats,
commonly referred as 8p23.1 deletion syndrome (Devriendt et a1. 1995; Wat et
a1. 2(09) and the reciprocal duplication syndrome (Barber 2005; Barber et a1.
2(07), respectively. Both syndromes are characterized by phenotypic
manifestations, including developmental delay, behavioural problems and
congenital heart disease associated with the deletion syndrome, while mild
dysmorphism and developmental and speech delay are associated with the
duplication syndrome (Barber 2005; Barber et aJ. 2(07). In addition to these
rearrangements, high copy number variants of rxIefensin can easily be
misinterpreted as duplications of the REPDjREPP interval region as observed
by microscopy, but they can be clearly distinguished at the molecular level
(Barher et al. 2(05).
A common large structural inversion polymorphism (4.7 Mb) involves the
region flanked hy the olfactory repeat gene clusters (REPD and REPP) at the
8p23.1 region. This polymorphism is present in 25% of Europeans and
approximately 33% of Japanese are heterozygous for the inversion
polymorphism (Giglio et al. 2001; Giglio et al. 2002). The presence of these
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polymorphisms can lead to unequal recombination between the olfactory
receptor regions and generate a variety of recurrent chromosomal
rearrangements including inverted duplications and deletions of Bp (inv. dup.
del. (Sp)) and its reciprocal rearrangement. This results in a supernumerary
marker chromosome (+der(S) (Sp23.lpter)) that contains the distal Bp region
duplicated (Giglio et a1. 2002; Sugawara et a1. 2003). The phenotype of patients
with such large chromosomal imbalances is characterized by facial
dysmorphism, agenesis of the corpus callosum, development delay, mental
retardation and congenital heart diseases (Guo et a1. 1995).
This chapter describes a study carried out in a Cologne family trio, kindly
supplied by Raoul Heller from Utrecht (Netherlands), in which the child
(patient) has a terminal hemizygous deletion extending into REPD and a
duplication starting at REPP extending up to roughly 20 Mb from pter. The
origin of this chromosomal rearrangement is unknown. The mother is a healthy
individual (karyotype: 46, XX) but the father has a supernumerary marker
chromosome at Bp (karyotype: 47, xy) showing evidence of mental retardation
and recorded epilepsy episodes during adolescence (Figure 36). With the aim
of identifying the parental origin of the !}-defensin repeats found in the child,
the measurement of !}-defensin copy number was carried out in the three
members of this family with the Triplex assay and a series of multi allelic
markers (microsatellite analysis). This analysis aimed to shed further light on
the structural origins of 8p23 rearrangements and if possible to reconstruct the
pattern of ~-defensin segregation in this family.
Grey shading = epilepsy in adolescent,
borderline functional alphabetic
Black shading = Patient (child) with 8p
chromosomal rearrangements
No shading = healthy
"1" = no high school degree
Figure 35: Cologne family pedigree showing the closest relatives of the patient with Bp
chromosomal rearrangements.
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Figure 36: Paternal karyotype, 47, XY, +der(8) (8p23.lpter). The red arrow in the figure
indicates the supernumerary marker chromosome at 8p (kindly provided by
Dr. Regine Shubert).
4.3.2 Results
Each sample was typed several times with the Triplex assay and copy
numbers were calculated from peak heights of each peR product using a
maximum likelihood analysis (section 2.2.7). The Triplex results agreed in
unique copy number value of 4 copies for "mother", 6 copies for "father" and
5 copies for "patient" (Figure 37). Regarding the 5DEL analysis on its own, the
ratio between the resultant alleles suggested copy number values based on
multiples of 4, 6 and 5, respectively for "mother", "father" and "patient" (Figure
37). Furthermore, different copy number haplotypes can be ascertained from
the pattern shown by 5DEL analysis (Table 14). However, segregation analysis
does not support the exclusion of any paternal or maternal haplotypes in order
to follow the segregation of alleles from parents to child.
In addition to the Triplex assay, microsatellites (EPEV3, EPEVI and
EPEV5) and an additional indel assay (9 bp indel) were used. These
methodologies, which were mainly used to attempt to follow the segregation of
the alleles from parents to child, could also confirm the copy number given by
the Triplex assay.
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Figure 37: Examples of the GeneMapper electropherogram for Triplex assay after capillary
electrophoresis from "mother" (a), "father" (b) and "patient" (c). In each
electropherogram is visualised the peR products of each system (5DEL, PRT107 A
and HSPD21) in two distinct fluorescent dyes.
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Table 14: Allele ratios obtained from 5DEL analysis for "mother", "father" and "patient"
(child) were used to define copy number values and predict haplotypes and
segregation patterns. The copy number values (CN) represented here were obtained
from the Triplex assay. In this analysis the possibility of zero-copy haplotypes was
disregarded.
Alleles
123 126
Patient 3 o
CN Possible Haplotypes
128
2 4 3:1 or 2:2
2 6 2:4 or 3:3
2 5 2:3 or 4:1
Mother
Father 3
The electropherograms in Figure 38 show the alleles obtained from the
EPEV3 microsatellite analysis and the ratio between them. The ratios suggest
copy number multiples of 4, 3 and 5 for "mother", "father" and "patient",
respectively. From the allelic information given by the EPEV3 analysis and the
copy number measured earlier by Triplex assay, the possible combination of
haplotypes can be determined for each individual (Table 15). The "patient"
could have either inherited 2 copies from one parent and 3 copies from the
other or 4 copies from "father" and 1 copy from "mother" (Table 15).
a) Mother = 4 copies
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c) Patient = 5 copies
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Figure 38: Examples of the GeneMapper electropherogram for EPEV3 assay after capillary
electrophoresis from "mother" (a), "father" (b) and "patient" (c). In each
electropherogram is visualised the alleles (136 bp, 140 bp and 142 bp) obtained from
EPEV3 and the ratios between them.
Table 15: Allele ratios obtained from EPEV3 analysis for "mother", "father" and "patient"
(child) were used to define copy number values and predict haplotypes and
segregation patterns. The copy number values (eN) represented here are given by the
Triplex assay. In this analysis the possibility of zero-copy haplotypes was disregarded.
Alleles
eN Possible Haplotypes
136 140 142
Mother 1 2 4 3:1 or 2:2
Father 2 2 2 6 2:4 or 3:3
Patient 1 2 2 5 2:3 or 4:1
In Figure 39, the three electropherograms, corresponding to the EPEV1
microsatellite allelic pattern of each sample, are not easy to interpret due to the
presence of "stutter peaks". However, after "stutter peak" correction (section
2.2.5) the allelic ratios suggested that "mother" has a copy number value
multiple of 4, "father" has 6 or 12 copies and "patient" has 5 or 10 copies of the
~-defensin repeat at 8p23.1. Table 16 shows the combination of copy number
haplotypes possible for each individual taking in consideration the copy
number obtained from Triplex analysis and the pattern observed for EPEV1
microsatellite. Following the segregation of the EPEV1 alleles from parents to
child, three possible haplotypes, corresponding only to two different copy
number states, can be inherited from each parent, as shown in Figure 40. The
possible maternal haplotypes inherited include two with one copy number of
the locus and one with two copies, while the paternal haplotypes include one
with a three copy number state and two with 4 copies.
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Figure 39: Examples of the GeneMapper electropherogram for EPEVI assay after capillary
electrophoresis from "mother" (a), "father" (b) and "patient" (c). In each
electropherogram the alleles obtained from EPEVI are visualised (180 bp, 182 bp, 186
bp and 188 bp) and the ratios between them displayed, after "slippage peak" correction.
Table 16: Allele ratios obtained from EPEVI analysis for "mother", "father" and "patient" (child)
were used to define copy number values and predict haplotypes and segregation
patterns. In this analysis the possibility of zero-copy haplotypes was disregarded.
Alleles
eN Possible haplotypes
180 182 186 188
Mother 0 2 4 3:1 or 2:2
Father 1 3 2 0 6 2:4 or 3:3
Patient 1 3 0 5 2:3 or 4:1
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Figure 40: Possible haplotypes suggested from the EPEVI analysis (microsatellite) for "mother",
"father" and "patient" (child).
An additional micro satellite, EPEV5, was developed to further clarify the
segregation in this family. The micro satellite patterns obtained from the EPEV5
analysis showed the presence of the same three alleles in all samples
(Figure 41). Therefore, it is only possible to predict that the child ("patient") has
inherited either 2 copies from one parent and 3 copies from the other or 4
copies from "father" and 1 copy from "mother" (Table 17). However, the ratios
between the alleles clearly indicate different copy number values,
corresponding to 4, 3 and 5 or multiples of them for "mother", "father" and
"patient", respectively.
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Figure 41: Examples of the GeneMapper electropherogram for EPEV5 assay after capillary
electrophoresis from "mother" (a), "father" (b) and "patient" (c). In each
electropherogram the alleles (152 bp, 157 bp and 159 bp) obtained from EPEV5 are
visualised and the ratios between them displayed, after "slippage peak" correction.
Table 17: Allele ratios obtained from EPEV5 analysis for "mother", "father" and "patient" (child)
were used to define copy number values and predict haplotypes and segregation
patterns. In this analysis the possibility of zero-copy haplotypes was disregarded.
Alleles
eN Possible Haplotypes
152 157 159
Mother 2 4 3:1 or 2:2
Father 2 2 2 6 2:4 or 3:3
Patient 2 2 5 2:3 or 4:1
Finally, a last attempt to clarify the segregation in this family was carried
out using the 9 bp indel system (Abu Bakar 2010). This assay was designed to
detect a 9 bp deletion within the DEFB4 gene; therefore only two alleles were
possible, corresponding to the deleted (297 bp) and inserted 9 bp sequence
(306 bp). As shown in the Figure 42, just one allele was observed for "father"
and "patient", which make the determination of the copy number impossible.
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However, due to the presence of the two alleles in the "mother", the allele ratio
suggested a copy number value of 4. The 9 bp indel analysis also suggested the
same possible inherited haplotypes, established earlier by SDEL, EPEV3 and
EPEVS, for these individuals (Table 18).
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Figure 42: Examples of the GeneMapper electropherogram for 9 bp indel assay after capillary
electrophoresis from "mother" (a), "father" (b) and "patient" (c). In each
electropherogram the alleles (297 bp and 306 bp) obtained from 9 bp indel are
visualised and the ratios between them displayed.
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Table 18: Allele ratios obtained from EPEV5 analysis for "mother", "father" and "patient" (child)
were used to define copy number values and predict haplotypes and segregation
patterns. In this analysis the possibility of zero-copy haplotypes was disregarded.
Alleles
CN Possible Haplotypea
297 306
Mother 3 4 3:1 or 2:2
Father 6 0 6 2:4 or 3:3
Patient 5 0 5 2:30r4:1
4.3.3 Discussion
The j3-defensin copy number values for the Cologne family trio were well
established by the Triplex assay and strongly supported by the micro satellites
and indel assays used. While the Triplex assay was able to ascertain precise
copy number values for each sample, the microsatellites and indel assays
determined ratios between the different alleles suggesting copy numbers based
on multiples of the values obtained. Combining the information from all assays,
a consensus copy number of 4, 6 and 5 was established for "mother", "father"
and "patient" (child), respectively.
Despite the copy number values suggested by 5DEL, EPEV3 and EPEV5
strongly supporting the copy numbers determined by the Triplex assay for
each sample, unfortunately these assays were not particularly helpful to
completely understand the segregation in this family. The allelic pattern given
by these assays was very similar between the three members of this family
making it difficult to follow the segregation of the alleles unambiguously from
parents to child and so uncover the haplotypes of each sample. Therefore,
from these analyses it was only possible to establish the inheritance of either
2 copies from one parent and 3 copies from the other or 4 copies from "father"
and 1 copy from "mother". The analysis carried out in this study did not take
in consideration the possibility of zero-copy haplotypes, since the frequency of
a diploid copy number of one is very low in all populations reported, so far.
While the analysis of EPEVI microsatellite was informative, the analysis of
9 bp indel assay on its own did not add any further information. However,
taking into consideration the combined analysis of EPEVI and 9 bp indel
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assay, it was possible to narrow down the number of potential inherited
haplotypes from parents to child. The diagram below shows the possible
haplotypes constructed from the analysis of the 9 bp indel (Figure 43). Adding
information from the EPEVI analysis and 9 bp indel assay it is possible to
exclude the third hypothesis (indicated with a red cross), so the microsatel1ite
information from EPEVI only suggests two possible inherited haploid copy
number states from each parent; 3 or 4 copies from "father" and 1 or 2 copies
from "mother". Therefore, the third hypothesis suggested by the 9 bp indel
assay, in which the child would inherit 2 copies from "father" and 3 copies
from "mother" was rejected. So, the "patient" could only inherit 3 or 4 paternal
copies and 1 or 2 maternal copies.
Father Mother
A B C 0
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~297
297 306
297
6 copies 4 copies
Father Mother
A B C 0
297 297 12971297
297 297 297
297 306
297
6 copies 4 copies
Father Mother
A B C 0
297 297 297 306
297 297 297
297 297
297
6 copies 4 copies
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A C
297 @Z]
297
297
297
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Figure 43: Possible haplotypes suggested from 9 bp indel analysis for "mother", "father" and
"patient" (child). Taking into consideration the information given by the EPEVl, it is
possible to exclude (crossed in red) one of the combinations.
The analysis carried out here follows the classic segregation pattern,
assuming the existence of just two haplotypes; however, father has abnormal
karyotype and the segregation patterns could be much more complicated. So,
the repeats inherited by child from father may not all be on one chromosome
and it is possible that arrangement changes on transmission from father to
child. For this reason it would be difficult to go much beyond defining the
parental origins of repeats found in the child.
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4.3.4 Conclusion
The copy number typing systems used could confidently establish the
copy number of 4, 6 and 5 for "mother", "father" and "patient", respectively.
Information gathered from the microsatellite and indel analysis did not
completely clarify the number of copies that the "patient" inherited from each
parent, but contributed to a certain extent to understanding the segregation of
alleles in this family, leaving the haplotypes to be identified. Nevertheless, it
was shown that the "patient" could only inherit 3 or 4 paternal copies and 1 or
2 maternal copies. These analyses, although efficient in detecting the copy
number of these individuals, were not able to completely clarify the origin of
the Bp rearrangements observed in the "patient". In order to clearly understand
the segregation of alleles in this family it would be necessary to access samples
from other family members, such as grandparents or siblings, but unfortunately
information was very limited and further samples were not available.
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CHAPTER 5: STUDY OF SNPs IN LD WITH THE
I3-DEFENSIN CNV
5.1 INTRODUCTION
Most common simple deletion and duplication polymorphisms (biallelic
CNV s) can be tagged by at least one neighbouring SNP with some even
showing a perfect match with proxy SNPs (r2=1.0) (Hinds et al. 2006;
McCarroll et al. 2006; Redon et al. 2006; McCarroll et al. 2008). Such
characteristics suggest that these polymorphisms share a similar evolutionary
history and originated from a unique ancestral mutational event that happened
once during human evolutionary history. As a consequence, these variants
appear in high linkage disequilibrium (LD) with nearby SNPs and can
effectively be tagged by proxy markers (Hinds et al. 2006; McCarroll et al.
2006; Redon et al. 2006). However, the level of linkage disequilibrium around
CNVs is not comparable with the LD observed around SNPs (Redon et al.
2006; McCarroll et al. 2008). This apparent difference could be due to
recurrent rearrangements at CNV sites or due to poor coverage of SNPs at
repeat-rich regions (Sharp et al. 2005; Locke et al. 2006; Redon et al. 2006).
Although SNPs can be use to tag biallelic CNV s, in the case of multiallelic
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copy number variants, due to their structurally dynamic nature and complex
evolutionary origin, this might not apply. For example at multiallelic CNVs,
such as the j3-defensin cluster at 8p23.l, Redon et al. (2006) described that
diploid copy number is poorly predicted by neighbouring SNPs.
Recombination between the distal and proximal sites of 8p23.1 is expected
at least in 4% of transmitted chromosomes. Additionally, this CNV shows a
germ-line rate of copy number change of 0.7%per gamete, the fastest-changing
CN variant currently known (Abu Bakar et al. 2(09). This evidence suggests
that it is very unlikely to find SNPs in strong LD with j3-defensin copy number,
to allow the prediction of the copy number from flanking SNPs. However,
combining information for several SNPs from the proximal and distal sites may
provide greater power to predict genomic copy number at these loci. In
previous studies SNP analysis just took into account the presence of ~-defensin
genes at the distal site (REPD) (Redon et al. 2006), but a recent study by Abu
Bakar et al. (2009) showed evidence of a J3-defensin copy number variable
repeat at the proximal site (REPP), as well. At REPP the copy number
haplotypes are more variable than at the distal site, which highlights the
importance of including information from both repeat sites, REPP and REPD,
when searching for tag SNPs.
To investigate if the j3-defensin copy number can be tagged by
neighbouring SNPs, both REPP and REPD sites of the j3-defensin copy number
repeat were investigated. The combination of SNP information from both sites
of the j3-defensin repeat will contribute to a more realistic and accurate
approach to investigate SNPs in LD with copy number. Thus the present study
hopes to address the question: can the copy number of j3-defensin be predicted
by nearby SNPs?
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5.2 RESULTS
The Haploview software was used to search for SNPs in LD with both
copy number repeats at REPD and REPP site of 8p23.1. SNP analysis was
performed using the CEPHjCEU SNP haplotype data from the International
Hap Map Project collections and the haploid copy number data generated for
the same sample cohort by Abu Bakar et al. (2009). For CEPHjCEU samples
only the diploid copy number was known from using the Triplex assay, so
haploid copy numbers were inferred when possible, following the copy
number segregation in families. In this analysis, 36 unrelated (CEU parents
only) samples (72 haplotypes) were used.
Since Haploview software is designed to just process haplotype analysis of
SNPs, in order to analyse the data, copy number data was coded as pseudo-
SNP genotypes. Copy numbers were coded in two different ways: in the first
instance, 1 and 2 copies were coded as A (adenine) and 3 or more copies as G
(guanine), while in the second instance, 1 copy was coded as A and 2 or more
copies as G. The adopted coding allowed the introduction of copy number
data together with SNP data in the software and thus searches for SNPs in LD
with copy number. The SNP data used for the CEPHjCEU population was
collected from the HapMap Phase II and ill across 1 Mb region at the proximal
site (11,700,700-12,700,000)and across approximately 2 Mb around the distal site
(6,730,000-8,500,000),each including the respective rHlefensin cluster.
At the proximal site of 8p23.1 region three SNPs were found to be in LD
with the copy number of rHlefensin. rs6989065 and rs12548700 (r2=O.103,D'=1
and LOD=2.48), mapped around 430 kb downstream (12,653,559 and
12,654,325) of the repeat unit at REPP site, show complete LD with the copy
number, as supported by the value of D'= 1. Additionally, these SNPs are in
strong LD with each other. The third SNP, rs6530976 is located at about 450
kb downstream (12,654,325) of the j3-defensin cluster and is in weak LD with
the other two SNPs, mentioned above. The measures of LD between rs6530976
and the copy number (r2=O.116, D'=O.833 and LOD=2.23) do not indicate
complete LD but values of D' near 1 (D'=O.833) provides a useful indication of
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disruption of LD by recombination. These LD measures indicate a significant
association oflower magnitude, weak LD (D'<l and r2<1).
At the distal site of 8p23.1 no SNPs were found to be in LD with
rHJefensin copy number. As the three SNPs found were in LD with each other,
just one SNP, rs12548700, was typed in the ECACC Human Random Control
(HRC) panels 1 and 2 and in CEPHjCEU cohort from the International
HapMap Project collections to test the association further.
5.2.1 Proximal site (REPP)of 8p23.1 - rs12548700
To genotype rs12548700 and investigate the correlation with copy number,
an RFLP assay was designed to test the association as described in section
2.2.6.1. This assay was applied in 181 samples of ECACC Human Random
Control (HRC) and in 90 CEPHjCEU samples from the HapMap cohorts to
confirm the accuracy of genotypes. The histograms below show the genotype
frequency distribution according to the copy number in the two cohorts
studied (Figure 44). Genotypes for the ECACC cohorts (Figure 44a) are widely
distributed across the different copy number haplotypes and all genotypes
show a similar mean copy number (between 4.31 and 4.59) (Table 19). From
the genotype frequency distribution represented in the histogram it is not
possible to visualize any association between each genotype and a particular
copy number. In the second histogram (Figure 44b) it is possible to observe
that 2 copy number haplotype is only represented by the GIG genotype, but
this is based on a very small number of samples (3 samples) with 2 copies.
Furthermore, the genotype C/C is apparently shifted towards high copy
numbers (4 or more copies), showing a higher mean copy number (mean
CN=5) than the other two genotypes (Table 19). The mean copy number
observed for each genotype ranged between 4.22 and 5, a slightly broader
range than the one observed for ECACC samples.
To test if there was any association between copy number and SNP
genotypes a correlation test was applied. No significant association was found
between these SNP genotypes and rHJefensin copy number for any of the
cohorts studied (pvalue=O.31, Pearson's correlation test, ECACC; p-value=O.l4
Pearson's correlation test, CEPHjCEU HapMap).
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Figure 44: Genotype frequency distribution of rs12548700 for ECACC Human Random
Control (lIRC) panels 1 and 2 (a) and CEPHjCEU Hap Map cohort (b). Genotype
frequency distribution is represented according to j3-defensin copy number.
Table 19: Genotype results of rs12548700 for the two cohorts studied: ECACC 1 and 2 panels
and HapMap CEPHjCEU cohort. The number of samples found with each
genotype, as the mean copy number and genotype frequency are indicated for each
genotype. Allele frequencies for each cohort are also shown below.
Cohort Genotypes Number Mean Genotype Allele Allele
of samples CN frequency Frequency
GjG 54 4.59 0.6279 G 0.7924
ECACC GjC 26 4.31 0.3023 C 0.2641
1& 2 panels CjC 6 4.33 0.0698
Total 86
GjG 55 4.22 0.6111 G 0.7817
HapMap GjC 31 4.45 0.3444 C 0.2108
CEPHjCEU CjC 4 5.00 0.0444
Total 90
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5.3 DISCUSSION
The results obtained from the genotype of rs12548700 show that this SNP
did not tag the copy number of ~-defensin at the REPP site, showing no
association in ECACC or HapMap CEPHjCEU samples. The apparently
Significant association initially found in Hap Map haplotypes between the
rsI2548700 and ~-defensin copy number for the CEPHjCEU cohort was not
confirmed after SNP genotyping, suggesting a type I error.
Since no other SNPs were found in LD with either REPP or REPD site of
~efensin copy number repeat, it suggests that different repeats arose at
different times in the human evolutionary history, hence with different genetic
"footprints". While most common diallelic CNPs are perfectly captured (r2=1.0)
by at least one SNP tag, multiallelic copy number loci with recurrent CNV
formation would show reduced correlation with flanking markers (McCarroll et
al. 2008). The results obtained are supported by previous evidence showing the
high rate of recombination of ~efensin loci that contributes to the continuous
formation of new repeats (Abu Bakar et al. 2009). Evidence from Redon et aJ.
(2006) also agrees with present results; in that study a low Pearson correlation
coefficient (r2) «0.58) was described for all the 13 multiallelic CNVs studied,
showing the poor ability of neighbouring SNPs in predicting the copy number.
Among the CNV s studied, the correlation of the best SNP proxy to the
~efensin repeat at REPD site was tested showing a very poor correlation with
copy number (r2=0.20) (Redon et aJ. 2006).
Our study confirms that multiallelic copy number variants are unlikely to
be tagged by nearby markers. As such, the study of copy number variation
cannot rely on the use of proxy SNPs. Instead, accurate and specific assays,
such as the Triplex assay, should be developed, as they are especially
important to measure multiallelic copy number variants such as the ~-defensin
copy number repeat.
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6.1 INTRODUCTION
CNVs in non-human primates have been investigated, so far, in a very
limited number of chimpanzees and rhesus macaques (Perry et aJ. 2006; Lee et
aJ. 2008; Perry et aJ. 2(08). Furthermore, very little is known about CNV in
other great apes, such as orangutan and gorilla. The sequence data available
for these primate species is very limited, which makes the study of genomic
variation, including CNV, difficult. Genes that are involved in immune
response often show high rates of genomic divergence and evidence of
adaptive evolution, in response to the rapid evolution of pathogens (Semple et
aJ. 2(05). The p-defensins are a family of multifunctional genes with key roles
in immunity, but also in reproduction and pigmentation. In primates, infection
is an important driving force for evolution modulating the survival rate to
infectious disease (Hollox and Armour 2(08). Therefore, investigation of CNV,
such as the CNV at p-d,efensin locus in great ape could shed light into the
origin of CNV in humans and their evolution through the primate lineage.
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For rhesus macaque (Macaca mulatta), Lee et al. (2008) reported multiple
copy number gains and losses at the Jklefensin locus, including changes in
DEFB4, using array-CGH. In the same year, using array-CGH and FISH, Perry
et al., (2008) showed that the beta-defensin CNV overlaps between humans
and chimpanzee (Pan troglodytes). The CNV of Jklefensins in chimpanzee was
recently analysed in more detail by Hardwick et al. (2011) using PRT, where
copy numbers of 4, 5 and 6 were reported. All genome comparative analysis of
chimpanzee, orangutan and rhesus macaque with the human genome shows
that Jklefensin region is highly conserved in chimpanzee but not as much in
orangutan or rhesus macaque (Vista Genome Browser). Here, the newly
developed PRT-based assays (PRT107A and HSPD2l) were applied to study
the recent evolution of Jklefensin CNV, investigating the copy number of
chimpanzee (Pan troglodytes), gorilla (Gorilla gorilla) and orangutan (Pongo
sp.) species (section 2.1.1.4).
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6.2 RESULTS
Considering the genome sequence similarity between the human and
other great ape genomes, it is expected that some of the CN measurement
systems developed for humans could also amplify orthologous regions of great
ape species. To measure the jklefensin copy number in non-human primates,
the possibility of using each of the Triplex systems developed for humans was
tested in chimpanzee and orangutan by in silica PCR and BLAT search using
the UCSC genome browser (CGSC 2.1.3jpanTro3 and WUGSC
2.0.2jponAbe2). To date, no sequence data is available in UCSC genome
browser for gorilla, so the Ensembl genome browser (gorGor 1 (Release 57,
Mar20 10)) was used instead. However, the sequence data available for gorilla
from Ensembl is very incomplete for the jklefensin region and just one
jklefensin gene (SPAG11) is annotated in the gorilla genome.
In chimpanzee, only HSPD21 PRT primers showed no mismatches with
the chimpanzee genome, amplifying uniquely test (chromosome 8) and
reference loci (chromosome 21). In orangutan neither of the PRTs (HSPD21 or
PRT107A) could be applied and all measurement systems tested showed
several mismatches under the primers in the orangutan genome. For HSPD21
primers, no matches were found on chromosome 8 in the orangutan genome,
but the primers matched the reference locus on chromosome 21. Further
analysis of test and reference loci in the orangutan and chimpanzee genome
was carried out by multiple sequence alignment with the human genome using
CiustalW2 software (from the European Bioinformatics Institute (EBI) (Figure
45). The results from the alignment confirm the findings for chimpanzee and
orangutan. On orangutan chromosome 21, the reference locus showed just one
mismatch in each primer, with a transition mismatch in the penultimate 3'
position of the forward primer, while on chromosome 8 very poor sequence
similarities were found for the HSPD3 pseudogene. This seems to show a
sequence gap in the orangutan genome when compared with human and
chimpanzee genomes, suggesting that this copy of the processed pseudogene
was inserted after the orangutan divergence from the human-chimpanzee
common ancestor.
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a) Chromosome 8 locus (test)
hg19
panTro2
ponAbe2
hg19
panTro2
ponAbe2
hg19
panTro2
ponAbe2
hg19
panTro2
ponAbe2
GTACAGTGTTTGGAGAAGAGGGCTGACACTAAATCTTGAAGACGTTCAGCCTCGTGACGT 25194
GTACAGTGTTTGGAGAAGAGGGCTGACACTAAATCTTGAAGACGTTCAGCCTCGTGACGT 19596
------------------------------AAAT-------------------------- 6651
F primer ....
AGGAGAAGTTGG GAGGTCACTGTGATCAAAGA ATGCCATGCTCTTAAAAGGAAAAGG 25254
AGGAGAAGTTGG GAGGTCACTGTGATCAAAGAT ATGCCATGCTCTTAAAAGGAAAAGG 19656
TAACAAGTCTCAAATTGAAAAATGTGTTCAAGAAATCATTGACCAGTCAGATGTCACAAC 25314
TAACAAGTCTCAAATTGAAAAATGTGTTCAAGAAATCATTGACCAGTCAGATGTCACAAC 19716
TAACAAG----------------------------------------------------- 6658
....... R primer
TAGTGAATACGAAAAGGAAAAAGTGAGTGGAGAAACTTTCAGAT GAGTAGCTGTGCTGA 25374
TAGTGAATACGAAAAGGAAAAACTGAATGGAGAAACTTTCAGAT GAGTAGCTGTGCTGA 19776
hg19 AGGiilGTGGGACAAGTGATGTTGAAGTGAATGAAGAGAAAGACAGAGTTATAGGTGCAC 25434
panTro2 ~GTGGGACAAGTGATGTTGAAGTGAATGAAGAGAAAGACAGAGTTACAGGTGCAC 19836
ponAbe2 ------------------------------------------------------------
hg19 TTAATGCTACAAGAGCTGCTGTTGAAGAAGGCATTGTTTAGGGAGGGGGTTGTGCCCTGC 25494
panTro2 TTAATGCTACAAGAGCTGCTGTTGAAGAAGGCATTGTTTAGGGACGGGGTTGTGCCCTGC 19896
ponAbe2 ------------------------------------------------------------
hg19 TTCGATGCATTCCAGCCTTGGACTCATTCACTCCAGCTAATGAAGATAAAATAATTGGTA 25554
panTro2 TTCGATGCATTCCAGCCTTGGACTCATTCACTCCAGCTAATGAAGATAAAATAATTGGTG 19956
ponAbe2 -------------------------------------------------AATAACT---- 6665
• • • • • •
b) Chromosome 2110cus
hg18
panTro2
ponAbe2
hg18
panTro2
ponAbe2
hg18
panTro2
ponAbe2
hg18
panTro2
ponAbe2
hg18
panTro2
ponAbe2
hg18
panTro2
ponAbe2
AAGGTATGACAATTGCTACTGGTGGTGCAGTGTTTGGAGAAGAGGAGTTGACCTCAAATC 1962
AAGGTATGACAATTGCCACTGGTGGTGCAGTGTTTGGAGAAGAGGAGTTGACCTCAAATC 1962
AAGGTATGACTATTGCTACTGGTGGTGCAGCGTTTGGAGAAGAGGAGTTGACCTTAAATC 1952
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • ** • • • • • • • • • • • • • • • • • • •• • • •
F primer
TTGAAGATGTTCAGCCTCATGACTTAGGAGAAGTTGG GAGGTCACTGTGATCAAAGAT 2022
TTGAAGATGTTCAGCCTCATGACTTAGGAGAAGCTGG GAGGTCACTGTGATCAAAGAT 2022
TTGAAGATGTTCAGCCTCATGACTTAGGAAAAGTTGG GAGGT(ACTGTGATCAAAGGT 2012
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • *.* • • • • • • • • • • • • • • •** • • •** •
mismatch in orangutan{;!J
ATGCTATGCTCTTAAAAGGAAAAGGTGACAAGGCTCAAATTTAAAAACGTATTCAAGAAA 2082
ATGCTATGCTCTTAAAAGGAAAAGGTGACAAGGCTCAAATTAAAAAACGTATTCAAGAAA 2082
ATGCTATGCTCTTAAAAGGAAAAGGTGACAAGGCTCAAATTAAAAAACGTATTCAAGAAA 2072
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • *** • • • • • • • • • • • • • •
TCATTGAGCAGTTGGATGTCACAACTAGTGAATATGAAAAGGAAAAACTGAATGAACAGC 2142
TCATTGAGCAGTTGGATGTCACAACTAGTGAATATGAAAAGGAAAAACTGAATGAACGGC 2142
TCATTGAGCAGTTGGATGTCACAACTAGTGAATATGAAAAGGAAAAACTGAATGAACGGC 2132
• • • • • • • • • • • • • • • • • • • • • • • • • • • • ** • • • • • • • • • • ** • • • • • • • • •**• • •
R primer
TGGCAAAACTTTCAGAT GAGTAGCTGTGCTGAAGGTT GTGGGACAAGTCACGTTGAAG 2202
TGGCAAAACTTTCAGAT GAGTAGCTGTGCTGAAGGTT GTGGGACAAGTCATGTTGAAG 2202
TGGCAAAACTTTCAGAT GAGTAGCTGTGCTGAAGGCT GTGGGACAAGTGATGTTGAAG 2192
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • ****.* * • •* • • •
. Ib> mismatch in orangutan
TGAATGAAAAGAAAAACAGAGTTACAGATGCCCTTAATGCTACAAGAGCTGCTGTTGAAG 2262
TGAATGAAAAGAAAAACAGAGTTACAGATGCCCTTAATGCTACAAGAGCTGCTGTTGAAG 2262
TGAATGAAAAGA--------GTTACAGATGCCCTTAATGCTACAAGAGCTGCTGTTAAAG 2244
• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
Figure 45: Multiple sequence alignment of test, chromosome 8 (a), and reference locus,
chromosome 21 (h), for human (hg18), chimpanzee (panTro2) and orangutan
(ponAhe2) genomes using the ClustalW2 software.
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To investigate the compatibility of the HSPD21 PRT system with the
gorilla genome, the sequence data available from Ensembl was investigated for
test (chromosome 8) and reference (chromosome 21) loci. Despite the fact that
all I3-defensin genes were partially sequenced in Ensembl, only SPAGll was
annotated for gorilla genome. From sequence alignments of test and reference
loci for human and gorilla it was possible to confirm the presence of the test
locus on gOrilla chromosome 8 (HSPD3 pseudogene), with both primers
having only one mismatch with the gorilla genome, with the forward primer
showing an internal transition mismatch (Figure 46). However, no matches
were found for the reference locus on chromosome 21, suggesting either the
absence of the HSPD3 pseudogene in gorilla genome or the poor coverage of
the gorilla genome sequence available in Ensembl.
Chromosome 8 locus (test)
Query: 25458 coocogcogctcttgtogcottaagtgcacctotoactctgtctttctcttcottcoctt 25399
11111111111111111111111111111111 111111111111111111111111111
Sbjct: 7561890 coocogcogctcttgtogcottaogtgcocctgtooctctgtctttctcttcottcoctt 7561949
R rimer
Query: 25398 caocotcocttgtcccoc ooccttcogcocogctoetc otctgooagtttetceocte 25339
1111111 11111111111 I 1111111111111 11111 1111111111111111 I
Sbjct: 7561950 coocotcocttgtcccoe 0 ecttco COCO ctocte ttetgooagtttctccotec 7562009
mismatch in gorilla
Query: 25338 octttttccttttcgtottcoctogttgtgocotctgoctggtcaotgotttcttgooeo 25279
I 11111111111111111111111111111111111111111 11111111111111111
Sbjct: 7562010 ogtttttcettttcgtottcoctogttgtgocotctgactggtcootgotttcttgoaco 7562069
F primer
Query: 25278 catttttcootttgogocttgttaccttttccttttoagogeatggcot otctttgotc 25219
III III I II III 1111 I II I II II III III III I 1111 III I III I I I I II I II I II I
Sbjct: 7562070 catttttcootttgagccttgttaccttttccttttoogogcatggcot atctttgotc 7562129
Query: 25218 acogtgocctc ccoacttctcctocgtcocgoggctgoocgtcttcoogatttogtgtc 25159
1111111111 111111111111111111 11111111111111111111111111111
Sbjct: 7562130 oeagegacetc ccoocttctcctacgtcatgoggctgoocgtcttcoagotttagtgtc 7562189
mismatch in gorilla
Figure 46: Multiple sequence alignment of test (chromosome 8) for human (Query) and gorilla (Sbjct)
genomes using the ClustalW2 software, showing positions of primers for HSPD21 PRT.
To further investigate the existence of HSPD3 pseudogene on chromosome 21
of gorilla (reference locus of HSPD21 PRT), sequencing of this locus was performed
as described in section 2.2.8.1. Sequencing of the chr21 locus was carried out, as
well, in all other non-human primates to give additional information about this locus
in chimpanzee and orangutan and to confirm the presence of this locus in bonobo
since no sequence data is available for this species. The sequencing data obtained
for each individual is displayed in Figure 47, showing a multiple sequence
alignment comparing with the human genome. As shown, the sequencing results
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demonstrated the presence of HSPD3 pseudogene in gorilla with no mismatches
observed in the forward and reverse primer of HSPD21 PRT. Moreover, the
sequencing data obtained for the other primates, chimpanzee, bonobo and
orangutan also confirms the presence of the HSPD3 pseudogene supporting the
use of HSPD21 PRT to measure the lklefensin copy number in great ape.
Chromosome 2110cus (reference)
F primer
human
Bonobo
Chimp candy
Chimpviolet
ChimpEB
GoEB
GoGuy
GoJ79
GoSy
GoTD
orang
human
Bonobo
Chimpcandy
Chimpviolet
ChimpEB
GoEB
GoGuy
GoJ79
GoSy
GoTD
orang
human
Bonobo
Chimpcandy
Chi.mpviolet
Chi.mpEB
GoEB
GoGuy
GoJ79
GoSy
GoTO
orang
human
Bonobo
Chimp candy
Chimpvi.olet
ChimpEB
GoEB
GoGuy
GoJ79
GoSy
GaTD
orang
AAGTTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 300
AAGTTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 264
AAGCTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 264
AAGCTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 263
AAGTTGG GAGGTCATTGTGACCAAAGAC ATGCCATGCTCTTAAAAGGAAAAGGTGACA 264
AAGTTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 263
AAGTTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 264
AAGCTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 266
AAGTTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 263
AAGTTGG GAGGTCACTGTGATCAAAGAT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 263
AAGTTGG GAGGTCACTGTGATCAAAGGT ATGCTATGCTCTTAAAAGGAAAAGGTGACA 265
• • • • • • • • • • • • • • • • • •• • • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
AGGCTCAAATTTAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 360
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 324
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 324
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 323
AGGTTAAAATTGAAAAACGTATTCAAGAAATCATTGAGCAGTTAGATGTCACAACTAGTG 324
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 323
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 324
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 326
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 323
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 323
AGGCTCAAATTAAAAAACGTATTCAAGAAATCATTGAGCAGTTGGATGTCACAACTAGTG 325
• • • • * • •** • • • • • • • • • • • • • • • • ** • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
R primer
AATATGAAAAGGAAAAACTGAATGAACAGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 420
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 384
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 384
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 383
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 384
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 383
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 384
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 386
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 383
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 383
AATATGAAAAGGAAAAACTGAATGAACGGCTGGCAAAACTTTCAGAT GAGTAGCTGTGC 385
......................... *. ** • • • • • • • • • • • • • • • • • • • • • • • • • • • • •
TGAAGGTT GTGGGACAAGTCACGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 480
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 444
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 444
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 443
TGAAGGTT GTGGGACAAGTGATGTTGAAGTGAATGAAAAGAAAGACAGAGTTACAGATG 444
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 443
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 444
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 446
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 443
TGAAGGTT GTGGGACAAGTCATGTTGAAGTGAATGAAAAGAAAAACAGAGTTACAGATG 443
TGAAGGCT GTGGGACAAGTGATGTTGAAGTGAATGAAAAGA--------GTTACAGATG 437
• • • • • • • • • • • • • • • •• • • • • • • • • • • • • • • • • • • •• • • • • • • • * •
Figure 47: Multiple sequence alignment of reference locus (chromosome 21) for human,
bonobo, chimpanzee (Candy, Violet and EB), gorilla and orangutan using the
ClustalW2 software, showing the positions of the HSPD21 PRT primers.
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Here, the HSPD21 PRT system (section 2.2.3.2) was used to measure the
j3-defensin copy number in three chimpanzees (Pan troglodytes); Candy, Violet
and EB and one bonobo (Pan paniscus). Each sample was typed with two
differently labelled primers (NED and FAM) (section 2.2.3.2), resulting in two
independent measurements of the p-defensin copy number (Figure 48). Copy
numbers were calculated from the test/reference ratio using peak heights, as
described in section 2.2.3.4.
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d) Bonobo
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Figure 48: GeneMapper electropherogram for HSPD21 assay after capillary electrophoresis
from Candy (a), Violet (b) and EB (c) and Bonoho (b). In each electropherogram
test (172 hp) and reference (180 hp) loci are shown in two distinct fluorescent dyes.
The duplicate HSPD21 PRT measurements agree between each other for
each of the samples, indicating a copy number of 1 for bonobo, 3 for Candy
and 4 for Violet and Chimpanzee EB when calibrated against human samples
of known copy number.
6.2.2 Gorilla
6.2.2.1 HSPD21 PRT
To measure the l3-defensin copy number in 5 gorilla individuals (Sylvia,
Tomoka, Guy,]79 and EB ]C), a modified version of the HSPD21 PRT system
was used (section 2.2.3). This included a gortlla-speciftc forward primer, which
takes into consideration the mismatch observed in the gOrilla sequence (Figure
46), used alongside the human specific forward primer in the same PCR
reaction (section 2.2.3.2). Each sample was typed with two differently labelled
primers (NED and FAM) (section 2.2.3.2) and the ratio between test and
reference locus, taken from peak heights, was used again to predict the copy
number (section 2.2.3.4). The copy number measurements taken from each
labelled primer agreed between each other for all samples typed and mean
copy numbers were calibrated against human samples of known copy number.
For all five gorillas (Sylvia, Tomoka, Guy, J79 and EB JC) an integer copy
number of 2 it was suggested by HSPD21 PRT (unrounded copy numbers
from 1.79 to 1.95) (Figure 49).
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e)EBJC
150 160 170 180 190
400
Figure 49: GeneMapper electropherograrn for HSPD21 PRT assay after capillary
electrophoresis from Sylvia (a), Tomoka (b), Guy (c),j79 (d) and EBJC (e). In each
electropherograrn, test (172 bp) and reference (180 bp) loci are shown in two distinct
fluorescent dyes.
6.2.2.2 DEFB103 locus sequencing
To further support the evidence of two copies of ~-defensins in the gorilla
genome, DNA sequence analysis was undertaken at the DEFBI03 locus to
investigate sequence polymorphisms within this locus for the 5 different gorilla
individuals. By following the segregation of the sequence variants in different
haplotypes, it should be possible to distinguish the sequences of each
~-defensin copy. In the presence of only two different haplotypes, the copy
number of two can be confirmed.
Sequencing data obtained for the DEFBI03locus was obtained for -95% of
the 1.8 kb sequence (chr8: 7273602-7275433 and chr8: 7775983-7777814,
including the entire coding sequence) by using two forward and three reverse
primers (section 2.2.8.2, Table 8). Sequencing data does not include poly T
repeats within this locus. Only three of the five gorillas, Sylvia, Tomoka and
J79 showed sequence variants at this locus. In total, four sequence variants
were found to convincingly represent the presence of two different alleles at the
same position (Figure 50). Sequence variants 1, 2 and 3 were found in the
gorilla J79 and another sequence variant, 4, was found in both Sylvia and
Tomoka. For all sequence variants the two alleles are approximately equal in
peak height (Figure 51).
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Figure 50: DEFB103 locus multiple sequence alignment of sequencing data obtained by using
DEFB103R and DEFB103R3 primers for gorilla (Sylvia, Guy, Tomoka,J79 and EBJC)
and human GOO, Cll and C62). In the figure, the three sequence variants in J79
(1,2 and 3) and the sequence variant (4) found in both Sylvia and Tomoka are shown.
a)J79
30
A A T G TGCATCA GAAAAC"TG TCA
b) Sylvia
~
AAGTGCTCGAC CGTGGCCGAAAA
•A A AT C T A AG GAT G "G eTA AT T G A A A G T GeT eGA C C G T G s c c G A A A A.
c) Tomoka
Figure 51: Patch of sequence traces collected from DEFB103 locus sequencing using
DEFB103R and DEFBI03R3 primers. Sequence variants 1, 2 and 3 are shown for
J79 (a) while sequence variant 4 is shown in Sylvia (b) and Tomoka (c).
6.2.2.3 Allele-specific peR
In order to follow the segregation of alleles in different haplotypes, allele
specific primers were designed for the relevant mixed positions found in J79,
Sylvia and Tomoka from the DEFB10310cus sequencing (section 2.2.8.3). The
sequence variant 1 was used to design an allele specific primer that would
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allow the analysis of the downstream sequence variants (2 and 3) in gorillaJ79.
For Sylvia and Tomoka, an allele specific primer was designed from the only
sequence variant found (4) in these individuals.
The sequence data obtained for J79 from allelic specific primers was
always of very poor quality, even after several attempts. Therefore, no further
information about the segregation of the alleles was obtained and no further
clarification about the p-defensin copy number ofJ79 was possible.
The sequence traces shown in Figure 52, show that two alleles at variant
4 in Sylvia and Tomoka were discriminated, confirming the presence of only
alleles A and G at this position. However, with only one mixed position
found at this locus for each of the gorillas it is not possible to reconstruct their
haplotypes.
a) Sylvia b) Tomoka
AGT GCT CGACACGTGG C G"A
4. A F primer T
,
AG TGC TCGACACG TGGC A
Fprimer T
4.A
AGTGCTCGACGCGTGGCG A AGTGCTCGACGCGTGGCG A
FprimerC FprimerC
4.G
Figure 52: Patch of sequence traces collected from DEFBI03locus sequencing using the allele
specific primers DEFBI03F_Sy.To_T and DEFB103F_Sy.To_C. For each gorilla,
Sylvia (a) and Tomoka (b) are shown the separated alleles after the allele specific
peR at the sequence variant (4).
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6.3 DISCUSSION
To investigate the evolutionary history of beta-defensin CNV in primates,
HSPD21 PRT was used to measure the copy number of p-defensins in
chimpanzee, bonobo, gorilla and orangutan. Great ape and human genomes
have high DNA sequence similarity (at least 97%) (Locke et al. 2011). After
comparing orthologous sequences, the HSPD21 PRT, initially designed to
measure the beta-defensin copy number variation in humans, proved to be a
versatile methodology with a vast applicability to different primate species.
Moreover, the PRT provides a more detailed analysis of this locus when
compared with array-CGH, which relies on the available genome assembly to
construct the probes.
HSPD21 showed that the number of copies of ~-defensin genes at the
chromosome 8 locus in chimpanzees varied between 3 and 4 copies. Our
results are also supported by evidence from array-CGH studies showing CNV
of the beta-defensin orthologous region in chimpanzee (Perry et al. 2008;
Marques-Bonet et al. 2009). Moreover, copy numbers of 4, 5 and 6 for this
locus were also recently reported for chimpanzee by PRT-based methods
(Hardwick et al. 2011). Despite the differences in the range of copy numbers
observed, which may reflect the small size cohorts, both studies report variation
in Il-defensin copy number. Therefore, this and other studies support the
evidence of beta-defensin CNV in chimpanzee in a similar range to that
observed in humans. Moreover, these findings contrast with the chimpanzee
genome assembly (CGSC 2.1.3jpanTro3), where only one copy is annotated at
this locus, which is not supported by this work. It would be of great advantage
for future investigations of CNV in primates if the chimpanzee genome
assembly could be updated to reflect recent fmdings.
For the bonobo individual, a Il-defensin copy number of one was typed
with HSPD21 PRT. This species is closely related to chimpanzee, with a
common ancestor at around 1 million years ago, therefore high sequence
similarity was expected to allow amplification of test and reference locus using
HSPD21 PRT. However, the copy number given by PRT, one copy, could not
be confirmed using only one individual and without any sequence data
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available from the test locus for this species. Even if a copy number of one is
described by PRT it is still possible that the bonobo could have a higher copy
number, which may not be revealed due to mismatches that prohibit the
amplification of all Iklefensin copies. Despite these facts, due to the close
evolutionary relationship to chimpanzee and the evidence of HSPD3 locus on
the bonobo genome shown by sequencing data, it is possible to suggest the
presence of only one copy for this individual with the evidence given by PRT.
The investigation of p-defensin CNV in orangutan was inconclusive.
Through sequence comparison, no orthologous region of the HSPD21 PRT test
locus was found, suggesting the absence of the HSPD3 pseudogene in
orangutan. To address the beta-defensin copy number in orangutan, further
work would be necessary to design an orangutan-specific PRT assay. However,
with the limitations of the existing orangutan genome assembly (WUGSC
2.0.2jponAbe2), with no annotated P-defensin genes, this would represent a
difficult and laborious task that could not be accomplished due to time restrictions.
The Iklefensin genes in all gorillas typed with HSPD21 PRT, were found
to have two copies. Allele-specific sequencing was carried out for sequence
variants found at the DEFBJ0310cus to confirm the results given by HSPD21
PRT. However, this approach proved not to be very successful or useful in
clarifying the copy number. As this assay relies in the presence of multiple
sequence variants in the same individual in order to follow the segregation of
alleles into different haplotypes, from our results only two gorillas, Sylvia and
J79 (from the 5 gorillas) presented multiple sequence variants. In Sylvia, the
two sequence variants, 3 and 4, were located too far apart (around 850 bp) to
be targeted by the same sequencing assay. On the other hand, the locations of
the sequence variants 1,2 and 3 (inJ79) allowed the design of an allele-specific
sequencing assay. Unfortunately, the sequencing assay did not successfully
clarify the copy number in J79. Finally, from the allele-specific sequencing
assay designed for the only sequence variant found in Sylvia and Tomoka, it
was possible to confirm the existence of only two alleles and therefore supports
the copy number of 2. Further work, either by designing other allele-specific
sequencing assays or by using restriction enzymes, could be developed in
order to confirm more confidently the copy number given by HSPD21 PRT.
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Despite the fact that no further confirmation of a copy number of two was
achieved with the allelic-specific sequencing assays, array-CGH data recently
reported for gorilla genome (Marques-Bonet et al. 2009) agrees with the copy
number reported here by PRT.
In summary, the beta-defensins are copy number variable in chimpanzee
and bonobo, but in gorilla, evidence suggests the presence of only two copies.
The chimpanzee showed a similar range of variation to that observed in
humans, suggesting that beta-defensins have a similar role in immunity in
humans and chimpanzees. The study of beta-defensin copy number variation
in gorilla suggests for the presence of only two copies in gorilla, implying that
the variation in copy number of beta-defensin only originated in the
chimpanzee-human lineage, so occurring after the divergence from gorilla in
evolutionary history (Figure 53). The possible phenotypic consequences of the
lack of variation in copy number of the beta-defensin genes in gorilla are
unknown. Nonetheless, it may suggest that gorilla and chimpanzee-human
lineages have been subjected to different evolutionary pressures forcing the
immune system to evolve in different directions.
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Figure 53: Old World primates (Catarrhine) phylogeny showing the divergence among great
apes, a small ape (Hylobatidae) and an Old World monkey (Cercopithecidae) with
respect to humans (adapted from Locke et al. (2011)).
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The studies of primate CNVs provide a new perspective on the divergence
and selective pressures acting on these genomic regions. Moreover, this
highlights the significance of CNV in evolution and their contribution for
interspecies and phenotypic variation, which consequently can account for
disease susceptibility. The knowledge of CNV in other primates is still limited
by the quality and coverage of the existing assemblies, which restricts the
clarity of the evolution of genomic variation and its importance in the primate
lineage. For a good evaluation of CNV in non-human primate genomes,
studies need to be scaled up and the use of species-specific techniques needs to
be adopted to access the copy number of functional and evolutionary
important CNV regions, such as the ~-defensin genes.
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CHAPTER 7: FINAL DISCUSSION AND CONCLUSIONS
7.1 MEASURING THE ~-DEFENSIN CNV
In this study a new copy number measurement method, the Triplex assay,
was developed to measure the ~-defensin copy number variation. The
j3-defensins are located on a multiallelic copy number locus at 8p23.1, which
shows extensive copy number variation, with individuals showing between
2 and 12 copies per diploid genome.
The measurement of copy number variation has been increasingly
reported in several studies by different methods, including real-time PCR and
array-CGH based methods. These methods have been extensively used to
study genome-wide copy number changes in human genomes (Iafrate et aJ.
2004; Sebat et aJ. 2004; Sharp et aJ. 2005; Redon et aJ. 2006; Wong et aJ. 2007;
McCarroll et aJ. 2(08). Although array-CGH methods have a good coverage of
the genome, they provide very poor coverage of complex regions containing
segmental duplications and copy number variation (Carter 2007). Moreover,
none of these methodologies combines a straightforward method with
accuracy, low cost and general applicability.
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PRT-based methods, in particular when combined in triplex, proved to be
a simple, inexpensive and high-throughput method to genotype loci such as
this, with copy numbers as high as 12. The evidence of the accuracy of this
method is shown by its capacity to classify samples into discrete integer copy
number classes. Moreover, the triplex gives the advantage of providing three
independent copy number measurements for each sample tested, which in the
analyses were generally concordant. Therefore, our data allowed us to
conclude that the Triplex assay is an accurate method to measure the
p-defensin copy number and shows considerably increased power in measuring
the multiallelic copy number variant of the p-defensin locus when compared
with the methods previously available, in particular with real-time PCR
(Aldhous et al. 2010; Fode et al. 2011). The Triplex assay was directly
compared with real-time PCR in two different studies to measure p-defensin copy
number variation in different human populations and in a Crohn's disease
association study (Aldhous et al. 2010; Fode et a1. 2011). Compared with the
clustered distribution of copy number values given by the Triplex, the copy
number values obtained from real-time PCR showed a continuous distribution
with no clear separation between different copy number classes. Such results
highlight the importance of assessing copy number accurately, which otherwise
could lead to false positive associations, such as the case of Crohn's disease,
when using real-time PCR (Fellennann et a1. 2006; Bentley et aJ. 2010).
The possibility of using SNPs in linkage disequilibrium to predict the copy
number has been explored in several studies (Hinds et aJ. 2006; McCarroll et
aJ. 2006; Redon et aJ. 2006; McCarroll et a1. 2008). Strong linkage
disequilibrium between SNPs and CNV regions is most frequently found for
biallelic CNV s, where SNPs can effectively tag an evolutionary lineage (Hinds
et a1. 2006; McCarroll et a1. 2006; Redon et al. 2006). Here, we investigated the
regions neighbouring the multiallelic p-defensin copy number locus with the
aim of finding possible SNPs in ill with the copy number. However, our
results indicate that no SNPs tag the p-defensin copy number variation at
8p23.1, agreeing with previous studies describing the poor level of ill around
CNV s, especially at multiallelic regions (Redon et aJ. 2006; McCarroll et al.
2008). This suggests that the p-defensin copy number is changing faster than
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other genomic properties, such as SNPs. The high rate of recurrent
recombination previously reported for the j3-defensin locus which contributes
for their high genomic instability, supports the poor correlation of CN with
neighbouring SNPs found here (Abu Bakar et al. 2009). Therefore, it is very
unlikely that multiallelic CNV s with recurrent rearrangements will show
correlation with flanking makers.
The development of new CNV methods is essential to investigate the
biological consequences of CNV in susceptibility to disease, human variation
and human evolution. Considering the number of copy variable loci in the
human genome and the number of these that are candidate loci for
susceptibility to several diseases, this work shows that PRT, especially when
used in Triplex, can be a powerful technique to determine copy numbers in
large case-control association studies.
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7.2 ~-DEFENSIN CNV IN HUMAN
DISEASEAND EVOLUTION
DIVERSITY,
In this study PRT-based assays (single and triplex assay) were used to
measure the J3--defensincopy number variation in a psoriasis case-control
association study. From the analysis of J3--defensincopy number variation in
patients with psoriasis, a new susceptibility locus was identified. A significant
association (p-value=9.44xlO-4) between psoriasis and J3--defensincopy number
variation was reported in a total of 516 samples (202 psoriatic cases) by two
independent studies, with high copy number showing a higher susceptibility to
psoriasis. Considering the significance standards currently defined for
candidate disease-loci at genome-wide studies, the p-value obtained here is only
of modest significance. The genome-wide level of significance for studies of
SNP markers has been determined to be a nominal p-value of around 5xl0-8
(Dudbridge and Gusnanto 2008). Since the prior probability of any given locus
to be associated with a complex disease is very low and the probability of a
type I error is much higher than the nominal level of the test, this explains the
fact that the nominal level of significance defined at the genome-wide studies is
much higher. The p-value for the association of beta-defensin with copy
number does not reach this threshold; however it is not clear whether this
threshold is too conservative for CNV testing or what threshold would
constitute an appropriate significant value for this study, which involves the
typing of a Single candidate locus. The results show however, a significant but
weak association between beta-defensin copy number and psoriasis.
The work presented here shows the importance of p-defensin in
susceptibility to psoriasis, as well as the role of structural variants, as opposed to
SNPs, in susceptibility to disease. Moreover, this study provides a good
example in defining new genetic factors responsible for the observed clinical
phenotypes, contributing to a better understanding of the pathogenesis and
susceptibility to psoriasis disease. As such, it seems clear that the importance of
copy number variation in disease status is still under-investigated and further
work should consider CNV as a possible source for disease susceptibility.
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Association studies need to rely on accurate and robust techniques to
precisely measure copy number variation and report relationships between
genetic variants and disease phenotypes. As demonstrated in the past, false
associations have been reported using real-time peR (Aldhous et aJ. 2010),
proving that careful analysis of copy number is essential in association studies.
Here, the Triplex assay was demonstrated to perform accurately in large case-
control association studies and proved to be essential for studies such as this.
The variation in copy number of the rHiefensins was further analysed
among six human populations to investigate the inter-population copy number
diversity. This study did not show any evidence of Significant differentiation
associated with geographical origin. These findings suggest that the observed
mean copy number of 4, in all populations, reflects balancing or intermediate
selection, suggesting that high copy number may increase susceptibility to
inflammatory or autoimmune diseases, such as psoriasis, and low copy number
could contribute to the risk of infectious diseases. This hypothesis fits the
multifunctional role of this gene family as "natural antibiotics" and signalling
molecules with important roles in several pathways in the innate and adaptive
immune system.
Finally, with the aim to track down the origin of beta-defensin copy
number variation in the evolutionary history of primates, the copy number in
great apes was analysed. The beta-defensins were found to be copy variable in
human and chimpanzee but not in gorilla; the data suggest the presence of
only two copies at this locus. This indicates that copy number variation of beta-
defensins might have originated by duplication in the human and chimpanzee
common ancestor after the divergence from gorilla about 6-8 million years ago.
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